# SiriusPoint (SPNT) 10-Q SEC filing - Q2 FY2026 - Filed: Jul 29, 2026, 4:15 PM EDT - Fiscal quarter: Q2 FY2026 - Calendar quarter: Q2 2026 - Accession: 0001576018-26-000085 - OpenCapital page: https://www.opencapital.sh/filings/0001576018-26-000085 - Markdown URL: https://www.opencapital.sh/filings/0001576018-26-000085.md - Official SEC filing index: https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/0001576018-26-000085-index.htm ## Filing documents - [10-Q (spnt-20260630.htm)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/spnt-20260630.htm) - [EX-10.1 EMPLOYMENT LETTER (a101employmentletterdatedj.htm)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/a101employmentletterdatedj.htm) - [EX-10.2 EMPLOYMENT LETTER (a102employmentletterdatedj.htm)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/a102employmentletterdatedj.htm) - [EX-31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER (exhibit31163026.htm)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit31163026.htm) - [EX-31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER (exhibit31263026.htm)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit31263026.htm) - [EX-32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER (exhibit32163026.htm)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit32163026.htm) - [EX-32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER (exhibit32263026.htm)](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit32263026.htm) --- ## 10-Q SEC source: [spnt-20260630.htm](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/spnt-20260630.htm) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ### Commission File Number 001-36052 SIRIUSPOINT LTD. (Exact name of registrant as specified in its charter) Bermuda 98-1599372 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Point Building 3 Waterloo Lane Pembroke HM 08, Bermuda +1 441 542-3300 (Address of Principal Executive Offices) (Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Shares, $0.10 par value SPNT New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes    ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ As of July 24, 2026, the registrant had 116,165,016 common shares issued and outstanding. ### SiriusPoint Ltd. ### INDEX Page [PART I](#i61c366f35a90444885e35497cd39e729_13). FINANCIAL INFORMATION [1](#i61c366f35a90444885e35497cd39e729_13) [Item 1.](#i61c366f35a90444885e35497cd39e729_16) Financial Statements [1](#i61c366f35a90444885e35497cd39e729_16) [Consolidated Balance Sheets](#i61c366f35a90444885e35497cd39e729_19) as of June 30, 2026 (unaudited) and December 31, 2025 [1](#i61c366f35a90444885e35497cd39e729_19) [Consolidated Statements of Income](#i61c366f35a90444885e35497cd39e729_25) for the three and six months ended June 30, 2026 and 2025 (unaudited) [2](#i61c366f35a90444885e35497cd39e729_25) [Consolidated Statements of Comprehensive Income](#i61c366f35a90444885e35497cd39e729_28) for the three and six months ended June 30, 2026 and 2025 (unaudited) [3](#i61c366f35a90444885e35497cd39e729_28) [Consolidated Statements of Shareholders' Equity](#i61c366f35a90444885e35497cd39e729_31) for the three and six months ended June 30, 2026 and 2025 (unaudited) [4](#i61c366f35a90444885e35497cd39e729_31) [Consolidated Statements of Cash Flows](#i61c366f35a90444885e35497cd39e729_34) for the three and six months ended June 30, 2026 and 2025 (unaudited) [5](#i61c366f35a90444885e35497cd39e729_34) [Notes to the Consolidated Financial Statements](#i61c366f35a90444885e35497cd39e729_40) [Note](#i61c366f35a90444885e35497cd39e729_43) 1. Organization [6](#i61c366f35a90444885e35497cd39e729_43) [Note](#i61c366f35a90444885e35497cd39e729_46) 2. Significant accounting policies [6](#i61c366f35a90444885e35497cd39e729_46) [Note](#i61c366f35a90444885e35497cd39e729_49) 3. Significant transactions [7](#i61c366f35a90444885e35497cd39e729_49) [Note](#i61c366f35a90444885e35497cd39e729_52) 4. Segment reporting [8](#i61c366f35a90444885e35497cd39e729_52) [Note](#i61c366f35a90444885e35497cd39e729_58) 5. Cash, cash equivalents, restricted cash and restricted investments [14](#i61c366f35a90444885e35497cd39e729_58) [Note](#i61c366f35a90444885e35497cd39e729_61) 6. Fair value measurements [14](#i61c366f35a90444885e35497cd39e729_61) [Note](#i61c366f35a90444885e35497cd39e729_64) 7. Investments [19](#i61c366f35a90444885e35497cd39e729_64) [Note](#i61c366f35a90444885e35497cd39e729_73) 8. Derivatives [23](#i61c366f35a90444885e35497cd39e729_73) [Note](#i61c366f35a90444885e35497cd39e729_76) 9. Variable and voting interest entities [24](#i61c366f35a90444885e35497cd39e729_76) [Note](#i61c366f35a90444885e35497cd39e729_82) 10. Loss and loss adjustment expense reserves [26](#i61c366f35a90444885e35497cd39e729_82) [Note](#i61c366f35a90444885e35497cd39e729_85) 11. Allowance for expected credit losses [27](#i61c366f35a90444885e35497cd39e729_85) [Note](#i61c366f35a90444885e35497cd39e729_91) 12. Debt and letter of credit facilities [28](#i61c366f35a90444885e35497cd39e729_91) [Note](#i61c366f35a90444885e35497cd39e729_97) 13. Income taxes [29](#i61c366f35a90444885e35497cd39e729_97) [Note](#i61c366f35a90444885e35497cd39e729_103) 14. Shareholders' equity [30](#i61c366f35a90444885e35497cd39e729_103) [Note](#i61c366f35a90444885e35497cd39e729_109) 15. Earnings per share available to SiriusPoint common shareholders [31](#i61c366f35a90444885e35497cd39e729_109) [Note](#i61c366f35a90444885e35497cd39e729_115) 16. Related party transactions [31](#i61c366f35a90444885e35497cd39e729_115) [Note](#i61c366f35a90444885e35497cd39e729_121) 17. Commitments and contingencies [32](#i61c366f35a90444885e35497cd39e729_121) [Item 2.](#i61c366f35a90444885e35497cd39e729_130)Management’s Discussion and Analysis of Financial Condition and Results of Operations [34](#i61c366f35a90444885e35497cd39e729_130) [Item 3.](#i61c366f35a90444885e35497cd39e729_202)Quantitative and Qualitative Disclosures About Market Risk [55](#i61c366f35a90444885e35497cd39e729_202) [Item 4.](#i61c366f35a90444885e35497cd39e729_205)Controls and Procedures [57](#i61c366f35a90444885e35497cd39e729_205) [PART II. OTHER INFORMATION](#i61c366f35a90444885e35497cd39e729_208) [57](#i61c366f35a90444885e35497cd39e729_211) [Item](#i61c366f35a90444885e35497cd39e729_211)1. Legal Proceedings [57](#i61c366f35a90444885e35497cd39e729_211) [Item](#i61c366f35a90444885e35497cd39e729_214)1A. Risk Factors [57](#i61c366f35a90444885e35497cd39e729_214) [Item](#i61c366f35a90444885e35497cd39e729_217)2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities [58](#i61c366f35a90444885e35497cd39e729_217) [Item](#i61c366f35a90444885e35497cd39e729_220)3. Defaults Upon Senior Securities [58](#i61c366f35a90444885e35497cd39e729_220) [Item](#i61c366f35a90444885e35497cd39e729_223)4. Mine Safety Disclosures [58](#i61c366f35a90444885e35497cd39e729_223) [Item](#i61c366f35a90444885e35497cd39e729_226)5. Other Information [58](#i61c366f35a90444885e35497cd39e729_226) [Item](#i61c366f35a90444885e35497cd39e729_229)6. Exhibits [59](#i61c366f35a90444885e35497cd39e729_229) PART I - Financial Information ## ITEM 1. Financial Statements SIRIUSPOINT LTD. CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of June 30, 2026 and December 31, 2025 (expressed in millions of U.S. dollars, except per share and share amounts) | Line item | June 30,2026 | December 31,2025 | | --- | --- | --- | | Assets | | | | Debt securities, available for sale, at fair value, net of allowance for credit losses of $0.0 (2025 - $0.0) (cost - $5,180.5; 2025 - $5,118.3) | $5,156.9 | $5,168.6 | | Debt securities, trading, at fair value (cost - $88.6; 2025 - $114.6) | 64.8 | 90.3 | | Short-term investments, at fair value (cost - $7.2; 2025 - $28.4) | 7.5 | 28.3 | | Other long-term investments, at fair value (cost - $399.3; 2025 - $421.9) (includes related party investments at fair value of $224.5 (2025 - $216.1)) | 285.8 | 315.1 | | Total investments | 5,515.0 | 5,602.3 | | Cash and cash equivalents | 614.8 | 731.2 | | Restricted cash and cash equivalents | 131.1 | 171.2 | | Due from brokers | 32.6 | 7.5 | | Interest and dividends receivable | 44.2 | 47.1 | | Insurance and reinsurance balances receivable, net | 2,606.7 | 2,260.3 | | Deferred acquisition costs, net | 408.7 | 384.1 | | Unearned premiums ceded | 630.7 | 487.4 | | Loss and loss adjustment expenses recoverable, net | 1,991.4 | 2,102.3 | | Deferred tax asset | 267.4 | 267.7 | | Goodwill | 18.6 | — | | Intangible assets | 137.4 | 121.2 | | Other assets | 253.1 | 272.1 | | Assets held for sale | — | 115.2 | | Total assets | $12,651.7 | $12,569.6 | | Liabilities | | | | Loss and loss adjustment expense reserves | $5,750.3 | $5,782.5 | | Unearned premium reserves | 2,119.7 | 1,855.4 | | Reinsurance balances payable | 1,461.3 | 1,447.6 | | Debt | 675.5 | 688.6 | | Due to brokers | 23.3 | 5.5 | | Deferred tax liability | 73.1 | 73.0 | | Other liabilities | 271.8 | 246.1 | | Total liabilities | 10,375.0 | 10,098.7 | | Commitments and contingent liabilities (refer to Note 17) | | | | Shareholders’ equity | | | | Series B preference shares (2025 - par value $0.10; authorized and issued: 8,000,000) | — | 200.0 | | Common shares (issued and outstanding: 116,065,965 (2025 - 116,989,799) | 11.6 | 11.7 | | Additional paid-in capital | 888.9 | 967.7 | | Retained earnings | 1,396.7 | 1,228.5 | | Accumulated other comprehensive income (loss), net of tax | (21.3) | 61.9 | | Shareholders’ equity attributable to SiriusPoint shareholders | 2,275.9 | 2,469.8 | | Noncontrolling interests | 0.8 | 1.1 | | Total shareholders’ equity | 2,276.7 | 2,470.9 | | Total liabilities, noncontrolling interests and shareholders’ equity | $12,651.7 | $12,569.6 | | The accompanying Notes to the Consolidated Financial Statements arean integral part of the Consolidated Financial Statements. | | | 1 SIRIUSPOINT LTD. CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) For the three and six months ended June 30, 2026 and 2025 (expressed in millions of U.S. dollars, except per share and share amounts) | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Revenues | | | | | | Net earned premium | $640.3 | $652.0 | $1,279.2 | $1,278.7 | | Net investment income | 65.5 | 68.2 | 131.9 | 139.4 | | Net investment gains (losses) | 7.9 | 0.7 | 19.3 | 0.4 | | Other revenues | 30.4 | 27.3 | 88.3 | 57.0 | | Total revenues | 744.1 | 748.2 | 1,518.7 | 1,475.5 | | Expenses | | | | | | Loss and loss adjustment expenses incurred, net | 358.2 | 372.6 | 721.1 | 774.4 | | Acquisition costs, net | 156.8 | 140.9 | 304.6 | 270.6 | | Other underwriting expenses | 51.8 | 48.3 | 102.3 | 89.4 | | Net corporate and other expenses | 73.7 | 70.9 | 144.9 | 131.5 | | Intangible asset amortization | 2.4 | 2.8 | 5.0 | 5.7 | | Interest expense | 18.7 | 21.1 | 35.5 | 39.2 | | Foreign exchange (gains) losses | (1.8) | 16.7 | (0.5) | 14.5 | | Total expenses | 659.8 | 673.3 | 1,312.9 | 1,325.3 | | Income before income tax expense | 84.3 | 74.9 | 205.8 | 150.2 | | Income tax expense | (15.8) | (11.6) | (35.0) | (24.9) | | Net income | 68.5 | 63.3 | 170.8 | 125.3 | | Net (income) loss attributable to noncontrolling interests | 0.1 | (0.1) | — | (0.5) | | Net income available to SiriusPoint | 68.6 | 63.2 | 170.8 | 124.8 | | Dividends on Series B preference shares | — | (4.0) | (2.6) | (8.0) | | Net income available to SiriusPoint common shareholders | $68.6 | $59.2 | $168.2 | $116.8 | | Earnings per share available to SiriusPoint common shareholders | | | | | | Basic earnings per share available to SiriusPoint common shareholders | $0.59 | $0.51 | $1.44 | $1.00 | | Diluted earnings per share available to SiriusPoint common shareholders | $0.58 | $0.50 | $1.40 | $0.98 | | Weighted average number of common shares used in the determination of earnings per share | | | | | | Basic | 116,732,354 | 116,523,435 | 116,728,906 | 116,252,739 | | Diluted | 119,011,731 | 118,669,471 | 120,237,742 | 118,598,535 | | The accompanying Notes to the Consolidated Financial Statements arean integral part of the Consolidated Financial Statements. | | | | | SIRIUSPOINT LTD. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) For the three and six months ended June 30, 2026 and 2025 (expressed in millions of U.S. dollars) | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Comprehensive income | | | | | | Net income | $68.5 | $63.3 | $170.8 | $125.3 | | Other comprehensive income (loss), net of tax | | | | | | Change in foreign currency translation adjustment | (1.6) | 3.4 | (6.9) | 3.2 | | Unrealized gains (losses) from debt securities held as available for sale investments | (27.8) | 19.1 | (85.1) | 51.8 | | Reclassifications from accumulated other comprehensive income (loss) | 1.8 | (2.4) | 8.8 | (4.4) | | Total other comprehensive income (loss) | (27.6) | 20.1 | (83.2) | 50.6 | | Comprehensive income | 40.9 | 83.4 | 87.6 | 175.9 | | Net (income) loss attributable to noncontrolling interests | 0.1 | (0.1) | — | (0.5) | | Comprehensive income available to SiriusPoint | $41.0 | $83.3 | $87.6 | $175.4 | | The accompanying Notes to the Consolidated Financial Statements arean integral part of the Consolidated Financial Statements. | | | | | SIRIUSPOINT LTD. CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED) For the three and six months ended June 30, 2026 and 2025 (expressed in millions of U.S. dollars) | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Series B preference shares | | | | | | Balance, beginning of period | — | $200.0 | $200.0 | $200.0 | | Redemption of preference shares | — | — | (200.0) | — | | Balance, end of period | — | 200.0 | — | 200.0 | | Common shares | | | | | | Balance, beginning of period | 11.6 | 11.6 | 11.7 | 11.6 | | Issuance of common shares, net | 0.2 | 0.1 | 0.2 | 0.2 | | Common shares repurchased and retired | (0.2) | — | (0.3) | (0.1) | | Balance, end of period | 11.6 | 11.7 | 11.6 | 11.7 | | Additional paid-in capital | | | | | | Balance, beginning of period | 956.4 | 944.7 | 967.7 | 945.0 | | Issuance of common shares, net | (0.2) | 0.2 | — | — | | Share compensation | (16.1) | 0.3 | (5.8) | 7.9 | | Exercise of options and warrants | — | 0.6 | — | 0.6 | | Common shares repurchased and retired | (51.2) | — | (73.0) | (7.7) | | Balance, end of period | 888.9 | 945.8 | 888.9 | 945.8 | | Retained earnings | | | | | | Balance, beginning of period | 1,328.1 | 842.5 | 1,228.5 | 784.9 | | Net income | 68.5 | 63.3 | 170.8 | 125.3 | | Net (income) loss attributable to noncontrolling interests | 0.1 | (0.1) | — | (0.5) | | Dividends on preference shares | — | (4.0) | (2.6) | (8.0) | | Balance, end of period | 1,396.7 | 901.7 | 1,396.7 | 901.7 | | Accumulated other comprehensive income (loss), net of tax | | | | | | Balance, beginning of period | 6.3 | 26.4 | 61.9 | (4.1) | | Change in foreign currency translation adjustment | | | | | | Balance, beginning of period | (6.2) | (3.2) | (0.9) | (3.0) | | Change in foreign currency translation adjustment | (1.6) | 3.4 | (6.9) | 3.2 | | Balance, end of period | (7.8) | 0.2 | (7.8) | 0.2 | | Unrealized gains (losses) from debt securities held as available for sale investments | | | | | | Balance, beginning of period | 12.5 | 29.6 | 62.8 | (1.1) | | Unrealized gains (losses) from debt securities held as available for sale investments | (27.8) | 19.1 | (85.1) | 51.8 | | Reclassifications from accumulated other comprehensive income (loss) | 1.8 | (2.4) | 8.8 | (4.4) | | Balance, end of period | (13.5) | 46.3 | (13.5) | 46.3 | | Balance, end of period | (21.3) | 46.5 | (21.3) | 46.5 | | Shareholders’ equity attributable to SiriusPoint shareholders | 2,275.9 | 2,105.7 | 2,275.9 | 2,105.7 | | Noncontrolling interests | 0.8 | 1.1 | 0.8 | 1.1 | | Total shareholders’ equity | $2,276.7 | $2,106.8 | $2,276.7 | $2,106.8 | | The accompanying Notes to the Consolidated Financial Statements arean integral part of the Consolidated Financial Statements. | | | | | SIRIUSPOINT LTD. CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) For the six months ended June 30, 2026 and 2025 (expressed in millions of U.S. dollars) | Line item | 2026 | 2025 | | --- | --- | --- | | Operating activities | | | | Net income | $170.8 | $125.3 | | Adjustments to reconcile net income to net cash provided by (used in) operating activities: | | | | Share compensation | 16.4 | 12.2 | | Net realized and unrealized gain on investments and derivatives | (19.3) | (0.4) | | Amortization of premium and accretion of discount, net | (13.7) | (19.8) | | Amortization of intangible assets | 5.0 | 5.7 | | Other items, net | (23.5) | 32.5 | | Changes in assets and liabilities: | | | | Insurance and reinsurance balances receivable, net | (346.4) | (236.6) | | Deferred acquisition costs, net | (24.6) | (52.0) | | Unearned premiums ceded | (143.3) | (20.1) | | Loss and loss adjustment expenses recoverable, net | 110.9 | 51.4 | | Deferred tax asset/liability | 11.7 | 10.2 | | Other assets | 21.5 | (54.5) | | Interest and dividends receivable | 2.9 | 1.5 | | Loss and loss adjustment expense reserves | (32.2) | 163.5 | | Unearned premium reserves | 264.3 | 214.8 | | Deferred gain on retroactive reinsurance | — | (8.5) | | Reinsurance balances payable | 13.7 | (241.7) | | Other liabilities | 7.3 | (10.3) | | Held for sale asset | 115.2 | — | | Net cash provided by (used in) operating activities | 136.7 | (26.8) | | Investing activities | | | | Purchases of debt securities, available-for-sale | (980.6) | (811.2) | | Purchases of short-term investments | (16.3) | (89.2) | | Purchases of other investments | (4.4) | (9.7) | | Proceeds from sales and maturities of debt securities, available-for-sale | 931.8 | 1,282.2 | | Proceeds from sales and maturities of debt securities, trading and short-term investments | 59.6 | 191.0 | | Proceeds from sales and maturities of other investments | 44.2 | 8.7 | | Change in due to/from brokers, net | (7.3) | (6.0) | | Business acquisitions, net (cash and restricted cash acquired of $4.9) | (29.4) | — | | Net cash provided by (used in) investing activities | (2.4) | 565.8 | | Financing activities | | | | Redemption of preference shares | (200.0) | — | | Purchases of SiriusPoint common shares under share repurchase program | (73.3) | (490.8) | | Net proceeds from exercise of options | — | 0.6 | | Net proceeds (payments) on deposit liability contracts | 7.6 | (7.3) | | Cash dividends paid to preference shareholders | (2.6) | (8.0) | | Taxes paid on withholding shares | (22.2) | (4.1) | | Change in total noncontrolling interests, net | (0.3) | (0.8) | | Net cash used in financing activities | (290.8) | (510.4) | | Net increase (decrease) in cash, cash equivalents and restricted cash | (156.5) | 28.6 | | Cash, cash equivalents and restricted cash at beginning of period | 902.4 | 894.6 | | Cash, cash equivalents and restricted cash at end of period | $745.9 | $923.2 | | The accompanying Notes to the Consolidated Financial Statements are an integral part of the Consolidated Financial Statements. | | | ### SiriusPoint Ltd. ### Notes to the Consolidated Financial Statements (UNAUDITED) (Expressed in U.S. Dollars) ### 1. Organization SiriusPoint Ltd. (together with its consolidated subsidiaries, “SiriusPoint” or the “Company”) was incorporated under the laws of Bermuda on October 6, 2011. Through its subsidiaries, the Company is a provider of global multi-line insurance and reinsurance products and services. These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 in Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual financial statements. This Quarterly Report on Form 10-Q (“Form 10-Q”) should be read in conjunction with the audited financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”) filed with the U.S. Securities and Exchange Commission on February 24, 2026. In the opinion of management, these unaudited consolidated financial statements reflect all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of the Company’s financial position and results of operations as at the end of and for the periods presented. All intercompany balances and transactions have been eliminated. The results for the six months ended June 30, 2026 are not necessarily indicative of the results for the full calendar year. Tabular amounts are in U.S. Dollars in millions, except share amounts, unless otherwise noted. ### 2. Significant accounting policies Other than the items listed below, there were no significant updates to the Company’s significant accounting policies as described in its 2025 Form 10-K. #### Business combinations The Company accounts for business combinations using the acquisition method of accounting, under which the purchase price of the acquisition is allocated to the assets acquired and liabilities assumed using the fair values determined by management as of the acquisition date. #### Goodwill Goodwill represents the excess of acquisition cost over the fair value of the identifiable assets acquired and liabilities assumed in connection with an acquisition. The Company tests goodwill for potential impairment annually, or more frequently if events or changes in circumstances indicate that the asset is impaired. For the purpose of evaluating goodwill for impairment, the Company may first perform a qualitative assessment to determine whether it is necessary to perform a quantitative goodwill impairment test. If determined to be necessary, the quantitative test compares the fair value of a reporting unit with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. If the carrying amount of the reporting unit exceeds the fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. #### Recently issued accounting standards #### Issued and effective as of June 30, 2026 #### Management of Credit Losses for Accounts Receivable and Contract Assets In July 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”). The amendment provides guidance for estimating expected credit losses on current accounts receivable and current contract assets. ASU 2025-05 is effective for all entities for annual periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted this accounting standard effective January 1, 2026 and its adoption did not have a material impact on the Company’s consolidated financial statements. 6 #### Issued but not yet effective as of June 30, 2026 #### Expense Disaggregation Disclosures In November 2024, the FASB issued Accounting Standards Update 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). The ASU requires a public business entity to provide disaggregated disclosures of certain categories of expenses on an annual and interim basis including employee compensation, depreciation, and intangible asset amortization for each income statement line item that contains those expenses. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Management is in the process of reviewing this update to assess the impact on its consolidated financial statements and disclosures. #### Internal-Use Software In September 2025, the FASB issued Accounting Standards Update 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”). The amendment updates accounting guidelines around capitalizing software costs. ASU 2025-06 is effective for all entities for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Management is in the process of reviewing this update to assess the impact on its consolidated financial statements and disclosures. The Company considers the applicability and impact of all accounting standard updates ("ASUs") issued by the FASB. ASUs issued during the three and six months ended June 30, 2026 and not listed above were assessed and either determined to be not applicable or expected to have minimal impact on the Company’s consolidated financial statements and disclosures. #### Reclassifications Certain comparative figures have been reclassified to conform to the current year presentation. These reclassifications had no impact on the previously reported net income (loss) or shareholders’ equity attributable to SiriusPoint shareholders. ### 3. Significant transactions #### Sale of Arcadian On October 3, 2025, the Company entered into an agreement to sell its 49% equity stake in Arcadian Risk Capital Ltd. (“Arcadian”) to Lee Equity Partners for total consideration of $140.4 million, inclusive of a pre-close dividend. The Company also renewed and extended its capacity agreement with Arcadian until the end of 2031. On January 30, 2026, the transaction closed following the satisfaction of customary closing conditions and the Company recognized a gain of $25.2 million in Other revenues in its consolidated income statement during the six months ended June 30, 2026. During 2025, the Company accounted for its 49% ownership in Arcadian under the equity method of accounting and recorded its share of net income in Other revenues in its consolidated income statement. As of December 31, 2025, a held for sale asset of $115.2 million was recorded in the Company’s consolidated balance sheet. #### Acquisition of Assist America On December 31, 2025, the Company, through its wholly owned subsidiaries, entered into an agreement to acquire Assist America Inc. and its affiliates (“Assist America”) for $44.0 million in cash and other contingent considerations. Pursuant to the agreement, Assist America became a consolidated subsidiary of the Company effective as of January 1, 2026 and the acquisition was accounted for as a business combination. The consideration was allocated to Assist America’s assets acquired and liabilities assumed based on their fair value as of the acquisition date. The consideration transferred is subject to customary post-closing adjustments, which could affect the preliminary goodwill recognized. Goodwill of $18.6 million was recognized within the Insurance & Services segment and is primarily attributable to the Company’s third-party medical and travel assistance capacities and the synergies that can be achieved subsequent to the Assist America acquisition. A majority of the goodwill recognized is expected to be deductible for tax purposes. #### Acquisition of World Nomads On February 12, 2026, Sirius International UK Holdings II Ltd, a subsidiary of SiriusPoint Ltd. (“SIUK II”), entered into a purchase agreement with nib Travel Pty Ltd., an Australian proprietary limited company (“nib”), in which SIUK II or its 7 subsidiaries will purchase equity interests and assets comprising the World Nomads travel insurance business currently operated by nib (collectively, “World Nomads”) for approximately $47 million. An initial closing on the majority of the World Nomads business is expected to occur in the second half of 2026, and a final closing is expected to occur in the second half of 2027, subject to the satisfaction of customary closing conditions. ### 4. Segment reporting The determination of the Company’s business segments is based on the manner in which management monitors the performance of its operations. The Company reports two operating segments: Insurance & Services and Reinsurance. The Company’s segments each have managers who are responsible for the overall profitability of their segments and who are directly accountable to the Company’s chief operating decision maker (“CODM”), the Chief Executive Officer. The CODM assesses segment operating performance, allocates capital and makes resource allocation decisions accordingly. Further, the CODM does not manage the Company’s assets by segment; accordingly, total assets are not allocated to the segments, excluding goodwill recognized due to the Assist America acquisition on January 1, 2026 which is allocated to the Insurance & Services segment. #### Insurance & Services In the Insurance & Services segment, the Company underwrites primary insurance in several sectors. The Insurance & Services segment includes Accident & Health, Property & Casualty, and Other Specialties. Accident and Health (“A&H”) – the Company provides insurance products to meet the risk management needs of diverse populations in select markets. This includes employer groups, associations, affinity groups, higher education and other niche markets. The Company also owns 100% of International Medical Group, Inc. (“IMG”), who receive fees for services provided within the Insurance & Services segment and to third parties. IMG offers a full line of international medical insurance products, travel insurance programs, medical management services and 24/7 emergency medical and travel assistance. The Company owned 100% of ArmadaCorp Capital, LLC (“Armada”) through October 31, 2025, when it was sold to Ambac Financial Group Inc. and deconsolidated as of November 1, 2025. SiriusPoint will continue its underwriting capacity partnership with Armada until the end of 2030. Armada operates as a supplemental medical insurance managing general agent (“MGA”). Property & Casualty – the Company is a carrier for program administrators and MGAs. The majority of its P&C insurance business is written through partners in the Property & Casualty space, covering Financial and Professional Liability, General Liability, Environmental and Commercial Auto lines around the world, including Bermuda, Europe, London and the U.S. Other Specialties – SiriusPoint’s business encompasses a broad range of worldwide insurance coverages. Other Specialties business lines in the Insurance & Services segment include Aviation, Marine & Energy, Credit, Surety and Mortgage. #### Reinsurance In the Reinsurance segment, the Company provides reinsurance products to insurance and reinsurance companies, government entities, and other risk bearing vehicles on a treaty or facultative basis. For reinsurance assumed, the Company participates in the reinsurance market with a global focus through the broker market distribution channel. The Company primarily writes treaty reinsurance, on both a proportional and excess of loss basis, and provides facultative reinsurance in some of its business lines. In the United States and Bermuda, the Company’s core focus is on distribution, risk and clients located in North America, while our international operation is focused primarily on distribution, risks and clients located in Europe. The Reinsurance segment predominantly underwrites Casualty, Property and Other Specialties lines of business. Casualty – the Company provides reinsurance to casualty insurers who underwrite a diverse range of casualty classes. The Company works with clients all over the world, including multi-national, nationwide and regional carriers, as well as risk retention groups and captives. The Company’s underwriting focus is on all major commercial casualty lines, including Financial and Professional Liability and General Liability lines, with an emphasis on specialty niche classes of business, including personal lines. Property – the Company works with leading global brokers as well as large national writers and regional companies. Underwriting is focused on providing critical catastrophe protection and worldwide coverage for natural perils, underwriting residential, commercial, and industrial risks in the United States, Europe and Asia. 8 Other Specialties – the Company’s business encompasses a broad range of worldwide reinsurance coverages, including proportional and excess of loss, treaty and facultative. Other Specialties business lines in the Reinsurance segment include Aviation & Space, Marine & Energy and Credit. Management uses segment income (loss) as the primary basis for assessing segment performance. Segment income (loss) is comprised of two components, underwriting income (loss) and net services income (loss). The Company calculates underwriting income (loss) by subtracting loss and loss adjustment expenses incurred, net, acquisition costs, net, and other underwriting expenses from net earned premium. Net services income (loss) consists of services revenues (fees for services revenues), services expenses, and services non-controlling (income) loss. This definition of segment income (loss) aligns with how business performance is managed and monitored. We continue to evaluate our segments as our business evolves and may further refine our segments and segment income (loss) measures. Certain items are presented in a different manner for segment reporting purposes than in the consolidated statements of income. These items are reconciled to the consolidated presentation in the segment measure reclass column below. Included in Insurance & Services segment income (loss) are services noncontrolling loss (income) attributable to minority shareholders on non-wholly-owned subsidiaries. In addition, services revenues and services expenses are reconciled to other revenues and net corporate and other expenses, respectively. Segment results are shown prior to corporate eliminations. Corporate eliminations are included in the elimination column below as necessary to reconcile to underwriting income (loss), net services income (loss), and segment income (loss) to the consolidated statements of income. Corporate includes the results of all run off business, which represents certain classes of business that the Company ceased underwriting as part of fundamental changes to its business strategy, including the effect of the restructuring of the underwriting platform announced in 2022 and certain reinsurance contracts that have interest crediting features. Corporate results also include asbestos and environmental and other latent liability exposures on a gross basis, which have mostly been ceded, as well as specific workers’ compensation and cyber programs which the Company no longer writes. In addition, revenue and expenses managed at the corporate level, including realized and unrealized gains (losses) and other investment income, non services-related other revenues, non services-related net corporate and other expenses, intangible asset amortization, interest expense, foreign exchange (gains) losses and income tax (expense) benefit are reported within Corporate. The CODM does not manage segment results or allocate resources to segments when considering these items and they are therefore excluded from our definition of segment income (loss). 9 The following is a summary of the Company’s operating segment results for the three and six months ended June 30, 2026 and 2025: _Three months ended June 30, 2026_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $644.6 | $336.9 | $981.5 | — | $(3.3) | — | $978.2 | | Net written premium | 422.4 | 287.1 | 709.5 | — | 0.8 | — | 710.3 | | Net earned premium | 381.7 | 257.1 | 638.8 | — | 1.5 | — | 640.3 | | Loss and loss adjustment expenses incurred, net | 216.5 | 140.1 | 356.6 | (1.8) | 3.4 | — | 358.2 | | Acquisition costs, net | 104.2 | 75.7 | 179.9 | (20.7) | (2.4) | — | 156.8 | | Other underwriting expenses | 25.6 | 21.7 | 47.3 | — | 4.5 | — | 51.8 | | Underwriting income (loss) | 35.4 | 19.6 | 55.0 | 22.5 | (4.0) | — | 73.5 | | Services revenues | 59.4 | — | 59.4 | (29.8) | — | (29.6) | — | | Services expenses | 49.6 | — | 49.6 | — | — | (49.6) | — | | Net services fee income | 9.8 | — | 9.8 | (29.8) | — | 20.0 | — | | Services noncontrolling loss | 0.1 | — | 0.1 | — | — | (0.1) | — | | Net services income | 9.9 | — | 9.9 | (29.8) | — | 19.9 | — | | Segment income (loss) | 45.3 | 19.6 | 64.9 | (7.3) | (4.0) | 19.9 | 73.5 | | Net investment income | | | | | 65.5 | — | 65.5 | | Net investment gains (losses) | | | | | 7.9 | — | 7.9 | | Other revenues | | | | | 0.8 | 29.6 | 30.4 | | Net corporate and other expenses | | | | | (24.1) | (49.6) | (73.7) | | Intangible asset amortization | | | | | (2.4) | — | (2.4) | | Interest expense | | | | | (18.7) | — | (18.7) | | Foreign exchange gains | | | | | 1.8 | — | 1.8 | | Income before income tax expense | $45.3 | $19.6 | 64.9 | (7.3) | 26.8 | (0.1) | 84.3 | | Income tax expense | | | — | — | (15.8) | — | (15.8) | | Net income | | | 64.9 | (7.3) | 11.0 | (0.1) | 68.5 | | Net loss attributable to noncontrolling interest | | | — | — | — | 0.1 | 0.1 | | Net income available to SiriusPoint | | | $64.9 | $(7.3) | $11.0 | — | $68.6 | | Attritional losses | $231.3 | $140.7 | $372.0 | $(1.8) | $1.7 | — | $371.9 | | Catastrophe losses | 1.3 | — | 1.3 | — | — | — | 1.3 | | Prior year loss reserve development | (16.1) | (0.6) | (16.7) | — | 1.7 | — | (15.0) | | Loss and loss adjustment expenses incurred, net | $216.5 | $140.1 | $356.6 | $(1.8) | $3.4 | — | $358.2 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 60.6% | 54.7% | 58.2% | | | | 58.0% | | Catastrophe loss ratio | 0.3% | — | 0.2% | | | | 0.2% | | Prior year loss development ratio | (4.2)% | (0.2)% | (2.6)% | | | | (2.3)% | | Loss ratio | 56.7% | 54.5% | 55.8% | | | | 55.9% | | Acquisition cost ratio | 27.3% | 29.4% | 28.2% | | | | 24.5% | | Other underwriting expenses ratio | 6.7% | 8.4% | 7.4% | | | | 8.1% | | Combined ratio | 90.7% | 92.3% | 91.4% | | | | 88.5% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. 10 _Three months ended June 30, 2025_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $560.4 | $369.7 | $930.1 | — | $18.1 | — | $948.2 | | Net written premium | 392.8 | 307.0 | 699.8 | — | 4.6 | — | 704.4 | | Net earned premium | 369.2 | 276.4 | 645.6 | — | 6.4 | — | 652.0 | | Loss and loss adjustment expenses incurred, net | 209.2 | 156.4 | 365.6 | (1.5) | 8.5 | — | 372.6 | | Acquisition costs, net | 97.9 | 70.5 | 168.4 | (28.2) | 0.7 | — | 140.9 | | Other underwriting expenses | 22.6 | 21.4 | 44.0 | — | 4.3 | — | 48.3 | | Underwriting income (loss) | 39.5 | 28.1 | 67.6 | 29.7 | (7.1) | — | 90.2 | | Services revenues | 58.1 | — | 58.1 | (31.7) | — | (26.4) | — | | Services expenses | 49.6 | — | 49.6 | — | — | (49.6) | — | | Net services fee income | 8.5 | — | 8.5 | (31.7) | — | 23.2 | — | | Services noncontrolling loss | 0.2 | — | 0.2 | — | — | (0.2) | — | | Net services income | 8.7 | — | 8.7 | (31.7) | — | 23.0 | — | | Segment income (loss) | 48.2 | 28.1 | 76.3 | (2.0) | (7.1) | 23.0 | 90.2 | | Net investment income | | | | | 68.2 | — | 68.2 | | Net investment gains (losses) | | | | | 0.7 | — | 0.7 | | Other revenues | | | | | 0.9 | 26.4 | 27.3 | | Net corporate and other expenses | | | | | (21.3) | (49.6) | (70.9) | | Intangible asset amortization | | | | | (2.8) | — | (2.8) | | Interest expense | | | | | (21.1) | — | (21.1) | | Foreign exchange losses | | | | | (16.7) | — | (16.7) | | Income before income tax expense | $48.2 | $28.1 | 76.3 | (2.0) | 0.8 | (0.2) | 74.9 | | Income tax expense | | | — | — | (11.6) | — | (11.6) | | Net income (loss) | | | 76.3 | (2.0) | (10.8) | (0.2) | 63.3 | | Net income attributable to noncontrolling interests | | | — | — | (0.3) | 0.2 | (0.1) | | Net income (loss) available to SiriusPoint | | | $76.3 | $(2.0) | $(11.1) | — | $63.2 | | Attritional losses | $218.9 | $161.0 | $379.9 | $(1.5) | $3.4 | — | $381.8 | | Catastrophe losses | — | (0.5) | (0.5) | — | — | — | (0.5) | | Prior year loss reserve development | (9.7) | (4.1) | (13.8) | — | 5.1 | — | (8.7) | | Loss and loss adjustment expenses incurred, net | $209.2 | $156.4 | $365.6 | $(1.5) | $8.5 | — | $372.6 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 59.3% | 58.3% | 58.8% | | | | 58.5% | | Catastrophe loss ratio | — | (0.2)% | (0.1)% | | | | (0.1)% | | Prior year loss development ratio | (2.6)% | (1.5)% | (2.1)% | | | | (1.3)% | | Loss ratio | 56.7% | 56.6% | 56.6% | | | | 57.1% | | Acquisition cost ratio | 26.5% | 25.5% | 26.1% | | | | 21.6% | | Other underwriting expenses ratio | 6.1% | 7.7% | 6.8% | | | | 7.4% | | Combined ratio | 89.3% | 89.8% | 89.5% | | | | 86.1% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. 11 _Six months ended June 30, 2026_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $1,329.2 | $656.1 | $1,985.3 | — | $(4.2) | — | $1,981.1 | | Net written premium | 883.5 | 522.8 | 1,406.3 | — | (0.8) | — | 1,405.5 | | Net earned premium | 761.8 | 515.3 | 1,277.1 | — | 2.1 | — | 1,279.2 | | Loss and loss adjustment expenses incurred, net | 432.2 | 274.1 | 706.3 | (3.6) | 18.4 | — | 721.1 | | Acquisition costs, net | 212.2 | 139.5 | 351.7 | (44.5) | (2.6) | — | 304.6 | | Other underwriting expenses | 51.9 | 41.3 | 93.2 | — | 9.1 | — | 102.3 | | Underwriting income (loss) | 65.5 | 60.4 | 125.9 | 48.1 | (22.8) | — | 151.2 | | Services revenues | 113.4 | — | 113.4 | (52.9) | — | (60.5) | — | | Services expenses | 95.7 | — | 95.7 | — | — | (95.7) | — | | Net services fee income | 17.7 | — | 17.7 | (52.9) | — | 35.2 | — | | Services noncontrolling loss | 0.6 | — | 0.6 | — | — | (0.6) | — | | Net services income | 18.3 | — | 18.3 | (52.9) | — | 34.6 | — | | Segment income (loss) | 83.8 | 60.4 | 144.2 | (4.8) | (22.8) | 34.6 | 151.2 | | Net investment income | | | | | 131.9 | — | 131.9 | | Net investment gains (losses) | | | | | 19.3 | — | 19.3 | | Other revenues | | | | | 27.8 | 60.5 | 88.3 | | Net corporate and other expenses | | | | | (49.2) | (95.7) | (144.9) | | Intangible asset amortization | | | | | (5.0) | — | (5.0) | | Interest expense | | | | | (35.5) | — | (35.5) | | Foreign exchange gains | | | | | 0.5 | — | 0.5 | | Income before income tax expense | $83.8 | $60.4 | 144.2 | (4.8) | 67.0 | (0.6) | 205.8 | | Income tax expense | | | — | — | (35.0) | — | (35.0) | | Net income | | | 144.2 | (4.8) | 32.0 | (0.6) | 170.8 | | Net (income) loss attributable to noncontrolling interests | | | — | — | (0.6) | 0.6 | — | | Net income available to SiriusPoint | | | $144.2 | $(4.8) | $31.4 | — | $170.8 | | Attritional losses | $462.1 | $286.4 | $748.5 | $(3.6) | $2.4 | — | $747.3 | | Catastrophe losses | 1.3 | 5.4 | 6.7 | — | — | — | 6.7 | | Prior year loss reserve development | (31.2) | (17.7) | (48.9) | — | 16.0 | — | (32.9) | | Loss and loss adjustment expenses incurred, net | $432.2 | $274.1 | $706.3 | $(3.6) | $18.4 | — | $721.1 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 60.6% | 55.6% | 58.6% | | | | 58.5% | | Catastrophe loss ratio | 0.2% | 1.0% | 0.5% | | | | 0.5% | | Prior year loss development ratio | (4.1)% | (3.4)% | (3.8)% | | | | (2.6)% | | Loss ratio | 56.7% | 53.2% | 55.3% | | | | 56.4% | | Acquisition cost ratio | 27.9% | 27.1% | 27.5% | | | | 23.8% | | Other underwriting expenses ratio | 6.8% | 8.0% | 7.3% | | | | 8.0% | | Combined ratio | 91.4% | 88.3% | 90.1% | | | | 88.2% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. 12 _Six months ended June 30, 2025_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $1,195.5 | $724.5 | $1,920.0 | — | $12.9 | — | $1,932.9 | | Net written premium | 876.3 | 575.5 | 1,451.8 | — | (4.4) | — | 1,447.4 | | Net earned premium | 705.4 | 566.0 | 1,271.4 | — | 7.3 | — | 1,278.7 | | Loss and loss adjustment expenses incurred, net | 419.1 | 351.7 | 770.8 | (3.5) | 7.1 | — | 774.4 | | Acquisition costs, net | 185.2 | 137.6 | 322.8 | (56.2) | 4.0 | — | 270.6 | | Other underwriting expenses | 41.5 | 40.2 | 81.7 | — | 7.7 | — | 89.4 | | Underwriting income (loss) | 59.6 | 36.5 | 96.1 | 59.7 | (11.5) | — | 144.3 | | Services revenues | 120.2 | — | 120.2 | (61.9) | — | (58.3) | — | | Services expenses | 92.7 | — | 92.7 | — | — | (92.7) | — | | Net services fee income | 27.5 | — | 27.5 | (61.9) | — | 34.4 | — | | Services noncontrolling loss | 0.1 | — | 0.1 | — | — | (0.1) | — | | Net services income | 27.6 | — | 27.6 | (61.9) | — | 34.3 | — | | Segment income (loss) | 87.2 | 36.5 | 123.7 | (2.2) | (11.5) | 34.3 | 144.3 | | Net investment income | | | | | 139.4 | — | 139.4 | | Net investment gains (losses) | | | | | 0.4 | — | 0.4 | | Other revenues | | | | | (1.3) | 58.3 | 57.0 | | Net corporate and other expenses | | | | | (38.8) | (92.7) | (131.5) | | Intangible asset amortization | | | | | (5.7) | — | (5.7) | | Interest expense | | | | | (39.2) | — | (39.2) | | Foreign exchange losses | | | | | (14.5) | — | (14.5) | | Income before income tax expense | $87.2 | $36.5 | 123.7 | (2.2) | 28.8 | (0.1) | 150.2 | | Income tax expense | | | — | — | (24.9) | — | (24.9) | | Net income | | | 123.7 | (2.2) | 3.9 | (0.1) | 125.3 | | Net income attributable to noncontrolling interests | | | — | — | (0.6) | 0.1 | (0.5) | | Net income available to SiriusPoint | | | $123.7 | $(2.2) | $3.3 | — | $124.8 | | Attritional losses | $426.5 | $325.0 | $751.5 | $(3.5) | $1.9 | — | $749.9 | | Catastrophe losses | 4.8 | 62.6 | 67.4 | — | — | — | 67.4 | | Prior year loss reserve development | (12.2) | (35.9) | (48.1) | — | 5.2 | — | (42.9) | | Loss and loss adjustment expenses incurred, net | $419.1 | $351.7 | $770.8 | $(3.5) | $7.1 | — | $774.4 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 60.4% | 57.3% | 59.1% | | | | 58.7% | | Catastrophe loss ratio | 0.7% | 11.1% | 5.3% | | | | 5.3% | | Prior year loss development ratio | (1.7)% | (6.3)% | (3.8)% | | | | (3.4)% | | Loss ratio | 59.4% | 62.1% | 60.6% | | | | 60.6% | | Acquisition cost ratio | 26.3% | 24.3% | 25.4% | | | | 21.2% | | Other underwriting expenses ratio | 5.9% | 7.1% | 6.4% | | | | 7.0% | | Combined ratio | 91.6% | 93.5% | 92.4% | | | | 88.8% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. 13 ### 5. Cash, cash equivalents, restricted cash and restricted investments The following table provides a summary of cash and cash equivalents, restricted cash and restricted investments as of June 30, 2026 and December 31, 2025: | Line item | June 30,2026 | December 31,2025 | | --- | --- | --- | | Cash and cash equivalents | $614.8 | $731.2 | | Restricted cash securing letter of credit facilities (1) | 39.5 | 69.1 | | Restricted cash securing reinsurance contracts (2) | 78.9 | 89.3 | | Restricted cash held by managing general underwriters | 12.7 | 12.8 | | Total cash, cash equivalents and restricted cash (3) | 745.9 | 902.4 | | Restricted investments securing reinsurance contracts and letter of credit facilities (1) (2) (4) | 1,768.7 | 2,040.7 | | Total cash, cash equivalents, restricted cash and restricted investments | $2,514.6 | $2,943.1 | (1) Restricted cash and restricted investments securing letter of credit facilities primarily pertains to letters of credit that have been issued to the Company’s clients in support of its obligations under reinsurance contracts. The Company will not be released from the obligation to provide these letters of credit until the reserves underlying the reinsurance contracts have been settled. The time period for which the Company expects each letter of credit to be in place varies from contract to contract but can last several years. (2) Restricted cash and restricted investments securing reinsurance contracts pertain to trust accounts securing the Company’s contractual obligations under certain reinsurance contracts that the Company will not be released from until the underlying risks have expired or have been settled. Restricted investments include certain investments in debt securities and short-term investments. The time period for which the Company expects these trust accounts to be in place varies from contract to contract, but can last several years. (3) Cash, cash equivalents and restricted cash as reported in the Company’s consolidated statements of cash flows. (4) Restricted investments include required deposits with certain insurance state regulatory agencies in order to maintain insurance licenses. ### 6. Fair value measurements U.S. GAAP disclosure requirements establish a framework for measuring fair value, including a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability. The three-level hierarchy of inputs is summarized below: - Level 1 – Quoted prices available in active markets/exchanges for identical investments as of the reporting date. - Level 2 – Observable inputs to the valuation methodology other than unadjusted quoted market prices for identical assets or liabilities in active markets. Level 2 inputs include, but are not limited to, prices quoted for similar assets or liabilities in active markets/exchanges, prices quoted for identical or similar assets or liabilities in markets that are not active and fair values determined through the use of models or other valuation methodologies. - Level 3 – Inputs are based all or in part on significant unobservable inputs for the investment, and include situations where there is little, if any, market activity for the investment. The inputs applied in the determination of fair value require significant management judgment and estimation. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including, but not limited to, assumptions about risk inherent in a particular valuation technique used to measure fair value such as a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources other than those of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment’s level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. 14 The following tables present the Company’s investments measured and reported at fair value, categorized by the level of the fair value hierarchy as of June 30, 2026 and December 31, 2025: _June 30, 2026 - (Level 1) - (Level 2) - (Level 3)_ | Line item | Quoted prices in active markets | Significant other observable inputs | Significant unobservable inputs | Total | | --- | --- | --- | --- | --- | | Assets | | | | | | Asset-backed securities | — | $842.9 | — | $842.9 | | Residential mortgage-backed securities | — | 960.0 | — | 960.0 | | Commercial mortgage-backed securities | — | 256.1 | — | 256.1 | | Corporate debt securities | — | 2,237.2 | — | 2,237.2 | | U.S. government and government agency | 840.6 | — | — | 840.6 | | Non-U.S. government and government agency | — | 20.1 | — | 20.1 | | Total debt securities, available for sale | 840.6 | 4,316.3 | — | 5,156.9 | | Asset-backed securities | — | 5.1 | — | 5.1 | | Residential mortgage-backed securities | — | 27.0 | — | 27.0 | | Commercial mortgage-backed securities | — | 26.4 | — | 26.4 | | Corporate debt securities | — | 3.4 | — | 3.4 | | U.S. government and government agency | 2.9 | — | — | 2.9 | | Total debt securities, trading | 2.9 | 61.9 | — | 64.8 | | Short-term investments | 7.5 | — | — | 7.5 | | Other long-term investments | — | — | 57.5 | 57.5 | | Derivative assets | — | — | 6.2 | 6.2 | | | $851.0 | $4,378.2 | $63.7 | 5,292.9 | | Cost and equity method investments | | | | 60.9 | | Investments in funds valued at NAV | | | | 167.4 | | Total assets | | | | $5,521.2 | | Liabilities | | | | | | Derivative liabilities | — | — | $29.1 | $29.1 | | Total liabilities | — | — | $29.1 | $29.1 | 15 _December 31, 2025 - (Level 1) - (Level 2) - (Level 3)_ | Line item | Quoted prices in active markets | Significant other observable inputs | Significant unobservable inputs | Total | | --- | --- | --- | --- | --- | | Assets | | | | | | Asset-backed securities | — | $921.1 | — | $921.1 | | Residential mortgage-backed securities | — | 963.1 | — | 963.1 | | Commercial mortgage-backed securities | — | 231.9 | — | 231.9 | | Corporate debt securities | — | 2,198.2 | — | 2,198.2 | | U.S. government and government agency | 835.7 | — | — | 835.7 | | Non-U.S. government and government agency | — | 18.6 | — | 18.6 | | Total debt securities, available for sale | 835.7 | 4,332.9 | — | 5,168.6 | | Asset-backed securities | — | 5.9 | — | 5.9 | | Residential mortgage-backed securities | — | 45.0 | — | 45.0 | | Commercial mortgage-backed securities | — | 31.9 | — | 31.9 | | Corporate debt securities | — | 3.7 | — | 3.7 | | U.S. Government and government agency | 3.8 | — | — | 3.8 | | Total debt securities, trading | 3.8 | 86.5 | — | 90.3 | | Short-term investments | 28.3 | — | — | 28.3 | | Other long-term investments | — | 5.2 | 82.9 | 88.1 | | Derivative assets | — | — | 14.4 | 14.4 | | | $867.8 | $4,424.6 | $97.3 | 5,389.7 | | Cost and equity method investments | | | | 69.3 | | Investments in funds valued at NAV | | | | 157.7 | | Total assets | | | | $5,616.7 | | Liabilities | | | | | | Derivative liabilities | — | — | $9.0 | $9.0 | | Total liabilities | — | — | $9.0 | $9.0 | During the six months ended June 30, 2026, the Company did not reclassify its assets or liabilities between Levels 2 and 3 (December 31, 2025 - no reclassifications). #### Valuation techniques The Company uses independent pricing services to assist in determining fair values for its investments. For investments in active markets, the Company uses the quoted market prices provided by independent pricing services to determine fair value. In circumstances where quoted market prices are unavailable or are not considered reasonable, the Company estimates the fair value using industry standard pricing models and observable inputs such as benchmark yields, reported trades, broker-dealer quotes, issuer spreads, benchmark securities, bids, offers, prepayment speeds, reference data including research publications, and other relevant inputs. Given that many debt securities do not trade on a daily basis, the independent pricing services evaluate a wide range of fixed maturity investments by regularly drawing parallels from recent trades and quotes of comparable securities with similar features. The characteristics used to identify comparable debt securities vary by asset type and take into account market convention. The techniques and inputs specific to asset classes within the Company’s debt securities and short-term investments for Level 2 securities that use observable inputs are as follows: #### Asset-backed and mortgage-backed securities The fair value of mortgage and asset-backed securities is primarily priced by independent pricing services using a pricing model that uses information from market sources and leveraging similar securities. Key inputs include benchmark yields, reported trades, underlying tranche cash flow data, collateral performance, plus new issue data, as well as broker-dealer 16 quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including issuer, vintage, loan type, collateral attributes, prepayment speeds, default rates, recovery rates, cash flow stress testing, credit quality ratings and market research publications. #### Corporate debt securities Corporate debt securities consist primarily of investment-grade debt of a wide variety of U.S. and non-U.S. corporate issuers and industries. The corporate fixed maturity investments are primarily priced by independent pricing services. When evaluating these securities, the independent pricing services gather information from market sources regarding the issuer of the security and obtain credit data, as well as other observations, from markets and sector news. Evaluations are updated by obtaining broker dealer quotes and other market information including actual trade volumes, when available. The independent pricing services also consider the specific terms and conditions of the securities, including any specific features which may influence risk. #### U.S. government and government agency U.S. government and government agency securities consist primarily of debt securities issued by the U.S. Treasury and mortgage pass-through agencies such as the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and the Government National Mortgage Association. Fixed maturity investments included in U.S. government and government agency securities are primarily priced by independent pricing services. When evaluating these securities, the independent pricing services gather information from market sources and integrate other observations from markets and sector news. Evaluations are updated by obtaining broker dealer quotes and other market information including actual trade volumes, when available. The fair value of each security is individually computed using analytical models which incorporate option adjusted spreads and other daily interest rate data. #### Non-U.S. government and government agency Non-U.S. government and government agency securities consist of debt securities issued by non-U.S. governments and their agencies along with supranational organizations (also known as sovereign debt securities). Securities held in these sectors are primarily priced by independent pricing services who employ proprietary discounted cash flow models to value the securities. Key quantitative inputs for these models are daily observed benchmark curves for treasury, swap and high issuance credits. The independent pricing services then apply a credit spread for each security which is developed by in-depth and real time market analysis. For securities in which trade volume is low, the independent pricing services utilize data from more frequently traded securities with similar attributes. These models may also be supplemented by daily market and credit research for international markets. #### U.S. states, municipalities, and political subdivisions The U.S. states, municipalities and political subdivisions portfolio contains debt securities issued by U.S. domiciled state and municipal entities. These securities are generally priced by independent pricing services using the techniques for U.S. government and government agency securities described above. #### Short-term investments Short-term investments consist of U.S. treasury bills, certificates of deposit and other securities, which, at the time of purchase, mature within a period of greater than three months but less than one year. These investments are generally priced by independent pricing services using the techniques for U.S. government and government agency securities and Corporate debt securities described above. #### Investments measured using Net Asset Value The Company values its investments in limited partnerships, including its investments in related party investment funds, at fair value. The Company has elected the practical expedient for fair value for these investments which is estimated based on the Company’s share of the net asset value (“NAV”) of the limited partnerships, as provided by the independent fund administrator, as the Company believes it represents the most meaningful measurement basis for the investment assets and liabilities. The NAV represents the Company’s proportionate interest in the members’ equity of the limited partnerships. The fair value of the Company's investments in certain hedge funds and certain private equity funds are also determined using NAV. The hedge fund's administrator provides quarterly updates of fair value in the form of the Company's proportional interest in the underlying fund's NAV, which is deemed to approximate fair value, generally with a three month delay in 17 valuation. The private equity funds provide monthly, quarterly, or semi-annual partnership capital statements primarily with a one- or three-month delay which are used as a basis for valuation. These private equity investments vary in investment strategies and are not actively traded in any open markets. Due to a lag in reporting, some of the fund managers, fund administrators, or both, are unable to provide final fund valuations as of the Company's reporting date. This includes utilizing preliminary estimates reported by its fund managers and using other information that is available to the Company with respect to the underlying investments, as necessary. In order to assess the reasonableness of the NAVs, the Company performs a number of monitoring procedures on a monthly, quarterly and annual basis, to assess the quality of the information provided by the investment manager and fund administrator underlying the preparation of the NAV. These procedures include, but are not limited to, regular review and discussion of the fund’s performance with the investment manager. These investments are included in investment in funds valued at NAV and excluded from the presentation of investments categorized by the level of the fair value hierarchy. #### Level 3 Investments Level 3 valuations are generated from techniques that use assumptions not observable in the market. These unobservable assumptions reflect the Company's assumptions that market participants would use in valuing the investment. Generally, certain securities may start out as Level 3 when they are originally issued but as observable inputs become available in the market, they may be reclassified to Level 2. The Company employs a number of procedures to assess the reasonableness of the fair value measurements for its other long-term investments, including obtaining and reviewing the audited annual financial statements of hedge funds and private equity funds and periodically discussing each fund's pricing with the fund manager. However, since the fund managers do not provide sufficient information to evaluate the pricing inputs and methods for each underlying investment, the inputs are considered to be unobservable. The fair values of the Company's investments in private equity securities, private debt instruments, certain private equity funds, and certain hedge funds have been classified as Level 3 measurements. Private equity securities and private debt instruments are initially valued based on transaction price and their valuation is subsequently estimated based on available evidence such as a market transaction in similar instruments and other financial information for the issuer. For strategic investments carried at fair value, management either engages a third-party valuation specialist to assist in determination of the fair value based on commonly accepted valuation methods (e.g., income approach, market approach) as of the valuation date or performs valuation internally. In addition, investors’ fair value analyses prepared by third party valuation specialists working with strategic investment operating management are referenced where available. Where criteria to be accounted for under the equity method is not met, we have elected to value our strategic investments at the cost adjusted for market observable events less impairment method, a measurement alternative in which the investment is measured at cost and remeasured to fair value when determined to be impaired or upon observable transactions prices becoming available. See Note 8 for additional information on the fair values of derivative financial instruments used for both risk management and investment purposes. #### Underwriting-related derivatives Underwriting-related derivatives include reinsurance contracts that are accounted for as derivatives. These derivative contracts are initially valued at cost which approximates fair value. In subsequent measurement periods, the fair values of these derivatives are determined using internally developed discounted cash flow models. As the significant inputs used to price these derivatives are unobservable, the fair values of these contracts are classified as Level 3. 18 The following tables present the reconciliation of investments measured at fair value using Level 3 inputs for the three and six months ended June 30, 2026 and 2025: | Line item | April 1,2026 | Transfers in to (out of) Level 3 | Purchases | Sales & Settlements | Realized and Unrealized Gains (Losses) (1) | June 30,2026 | | --- | --- | --- | --- | --- | --- | --- | | Other long-term investments | $63.7 | — | — | — | $(6.2) | $57.5 | | Net derivatives (2) | $(31.7) | — | — | — | $8.8 | $(22.9) | | Line item | January 1, 2026 | Transfers in to (out of) Level 3 | Purchases | Sales & Settlements | Realized and Unrealized Gains(Losses) (1) | June 30,2026 | | --- | --- | --- | --- | --- | --- | --- | | Other long-term investments | $82.9 | — | — | $(22.7) | $(2.7) | $57.5 | | Net derivatives (2) | $5.4 | — | — | $(1.3) | $(27.0) | $(22.9) | | Line item | April 1,2025 | Transfers in to (out of) Level 3 | Purchases | Sales & Settlements | Realized and Unrealized Gains (Losses) (1) | June 30,2025 | | --- | --- | --- | --- | --- | --- | --- | | Other long-term investments | $87.0 | — | — | — | — | $87.0 | | Net derivatives (2) | $21.7 | — | — | — | $(14.9) | $6.8 | | Line item | January 1, 2025 | Transfers in to (out of) Level 3 | Purchases | Sales & Settlements | Realized and Unrealized Gains (Losses) (1) | June 30,2025 | | --- | --- | --- | --- | --- | --- | --- | | Other long-term investments | $86.6 | — | — | — | $0.4 | $87.0 | | Net derivatives (2) | $(13.4) | — | — | $5.4 | $14.8 | $6.8 | (1) Total change in realized and unrealized gains (losses) recorded on Level 3 financial instruments is included in net investment gains (losses) in the consolidated statements of income. Realized and unrealized gains (losses) related to underwriting related derivative assets and liabilities are included in other revenues, net of foreign exchange (gains) losses, in the consolidated statements of income. See Note 8 “Derivatives” for classifications of gains (losses) on derivatives. (2) Derivative assets are presented within Other assets on the consolidated balance sheets and derivative liabilities are presented within Other liabilities on the consolidated balance sheets. The amounts are presented net in the tables above for the purposes of the rollforward. For assets and liabilities that were transferred into Level 3 during the period, gains (losses) are presented as if the assets or liabilities had been transferred into Level 3 at the beginning of the period; similarly, for assets and liabilities that were transferred out of Level 3 during the period, gains (losses) are presented as if the assets or liabilities had been transferred out of Level 3 at the beginning of the period. The following table includes financial instruments for which the carrying value differs from the estimated fair values as of June 30, 2026 and December 31, 2025. The fair values of the below financial instruments are based on observable inputs and are considered Level 2 measurements. | Line item | June 30, 2026 / Fair Value | June 30, 2026 / Carrying Value | December 31, 2025 / Fair Value | December 31, 2025 / Carrying Value | | --- | --- | --- | --- | --- | | 2024 Senior Notes | $417.6 | $396.6 | $424.2 | $396.0 | | 2017 SEK Subordinated Notes | 284.8 | 278.9 | 293.3 | 292.6 | | Series B preference shares (1) | — | — | $202.2 | $200.0 | (1) The Series B preference shares were fully redeemed on February 26, 2026. See Note 14 for further discussion on the redemption. ### 7. Investments The Company’s invested assets consist of investment securities and other long-term investments held for general investment purposes. The portfolio of investment securities includes debt securities available for sale, debt securities held for trading, short-term investments, and other long-term investments. Realized investment gains and losses on debt securities are reported in pre-tax revenues. Unrealized investment gains and losses on debt securities are reported based on classification. Trading securities flow through pre-tax revenues, whereas securities classified as available for sale (“AFS”) flow through other comprehensive income. For debt securities classified as AFS for which a decline in the fair value between the amortized cost is due to credit-related factors, an allowance is established for the difference between the estimated recoverable value and amortized cost with a 19 corresponding impact to the consolidated statements of income. The allowance is limited to the difference between amortized cost and fair value. A credit loss impairment assessment is performed on securities using both quantitative and qualitative factors. Qualitative factors include significant declines in fair value below amortized cost. Additionally, a qualitative assessment is also performed over debt securities to evaluate potential credit losses. Examples of qualitative indicators include issuer credit downgrades as well as changes to credit spreads. Declines in fair value related to a debt security that do not relate to a credit loss are recorded as a component of accumulated other comprehensive income. #### Debt securities The following tables provide the cost or amortized cost, gross unrealized investment gains (losses), net foreign currency gains (losses), and fair value of the Company's debt securities as of June 30, 2026 and December 31, 2025: | Line item | June 30, 2026 / Cost oramortizedcost | June 30, 2026 / Grossunrealizedgains | June 30, 2026 / Grossunrealizedlosses | June 30, 2026 / Net foreign currency gains (losses) | Fair value | | --- | --- | --- | --- | --- | --- | | Debt securities, available for sale | | | | | | | Asset-backed securities | $853.3 | $3.2 | $(13.6) | — | $842.9 | | Residential mortgage-backed securities | 960.7 | 8.8 | (9.5) | — | 960.0 | | Commercial mortgage-backed securities | 256.5 | 1.2 | (1.6) | — | 256.1 | | Corporate debt securities | 2,242.5 | 9.6 | (13.7) | (1.2) | 2,237.2 | | U.S. government and government agency | 847.8 | 0.9 | (8.1) | — | 840.6 | | Non-U.S. government and government agency | 19.7 | 0.1 | (0.1) | 0.4 | 20.1 | | Total debt securities, available for sale (1) | $5,180.5 | $23.8 | $(46.6) | $(0.8) | $5,156.9 | | Debt securities, trading | | | | | | | Asset-backed securities | $7.8 | — | $(2.7) | — | $5.1 | | Residential mortgage-backed securities | 31.4 | 0.1 | (4.5) | — | 27.0 | | Commercial mortgage-backed securities | 29.6 | — | (3.2) | — | 26.4 | | Corporate debt securities | 16.8 | — | (13.4) | — | 3.4 | | U.S. government and government agency | 3.0 | — | (0.1) | — | 2.9 | | Total debt securities, trading | $88.6 | $0.1 | $(23.9) | — | $64.8 | _December 31, 2025_ | Line item | Cost oramortizedcost | Grossunrealizedgains | Grossunrealizedlosses | Net foreign currency gains (losses) | Fair value | | --- | --- | --- | --- | --- | --- | | Debt securities, available for sale | | | | | | | Asset-backed securities | $917.1 | $7.3 | $(3.3) | — | $921.1 | | Residential mortgage-backed securities | 950.1 | 17.7 | (4.7) | — | 963.1 | | Commercial mortgage-backed securities | 231.3 | 3.1 | (2.5) | — | 231.9 | | Corporate debt securities | 2,170.8 | 32.3 | (2.4) | (2.5) | 2,198.2 | | U.S. government and government agency | 830.5 | 5.6 | (0.4) | — | 835.7 | | Non-U.S. government and government agency | 18.5 | 0.2 | — | (0.1) | 18.6 | | Total debt securities, available for sale (1) | $5,118.3 | $66.2 | $(13.3) | $(2.6) | $5,168.6 | | Debt securities, trading | | | | | | | Asset-backed securities | $8.3 | — | $(2.4) | — | $5.9 | | Residential mortgage-backed securities | 50.7 | 0.1 | (5.8) | — | 45.0 | | Commercial mortgage-backed securities | 34.6 | 0.4 | (3.1) | — | 31.9 | | Corporate debt securities | 17.1 | — | (13.4) | — | 3.7 | | U.S. government and government agency | 3.9 | — | (0.1) | — | 3.8 | | Total debt securities, trading | $114.6 | $0.5 | $(24.8) | — | $90.3 | (1) As of June 30, 2026 and December 31, 2025, the Company did not record an allowance for credit losses on the AFS portfolio. 20 As of June 30, 2026, 318 unique debt securities classified as AFS were in a gross unrealized loss position for greater than 12 months (December 31, 2025 - 379 unique debt securities). Refer to the tables below for the Company’s breakdown of AFS debt securities in a gross unrealized loss position as of June 30, 2026 and December 31, 2025. | Line item | June 30, 2026 | June 30, 2026 | June 30, 2026 | June 30, 2026 | June 30, 2026 | June 30, 2026 | June 30, 2026 | June 30, 2026 | June 30, 2026 | June 30, 2026 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 12 Months or Less | | | | Greater than 12 Months | | | | Total | | | | | | Fair value | | Gross unrealized losses | | Fair value | | Gross unrealized losses | | Fair value | | Gross unrealized losses | | | Debt securities, available for sale | | | | | | | | | | | | | | Asset-backed securities | $ | $312.7 | $ | $(5.7) | $ | $36.6 | $ | $(7.9) | $ | $349.3 | $ | $(13.6) | | Residential mortgage-backed securities | 369.2 | | (4.7) | | 140.5 | | (4.8) | | 509.7 | | (9.5) | | | Commercial mortgage-backed securities | 129.9 | | (1.3) | | 10.1 | | (0.3) | | 140.0 | | (1.6) | | | Corporate debt securities | 1,148.7 | | (13.3) | | 48.4 | | (0.4) | | 1,197.1 | | (13.7) | | | U.S. government and government agency | 630.3 | | (7.8) | | 21.1 | | (0.3) | | 651.4 | | (8.1) | | | Non-U.S. government and government agency | 11.0 | | (0.1) | | — | | — | | 11.0 | | (0.1) | | | Total debt securities, available for sale | $ | $2,601.8 | $ | $(32.9) | $ | $256.7 | $ | $(13.7) | $ | $2,858.5 | $ | $(46.6) | | Line item | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 12 Months or Less | | | | Greater than 12 Months | | | | Total | | | | | | Fair value | | Gross unrealized losses | | Fair value | | Gross unrealized losses | | Fair value | | Gross unrealized losses | | | Debt securities, available for sale | | | | | | | | | | | | | | Asset-backed securities | $ | $184.5 | $ | $(1.5) | $ | $20.6 | $ | $(1.8) | $ | $205.1 | $ | $(3.3) | | Residential mortgage-backed securities | 84.5 | | (0.5) | | 190.5 | | (4.2) | | 275.0 | | (4.7) | | | Commercial mortgage-backed securities | 46.2 | | (1.2) | | 9.0 | | (1.3) | | 55.2 | | (2.5) | | | Corporate debt securities | 309.4 | | (1.8) | | 54.5 | | (0.6) | | 363.9 | | (2.4) | | | U.S. government and government agency | 107.9 | | (0.1) | | 42.2 | | (0.2) | | 150.1 | | (0.3) | | | Non-U.S. government and government agency | 7.1 | | — | | — | | — | | 7.1 | | — | | | Total debt securities, available for sale | $ | $739.6 | $ | $(5.1) | $ | $316.8 | $ | $(8.1) | $ | $1,056.4 | $ | $(13.2) | The weighted average duration of the Company's debt securities, net of short positions in U.S. treasuries, as of June 30, 2026 was approximately 3.1 years, including short-term investments (December 31, 2025 - approximately 3.2 years). The following table provides the cost or amortized cost and fair value of the Company's debt securities bifurcated into debt securities held for trading and AFS as of June 30, 2026 and December 31, 2025 by contractual maturity. Actual maturities could differ from contractual maturities because borrowers may have the right to call or prepay certain obligations with or without call or prepayment penalties. | Line item | June 30, 2026 / Debt securities, AFS / Cost oramortized cost | June 30, 2026 / Debt securities, AFS / Fair value | June 30, 2026 / Debt securities, trading / Cost oramortized cost | June 30, 2026 / Debt securities, trading / Fair value | December 31, 2025 / Debt securities, AFS / Cost oramortized cost | December 31, 2025 / Debt securities, AFS / Fair value | December 31, 2025 / Debt securities, trading / Cost oramortized cost | December 31, 2025 / Debt securities, trading / Fair value | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Due in one year or less | $262.4 | $261.8 | $3.2 | $3.1 | $202.6 | $203.9 | $4.1 | $3.9 | | Due after one year through five years | 2,192.4 | 2,186.2 | 2.1 | 2.0 | 1,954.5 | 1,974.7 | 2.4 | 2.3 | | Due after five years through ten years | 625.3 | 619.5 | — | — | 713.7 | 723.6 | — | — | | Due after ten years | 30.0 | 30.3 | 14.5 | 1.2 | 149.1 | 150.4 | 14.5 | 1.2 | | Mortgage-backed and asset-backed securities | 2,070.4 | 2,059.1 | 68.8 | 58.5 | 2,098.4 | 2,116.0 | 93.6 | 82.9 | | Total debt securities | $5,180.5 | $5,156.9 | $88.6 | $64.8 | $5,118.3 | $5,168.6 | $114.6 | $90.3 | 21 #### Other long-term investments The cost or amortized cost, gross unrealized investment gains and losses, net foreign currency gains, and fair values of the Company’s other long-term investments as of June 30, 2026 and December 31, 2025 were as follows: | June 30, 2026 | Cost oramortizedcost | Grossunrealizedgains | Grossunrealizedlosses | Net foreigncurrencygains | Fair value | | --- | --- | --- | --- | --- | --- | | Other long-term investments | $399.3 | $36.4 | $(151.8) | $1.9 | $285.8 | | December 31, 2025 | | | | | | | Other long-term investments | $421.9 | $35.1 | $(143.3) | $1.4 | $315.1 | The Company’s other long-term investments may be accounted for under either the equity method (“equity method investments”) or the fair value option (“equity method eligible unconsolidated entities”). The following table presents the components of other long-term investments as of June 30, 2026 and December 31, 2025: | Line item | June 30, 2026 | December 31, 2025 | | --- | --- | --- | | Equity method eligible unconsolidated entities, using the fair value option | $66.2 | $66.3 | | Equity method investments | 44.6 | 33.1 | | Other unconsolidated investments, at fair value (1) | 158.9 | 179.5 | | Other unconsolidated investments, at cost (2) | 16.1 | 36.2 | | Total other long-term investments (3) | $285.8 | $315.1 | (1) Includes other long-term investments that are not equity method eligible and are measured at fair value. (2) The Company has elected to apply the cost adjusted for market observable events impairment measurement alternative to investments that do not meet the criteria to be accounted for under the equity method, in which the investment is measured at cost and remeasured to fair value when impaired or upon observable transaction prices. (3) As of June 30, 2026, the Company had $31.0 million of unfunded commitments relating to these investments (December 31, 2025 - $58.5 million). #### Net investment income Net investment income for the three and six months ended June 30, 2026 and 2025 consisted of the following: | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Debt securities, available for sale | $60.2 | $61.6 | $124.9 | $122.9 | | Debt securities, trading | 0.4 | 1.2 | 2.2 | 4.3 | | Short-term investments | 0.2 | (0.2) | 0.5 | 1.0 | | Other long-term investments | 3.5 | 2.8 | 3.8 | 4.4 | | Cash, cash equivalents and other | 6.0 | 6.5 | 11.3 | 15.8 | | Gross investment income | 70.3 | 71.9 | 142.7 | 148.4 | | Investment expenses | (4.8) | (3.7) | (10.8) | (9.0) | | Net investment income | $65.5 | $68.2 | $131.9 | $139.4 | 22 #### Net investment gains (losses) Net investment gains (losses) for the three and six months ended June 30, 2026 and 2025 consisted of the following: | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Debt securities, available for sale | | | | | | Gross realized gains | $5.2 | $3.0 | $15.2 | $10.1 | | Gross realized losses | (3.4) | (5.4) | (6.4) | (14.5) | | Net realized gains (losses) on Debt securities, available for sale | 1.8 | (2.4) | 8.8 | (4.4) | | Debt securities, trading | | | | | | Net realized gains (losses) | (1.3) | (0.3) | (1.3) | (1.8) | | Net unrealized gains (losses) | 1.4 | 2.0 | (0.2) | 3.8 | | Other long-term investments | | | | | | Net realized gains (losses) | 44.5 | (0.2) | 58.9 | (2.3) | | Net unrealized gains (losses) | (39.4) | 1.1 | (47.8) | 3.7 | | Other (1) | 0.9 | 0.5 | 0.9 | 1.4 | | Total net investment gains (losses) | $7.9 | $0.7 | $19.3 | $0.4 | (1) Includes short-term investments, cash and cash equivalents, and derivatives. ### 8. Derivatives The Company holds derivatives for both risk management and investment purposes. #### Foreign currency exchange rate derivatives The Company executes foreign currency forwards, swaps, and futures to manage foreign currency exposure. The foreign currency exchange rate derivatives are not designated or accounted for under hedge accounting. The fair value of the swaps and forwards are estimated using a single broker quote, and accordingly, are classified as a Level 3 measurement. The fair value of the futures is widely available and have quoted prices in active markets, and accordingly, were classified as a Level 1 measurement. As of June 30, 2026, the Company pledged no securities collateral associated with the foreign currency derivatives (December 31, 2025 - none). Securities pledged as collateral are included in debt securities, available for sale, in the Company’s consolidated balance sheets. #### Weather derivatives The Company holds assets and assumes liabilities related to weather and weather contingent risk management products. Weather and weather contingent derivative contracts are entered into with the objective of generating profits in normal climatic conditions. Accordingly, the Company’s weather and weather contingent derivatives are not designed to meet the criteria for hedge accounting under U.S. GAAP. The Company receives payment of premium at the contract inception in exchange for bearing the risk of variations in a quantifiable weather index. Management uses available market data and internal pricing models based upon consistent statistical methodologies to estimate the fair value. Because of the significance of the unobservable inputs used to estimate the fair value of the Company's weather risk contracts, the fair value measurements of the contracts are deemed to be Level 3 measurements in the fair value hierarchy. The Company does not provide or hold any collateral associated with the weather derivatives. #### Credit default swap Credit default swaps protect the buyer against the loss of principal on one or more underlying bonds, loans, or mortgages in the event the issuer suffers a credit event. The Company uses its credit default swap to provide a client with protection against financial non-performance of a subsidiary. The fair value of the swap is estimated using a single broker quote, and accordingly, is classified as a Level 3 measurement. As of June 30, 2026, the Company has $15.5 million pledged in securities collateral associated with the credit default swap (December 31, 2025 - $15.0 million). Securities pledged as collateral are included in debt securities, available for sale, in the Company’s consolidated balance sheets. 23 The following table summarizes information on the classification and amount of the fair value of derivatives not designated as hedging instruments within the Company's consolidated balance sheets as of June 30, 2026 and December 31, 2025: | Derivatives not designated as hedging instruments | June 30, 2026 / Derivative assetsat fair value(1) | June 30, 2026 / Derivative liabilitiesat fair value(2) | June 30, 2026 / Notional Value | December 31, 2025 / Derivative assetsat fair value(1) | December 31, 2025 / Derivative liabilitiesat fair value(2) | December 31, 2025 / Notional Value | | --- | --- | --- | --- | --- | --- | --- | | Foreign currency forwards | $5.7 | $22.4 | $823.8 | $13.8 | $3.6 | $853.7 | | Interest rate swaps | — | — | 29.8 | — | — | 29.8 | | Credit default swap | 0.5 | — | 73.1 | 0.6 | — | 73.1 | | Reinsurance contracts accounted for as derivatives | — | $6.7 | $90.3 | — | $5.4 | $77.7 | (1) Derivative assets are classified within Other assets in the Company’s consolidated balance sheets. (2) Derivative liabilities are classified within Other liabilities in the Company’s consolidated balance sheets. The following table summarizes information on the classification and net impact on earnings, recognized in the Company’s consolidated statements of income relating to derivatives during the three and six months ended June 30, 2026 and 2025: | Derivatives not designated as hedging instruments | Classification of gains (losses) recognized in earnings | Three months ended / June 30,2026 | Three months ended / June 30,2025 | Six months ended / June 30,2026 | Six months ended / June 30,2025 | | --- | --- | --- | --- | --- | --- | | Foreign currency forwards | Foreign exchange (gains) losses | $(19.5) | $33.4 | $(35.5) | $74.3 | | Weather derivatives | Other revenues | 0.1 | 0.2 | 0.2 | 0.4 | | Interest rate swaps | Net investment gains (losses) | — | (0.3) | — | (0.5) | | Reinsurance contracts accounted for as derivatives | Other revenues | $(0.2) | $(0.1) | $(0.2) | $(0.1) | ### 9. Variable and voting interest entities The Company consolidates the results of operations and financial position of every voting interest entity ("VOE") in which it has a controlling financial interest and variable interest entities (“VIE”) in which it is considered to be the primary beneficiary in accordance with guidance in ASC 810, Consolidation. The consolidation assessment, including the determination as to whether an entity qualifies as a VOE or VIE, depends on the facts and circumstances surrounding each entity. #### Consolidated variable interest entities #### Alstead Re Alstead Reinsurance Ltd. (“Alstead Re”) is considered a VIE and the Company has concluded that it is the primary beneficiary of Alstead Re because the Company can exercise control over the activities that most significantly impact the economic performance of Alstead Re. As a result, the Company has consolidated the results of Alstead Re in its consolidated financial statements. As of June 30, 2026, Alstead Re’s assets and liabilities included in the Company’s consolidated balance sheets were $8.3 million and $2.8 million, respectively (December 31, 2025 - $6.8 million and $0.9 million, respectively). #### Consolidated voting interest entities #### Alta Signa Alta Signa Holdings (“Alta Signa”) is considered a VOE and the Company holds a majority of the voting interests through its seats on Alta Signa’s board of directors. As a result, the Company has consolidated the results of Alta Signa in its consolidated financial statements. The Company’s ownership in Alta Signa as of June 30, 2026 was 75.1%. As of June 30, 2026, Alta Signa’s assets and liabilities, before intercompany eliminations, included in the Company’s consolidated balance sheets were $2.0 million and $1.4 million, respectively (December 31, 2025 - $1.8 million and $1.3 million, respectively). #### Non-consolidated variable interest entities The Company is a passive investor in certain third-party-managed hedge and private equity funds, some of which are VIEs. The Company is not involved in the design or establishment of these VIEs, nor does it actively participate in the management 24 of the VIEs. The exposure to loss from these investments is limited to the carrying value of the investments at the balance sheet date. The Company calculates maximum exposure to loss to be (i) the amount invested in the debt or equity of the VIE, (ii) the notional amount of VIE assets or liabilities where the Company has also provided credit protection to the VIE with the VIE as the referenced obligation, and (iii) other commitments and guarantees to the VIE. The Company does not have any VIEs that it sponsors, nor any VIEs where it has recourse to it or has provided a guarantee to the VIE interest holders. The following table presents the carrying amount of unconsolidated VIEs in which the Company holds a variable interest, as well as the maximum exposure to loss associated with these VIEs as of June 30, 2026 and December 31, 2025: | Line item | June 30, 2026 / Carrying Amount | June 30, 2026 / Maximum Exposure to Loss (1) | December 31, 2025 / Carrying Amount | December 31, 2025 / Maximum Exposure to Loss (1) | | --- | --- | --- | --- | --- | | Debt securities, available for sale | $73.5 | $99.8 | $54.1 | $78.8 | | Other long-term investments (2) | 214.3 | 268.6 | 210.1 | 293.9 | | | $287.8 | $368.4 | $264.2 | $372.7 | (1) Maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments. (2) Includes investments in related parties, which are also VIEs and are discussed below. #### Third Point Enhanced LP As of June 30, 2026, the Company and Third Point Advisors LLC (“TP GP”) hold interests of approximately 89.0% and 11.0%, respectively, of the net asset value of TP Enhanced Fund. As a result, both entities hold significant financial interests in TP Enhanced Fund. However, TP GP controls all of the investment decision-making authority and the Company does not have the power to direct the activities which most significantly impact the economic performance of TP Enhanced Fund. As a result, the Company is not considered the primary beneficiary and does not consolidate TP Enhanced Fund. The Company has no unfunded commitments on this investment, and its maximum exposure to loss on this investment corresponds to the carrying amount, which is included in Other long-term investments in the table above. On February 28, 2025, the Company provided notice to Third Point LLC of its intent to redeem all of its capital accounts for TP Enhanced Fund. The redemptions will occur over time and may be in cash or underlying investments. #### Investment in Third Point Venture Offshore Fund I LP Third Point Venture GP LLC controls all of the investment decision-making authority of the TP Venture Fund. The Company does not have the power to direct the activities which most significantly impact the economic performance of the TP Venture Fund. As of June 30, 2026, the Company’s maximum exposure to loss on this investment corresponds to the carrying amount plus unfunded commitments of $6.6 million (December 31, 2025 - $7.1 million), which is included in Other long-term investments in the table above. #### Investment in Third Point Venture Offshore Fund II LP Third Point Venture GP II LLC controls all of the investment decision-making authority of the TP Venture Fund II. The Company does not have the power to direct the activities which most significantly impact the economic performance of the TP Venture Fund II. As of June 30, 2026, the Company’s maximum exposure to loss on this investment corresponds to the carrying amount plus unfunded commitments of $16.0 million (December 31, 2025 - $18.2 million), which is included in Other long-term investments in the table above. #### Investment in Third Point Insurance Solutions Fund I LLC Third Point GP controls all of the investment decision making authority of Third Point Insurance Solutions Fund I LLC (“TP ISF”). The Company does not have the power to direct the activities which most significantly impact the economic performance of TP ISF. As of June 30, 2026, the Company’s maximum exposure to loss on this investment corresponds to the carrying amount plus unfunded commitments of $13.0 million (December 31, 2025 - $25.0 million), which is included in Other long-term investments in the table above. 25 #### Investment in Third Point Structured Credit Opportunities Offshore Fund LP During three months ended June 30, 2026, the Company transferred a portion of its investment in TP Enhanced Fund into an investment in Third Point Structured Credit Opportunities Offshore Fund LP (“TP SCOF”). Third Point GP controls all of the investment decision making authority of TP SCOF. The Company does not have the power to direct the activities which most significantly impact the economic performance of TP SCOF. As of June 30, 2026, the Company’s maximum exposure to loss on this investment corresponds to the carrying amount, which is included in Other long-term investments in the table above. ### 10. Loss and loss adjustment expense reserves The following table represents the activity in the loss and loss adjustment expense reserves for the three and six months ended June 30, 2026 and 2025: | Line item | June 30,2026 | June 30,2025 | | --- | --- | --- | | Gross reserves for loss and loss adjustment expenses, beginning of period | $5,782.5 | $5,653.9 | | Less: loss and loss adjustment expenses recoverable, beginning of period | (2,102.3) | (2,315.3) | | Less: deferred gains (charges) on retroactive reinsurance contracts (2) | — | 8.5 | | Net reserves for loss and loss adjustment expenses, beginning of period | 3,680.2 | 3,347.1 | | Increase (decrease) in net loss and loss adjustment expenses incurred in respect of losses occurring in: | | | | Current year | 754.0 | 817.3 | | Prior years | (32.9) | (42.9) | | Total incurred loss and loss adjustment expenses | 721.1 | 774.4 | | Net loss and loss adjustment expenses paid in respect of losses occurring in: | | | | Current year | (234.7) | (297.9) | | Prior years | (396.7) | (325.7) | | Total net paid losses | (631.4) | (623.6) | | Foreign currency translation | (11.0) | 55.6 | | Net reserves for loss and loss adjustment expenses, end of period | 3,758.9 | 3,553.5 | | Plus: loss and loss adjustment expenses recoverable, end of period | 1,991.4 | 2,263.9 | | Gross reserves for loss and loss adjustment expenses, end of period | $5,750.3 | $5,817.4 | (1) Deferred gains on retroactive reinsurance were previously presented as a separate line item on the Company’s consolidated balance sheets. As of June 30, 2026 and December 31, 2025, the deferred gain is fully amortized. The Company's prior year reserve development arises from changes to estimates of losses and loss adjustment expenses related to loss events that occurred in previous calendar years. For the six months ended June 30, 2026, the Company recorded $32.9 million of net favorable prior year loss reserve development primarily driven by favorable development in A&H and Credit in Other Specialties, mainly from better than expected loss experience. For the six months ended June 30, 2025, the Company recorded $42.9 million of net favorable prior year loss reserve development primarily resulting from favorable development in Property, mainly from reserve releases relating to prior year’s catastrophe events, as well as favorable development in A&H, due to lower than expected reported attritional losses. #### Loss Portfolio Transfers #### Workers’ Compensation Loss Portfolio Transfer On October 1, 2024, SiriusPoint America Insurance Company (“SiriusPoint America”), a subsidiary of the Company, and Clarendon National Insurance Company (“Clarendon National”), an insurer domiciled in Texas and an affiliate of Enstar Group Limited, a Bermuda exempted company (“Enstar”) entered into a Loss Portfolio Transfer Reinsurance Agreement (the “2024 LPT”), pursuant to which SiriusPoint America cedes and Clarendon National assumes 100% of the net liability with respect to certain worker’s compensation insurance exposures of SiriusPoint America on a funds withheld basis. The transaction price of approximately $400 million covered SiriusPoint loss and unearned premium reserves, including commuted liabilities, and the reinsurance premium as of the December 31, 2023 valuation date. The subject loss reserves are 26 included in Loss and loss adjustment expenses recoverable in the Company’s consolidated balance sheets. The agreement between SiriusPoint America and Clarendon National is on a funds withheld basis, and the funds held liability (including reinsurance premium) of $175.7 million as of June 30, 2026 is included within Reinsurance balances payable in the Company’s consolidated balance sheets. The aggregate limit under the 2024 LPT is 150% of the premium paid. #### SiriusPoint International Loss Portfolio Transfer On March 2, 2023, the Company agreed, subject to applicable regulatory approvals and other closing conditions, to enter into a loss portfolio transfer transaction (the “2023 LPT”), on a funds withheld basis, with Pallas Reinsurance Company Ltd., a subsidiary of the Compre Group, an insurance and reinsurance legacy specialist. The transaction covered loss reserves ceded initially estimated at $1.3 billion as of the valuation date of September 30, 2022, which were reduced to $905.6 million as of June 30, 2023 at closing, as a result of paid losses and favorable prior accident year reserve development recognized during the interim period. As of June 30, 2026, the Company recorded funds held payable of $297.6 million in Reinsurance balances payable and reinsurance recoverable of $305.4 million. The 2023 LPT comprises several classes of business from 2021 and prior underwriting years. The aggregate limit under the 2023 LPT is 130% of roll forward reserves at the inception of the contract. ### 11. Allowance for expected credit losses The Company is exposed to credit losses primarily through sales of its insurance and reinsurance products and services. The financial assets in scope of the current expected credit losses impairment model primarily include the Company’s insurance and reinsurance balances receivable and loss and loss adjustment expenses recoverable. The Company pools these amounts by counterparty credit rating and applies a credit default rate that is determined based on the studies published by the rating agencies (e.g., AM Best, Standard & Poor's, Fitch Ratings, Demotech). In circumstances where ratings are unavailable, the Company applies an internally developed default rate based on historical experience, reference data including research publications, and other relevant inputs. The Company's assets in scope of the current expected credit loss assessment as of June 30, 2026 and December 31, 2025 are as follows: | Line item | June 30,2026 | December 31,2025 | | --- | --- | --- | | Insurance and reinsurance balances receivable, net | $2,606.7 | $2,260.3 | | Loss and loss adjustment expenses recoverable, net | 1,991.4 | 2,102.3 | | Other assets (1) | 80.3 | 75.2 | | Total assets in scope | $4,678.4 | $4,437.8 | (1) Relates to MGA trade receivables (included in Other assets in the Company’s consolidated balance sheets), loans receivables (included in Other long-term investments in the Company’s consolidated balance sheets) and interest and dividend receivables. The Company’s allowance for expected credit losses was $28.4 million as of June 30, 2026 (December 31, 2025 - $27.6 million). For the three and six months ended June 30, 2026, the Company recorded a current expected credit losses of $0.6 million and $1.0 million (2025 - the Company did not record current expected credit losses). Changes to the current expected credit losses are included in net corporate and other expenses in the consolidated statements of income. The Company monitors counterparty credit ratings and macroeconomic conditions, and considers the most current ratings from credit rating agencies to determine the allowance each quarter. As of June 30, 2026, approximately 64% of the total gross assets in scope were balances with counterparties rated by major credit rating agencies and, of the total rated, 97% were rated A- or better. 27 ### 12. Debt and letter of credit facilities #### Debt obligations The following table represents a summary of the Company’s debt obligations on its consolidated balance sheets as of June 30, 2026 and December 31, 2025: | Line item | June 30, 2026 / Amount | June 30, 2026 / Effective rate (1) | December 31, 2025 / Amount | December 31, 2025 / Effective rate (1) | | --- | --- | --- | --- | --- | | 2024 Senior Notes, at face value | $400.0 | 7.4% | $400.0 | 7.4% | | Unamortized discount and issuance costs | (3.4) | | (4.0) | | | 2024 Senior Notes, carrying value | 396.6 | | 396.0 | | | 2017 SEK Subordinated Notes, at face value | 284.1 | 6.2% | 298.2 | 7.1% | | Unamortized discount | (5.2) | | (5.6) | | | 2017 SEK Subordinated Notes, carrying value | 278.9 | | 292.6 | | | Total debt | $675.5 | | $688.6 | | (1) Effective rate considers the effect of the debt issuance costs, discount, and premium. The Company was in compliance with all debt covenants as of and for the periods ended June 30, 2026 and December 31, 2025. #### Interest expense For the three and six months ended June 30, 2026, total interest expense includes $11.8 million and $23.5 million, respectively, associated with debt obligations (2025 - $12.0 million and $23.8 million, respectively) and $5.2 million and $10.9 million, respectively, of funds withheld interest from loss portfolio transfers (2025 - $8.0 million and $16.4 million, respectively). See Note 10 - “Loss and loss adjustment expense reserves” for further discussion on the 2024 LPT and 2023 LPT. #### Standby letter of credit facilities As of June 30, 2026, the Company had entered into the following letter of credit facilities: | Line item | Letters of Credit / Committed Capacity | Letters of Credit / Issued | Collateral / Cash and Cash Equivalents | Collateral / Debt securities | | --- | --- | --- | --- | --- | | Committed - Secured letters of credit facilities | $330.0 | $219.6 | $3.2 | $131.6 | | Uncommitted - Secured letters of credit facilities | n/a | 590.4 | 36.3 | 708.3 | | | $330.0 | $810.0 | $39.5 | $839.9 | The Company’s secured letter of credit facilities are bilateral agreements that generally renew on an annual basis. The letters of credit issued under the secured letter of credit facilities are fully collateralized. The above referenced facilities are subject to various affirmative, negative and financial covenants that the Company considers to be customary for such borrowings, including certain minimum net worth and maximum debt to capitalization standards. See Note 5 for additional information. #### Revolving credit facility In addition to the letter of credit facilities above, the Company entered into a four-year, $400.0 million senior unsecured revolving credit facility (the “Facility”) with JPMorgan Chase Bank, N.A. as administrative agent, effective December 19, 2024. The Facility includes an option for the Company to request a 12-month extension, subject to satisfaction of certain conditions including, but not limited to, the consent of lenders representing a majority-in-interest of commitments, of the Facility maturity date. Subject to customary conditions precedent upon any Company borrowing request, the Facility provides access to loans for working capital and general corporate purposes, and letters of credit to support obligations under insurance and reinsurance agreements, retrocessional agreements and for general corporate purposes. As of June 30, 2026, there were no outstanding borrowings under the Facility. In addition, as of and for the periods ended June 30, 2026 and December 31, 2025, the Company was in compliance with all of the covenants under the Facility. 28 #### Federal Home Loan Bank On September 25, 2025, SiriusPoint America, a subsidiary of the Company, was approved as a new member to the Federal Home Loan Bank of New York (“FHLBNY”). As a member of the FHLBNY, the Company will have access to FHLBNY borrowings to support general corporate purposes. The Company has the ability to obtain this funding from the FHLBNY based on a percentage of the value of its admitted assets in the State of New York, and its ability to borrow is subject to availability of eligible collateral. The borrowing limit for this program is 5% of the admitted assets of SiriusPoint America. As of March 31, 2026, SiriusPoint America’s admitted assets were $3.4 billion. The Company did not receive advances or make repayments of FHLBNY borrowings during the three and six months ended June 30, 2026. There were no advances from the FHLBNY outstanding at June 30, 2026. ### 13. Income taxes The Company has subsidiaries and branches that operate in various other jurisdictions around the world that are subject to tax in the jurisdictions in which they operate. The jurisdictions in which the Company's subsidiaries and branches are subject to tax are Belgium, Bermuda, Canada, Luxembourg, Sweden, Switzerland, the United Kingdom, and the United States. The Company recognizes income tax expense or benefit based upon pre-tax income or loss reported in the consolidated statements of income and the provisions of currently enacted tax laws. Effective January 1, 2025, a 15% corporate income tax is applied to the Company’s Bermuda operations as a result of the enactment of the Corporate Income Tax Act 2023 (the “Bermuda CIT”) on December 27, 2023. For the three and six months ended June 30, 2026, the Company recorded income tax expense of $15.8 million and $35.0 million, respectively (2025 - $11.6 million and $24.9 million, respectively) on pre-tax income of $84.3 million and $205.8 million, respectively (2025 - $74.9 million and $150.2 million, respectively). The effective tax rates for the three and six months ended June 30, 2026 were 18.7% and 17.0%, respectively. The difference between the effective tax rate on income from continuing operations and the Bermuda statutory tax rate of 15% is primarily due to income recognized in higher-tax jurisdictions, non-taxable investment gains, and adjustments pursuant to applicable U.S. GAAP guidance on interim period financial reporting of taxes, which are based on the annual estimated effective tax rate. In arriving at the estimated annual effective tax rate for the three and six months ended June 30, 2026 and 2025, the Company took into consideration all year-to-date income and expense items including the change in unrealized investment gains (losses) and realized investment gains (losses) and such items on a forecasted basis for the remainder of each year. The Organisation for Economic Co-Operation and Development (“OECD”) has published global anti-base erosion model rules under Pillar Two (the “GloBE Rules”), which implement a 15% global minimum tax applicable for in-scope multinational groups (“GMT”). Since January 1, 2024, the GloBE Rules have been in effect in the EU and other jurisdictions, including a minimum top-up tax rate of 15% for multinational companies, with many E.U. member states enacting corollary legislation as part of their respective domestic tax laws. Consistent with accounting guidance, the Company will treat the GMT as an in-period tax charge when incurred for which no deferred taxes need to be provided. The Company has recorded top-up tax of $0.7 million for the period ended June 30, 2026, based on its current estimation of 2026 GMT applied to the Company’s facts and financial data. The Company will continue to reassess and re-estimate 2026 GMT. #### Uncertain tax positions Recognition of the benefit of a given tax position is based upon whether a company determines that it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. In evaluating the more likely than not recognition threshold, the Company must presume that the tax position will be subject to examination by a taxing authority with full knowledge of all relevant information. If the recognition threshold is met, then the tax position is measured at the largest amount of benefit that is more than 50% likely of being realized upon ultimate settlement. The total reserve for unrecognized tax benefits is $0.2 million as of June 30, 2026, which did not materially change compared to December 31, 2025. If the Company determines in the future that its reserves for unrecognized tax benefits on permanent differences and interest and penalties are not needed, the reversal of $0.1 million of such reserves as of June 30, 2026 would be recorded as an income tax benefit and would impact the effective tax rate. The remaining balance is accrued interest and penalties. 29 ### 14. Shareholders' equity #### Common shares The following table presents a summary of the common shares issued and outstanding and shares repurchased as of and for the six months ended June 30, 2026 and 2025: | Line item | 2026 | 2025 | | --- | --- | --- | | Common shares issued and outstanding, beginning of period | 116,989,799 | 116,429,057 | | Issuance of common shares, net of forfeitures and shares withheld | 2,366,464 | 730,482 | | Issuance of common shares upon exercise of options | — | 100,000 | | Shares repurchased (1) | (3,290,298) | (500,000) | | Common shares issued and outstanding, end of period | 116,065,965 | 116,759,539 | The Company’s authorized share capital consists of 300,000,000 common shares with a par value of $0.10 each. During the six months ended June 30, 2026 and 2025, the Company did not pay any dividends to its common shareholders. #### Preference shares The Company’s authorized share capital also consists of 30,000,000 preference shares with a par value of $0.10 each. #### Series B preference shares On January 29, 2026, the Company announced a notice of redemption to the holders of its Series B preference shares. The Series B preference shares were previously listed on the New York Stock Exchange under the symbol “SPNT PB” and the Company had 8,000,000 of Series B preference shares outstanding, par value $0.10. Dividends on the Series B preference shares were cumulative and payable quarterly in arrears at an initial rate of 8.0% per annum. On February 26, 2026, the Company fully redeemed its 8,000,000 Series B preference shares at a redemption price of $25.00 per share plus $0.49 per share, which represented any accrued and unpaid cumulative dividends but excluding the date of redemption, for an aggregated redemption price of $203.9 million in cash, including dividends of $2.6 million for the three and six months ended June 30, 2026 (2025 - $4.0 million and $8.0 million, respectively). Following the redemption, no Series B preference shares are outstanding and all rights with respect to such Series B preference shares have ceased and terminated, except for the right to receive the redemption price. The Series B preference shares were deregistered under the Securities Exchange Act of 1934 and delisted from the New York Stock Exchange on February 26, 2026. #### Share repurchase program Under the Board authorized share repurchase programs, the Company may repurchase its common stock from time to time, in amounts, at prices and at times the Company deems appropriate in its sole discretion, subject to market conditions and a variety of factors, including, but not limited to, legal requirements, price and economic conditions. Shares of common stock may be repurchased in open market purchases, privately negotiated transactions or otherwise. The Company expects that the program will be in effect until the maximum approved dollar amount has been used. The program does not require the Company to repurchase any specific number of shares of common stock, and the program may be suspended, modified or discontinued at any time. As of June 30, 2026, the Company was authorized to repurchase a maximum value of approximately $101.1 million of outstanding common shares under its repurchase program. The share repurchase program does not have an expiration date. During the three months ended June 30, 2026, the Company repurchased 2,237,688 of its common shares in the open market for a total cost of $51.5 million, at an average cost of $23.00 per share, including commissions of $0.03 per share. During the six months ended June 30, 2026, the Company repurchased 3,290,298 of its common shares in the open market for a total cost of $73.3 million, at an average cost of $22.29 per share, including commissions of $0.03 per share. Common shares repurchased by the Company during the period were cancelled and retired. During the six months ended June 30, 2025, the Company completed a previously announced transaction with CM Bermuda and repurchased 45,720,732 of its common shares from CM Bermuda at $14.25 per common share on February 27, 2025. This share repurchase was accounted for during the year ended December 31, 2024 in accordance with U.S. GAAP. For further detail on this transaction, please refer to Note 3 “Significant Transactions” of Part II, Item 8. “Financial Statements and Supplementary Data” included in our 2025 Form 10-K. Also on February 27, 2025, the Company repurchased 500,000 of its common shares from Daniel S. Loeb at the public offering price of $14.00 per share. 30 ### 15. Earnings per share available to SiriusPoint common shareholders The following sets forth the computation of basic and diluted earnings per share available to SiriusPoint common shareholders for the three and six months ended June 30, 2026 and 2025: | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Weighted-average number of common shares outstanding: | | | | | | Basic number of common shares outstanding | 116,732,354 | 116,523,435 | 116,728,906 | 116,252,739 | | Dilutive effect of restricted share awards and units | 932,651 | 893,262 | 2,195,990 | 1,169,673 | | Dilutive effect of options | 1,346,726 | 1,252,774 | 1,312,846 | 1,176,123 | | Diluted number of common shares outstanding | 119,011,731 | 118,669,471 | 120,237,742 | 118,598,535 | | Basic earnings per common share: | | | | | | Net income available to SiriusPoint common shareholders | $68.6 | $59.2 | $168.2 | $116.8 | | Net income allocated to SiriusPoint participating shareholders | — | (0.1) | (0.1) | (0.1) | | Net income allocated to SiriusPoint common shareholders | $68.6 | $59.1 | $168.1 | $116.7 | | Basic earnings per share available to SiriusPoint common shareholders | $0.59 | $0.51 | $1.44 | $1.00 | | Diluted earnings per common share: | | | | | | Net income available to SiriusPoint common shareholders | $68.6 | $59.2 | $168.2 | $116.8 | | Net income allocated to SiriusPoint participating shareholders | — | (0.1) | (0.1) | (0.1) | | Net income allocated to SiriusPoint common shareholders | $68.6 | $59.1 | $168.1 | $116.7 | | Diluted earnings per share available to SiriusPoint common shareholders | $0.58 | $0.50 | $1.40 | $0.98 | For the three and six months ended June 30, 2026, anti-dilutive restricted share units of 3,370 and 410,988, respectively, were excluded from the computation of diluted earnings per share attributable to SiriusPoint common shareholders. For the three and six months ended June 30, 2025, anti-dilutive restricted share units of 48,727 and 26,933, respectively, were excluded from the computation of diluted earnings per share attributable to SiriusPoint common shareholders. ### 16. Related party transactions In addition to the transactions disclosed in Notes 3, 9, and 14 to these consolidated financial statements, the following transactions are classified as related party transactions, as the counterparties have either a direct or indirect shareholding in the Company or the Company has an investment in such counterparty. #### (Re)insurance contracts During the three and six months ended June 30, 2026, insurance and reinsurance contracts with certain of the Company’s insurance and MGA related parties resulted in gross written premium of $33.6 million and $56.4 million, respectively (2025 - $4.9 million and $11.4 million, respectively). As of June 30, 2026, the Company had total receivables of $92.1 million and payables of $1.7 million, respectively, from these related parties (December 31, 2025 - receivables of $86.4 million and no payables). 31 #### Investments managed by related parties The following table provides the fair value of the Company's investments managed by related parties as of June 30, 2026 and December 31, 2025: | Line item | June 30,2026 | December 31,2025 | | --- | --- | --- | | Third Point Enhanced LP (1) | $49.3 | $82.2 | | Third Point Insurance Solutions Fund I LLC (1) | 3.4 | 1.6 | | Third Point Structured Credit Opportunities Fund (1) | 36.1 | — | | Third Point Venture Offshore Fund I LP (1) | 33.1 | 27.7 | | Third Point Venture Offshore Fund II LP (1) | 9.0 | 6.3 | | Third Point Optimized Credit Portfolio (2) | 193.4 | 652.8 | | Total investments managed by related parties | $324.3 | $770.6 | (1) The Third Point Enhanced LP, Third Point Insurance Solutions Fund I LLC, Third Point Structured Credit Opportunities Fund, Third Point Venture Offshore Fund I LP, and Third Point Venture Offshore Fund II LP are reported in Other long-term investments in the consolidated balance sheets. (2) The Third Point Optimized Credit Portfolio is primarily reported in Debt securities, available for sale and trading, in the consolidated balance sheets. On February 28, 2025, the Company provided notice to Third Point LLC of its intent to redeem all of its capital accounts for TP Enhanced Fund. The redemptions will occur over time and may be in cash or underlying investments. On September 23, 2025, the Company notified Third Point LLC of its intent to withdraw investments from the Third Point Optimized Credit Portfolio. The liquidation and withdrawal of the investments is proceeding in an orderly manner, pursuant to the existing investment management agreement and consistent with the parties' discussions. #### Management, advisory and performance fees to related parties The total management, advisory and performance fees to related parties for the three and six months ended June 30, 2026 and 2025 were as follows: | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Management and advisory fees | $0.4 | $1.3 | $1.6 | $2.4 | | Performance fees | — | (0.2) | — | (0.4) | | Total management, advisory and performance fees to related parties (1) | $0.4 | $1.1 | $1.6 | $2.0 | (1) Management, advisory and performance fees to related parties, where applicable, are presented within Net investment gains (losses) in the consolidated statements of income. ### 17. Commitments and contingencies #### Litigation From time to time in the normal course of business, the Company may be involved in formal and informal dispute resolution processes, which may include arbitration or litigation, the outcomes of which determine the rights and obligations under the Company’s insurance and reinsurance contracts and other contractual agreements. In some disputes, the Company may seek to enforce its rights under an agreement or to collect funds owed to it. In other matters, the Company may resist attempts by others to collect funds or enforce alleged rights. The Company may also be involved, from time to time in the normal course of business, in formal and informal dispute resolution processes that do not arise from, or are not directly related to, claims activity. The Company believes that no individual litigation or arbitration to which it is presently a party is likely to have a material adverse effect on its results of operations, financial condition, business or operations. #### Leases The Company operates globally and leases office space under various non-cancelable operating lease agreements. During the three and six months ended June 30, 2026, the Company recognized operating lease expense of $2.2 million and $4.7 million, respectively (2025 - $2.6 million and $4.5 million, respectively), including property taxes and routine maintenance expense, as well as rental expenses related to short-term leases. 32 The following table presents the lease balances within the consolidated balance sheets as of June 30, 2026 and December 31, 2025: | Line item | June 30,2026 | December 31,2025 | | --- | --- | --- | | Operating lease right-of-use assets (1) | $22.3 | $20.7 | | Operating lease liabilities (2) | $25.4 | $24.6 | | Weighted average lease term (years) | 4.4 | 4.6 | | Weighted average discount rate | 2.9% | 3.2% | (1) Operating lease right-of-use assets are included in Other assets on the Company’s consolidated balance sheets. (2) Operating lease liabilities are included in Other liabilities on the Company’s consolidated balance sheets. Future minimum rental commitments as of June 30, 2026 under these leases are expected to be as follows: | Line item | Future Payments | Future Payments | | --- | --- | --- | | Remainder of 2026 | $ | $3.5 | | 2027 | 6.3 | | | 2028 | 6.5 | | | 2029 | 5.4 | | | 2030 and thereafter | 4.7 | | | Total future annual minimum rental payments | 26.4 | | | Less: present value discount | (1.0) | | | Total lease liability as of June 30, 2026 | $ | $25.4 | 33 ## ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. You should read this discussion in conjunction with our unaudited consolidated financial statements and the related notes contained elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) and the information under "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”). The terms “we,” “our,” “us” and the “Company,” as used in this report, refer to SiriusPoint Ltd. (“SiriusPoint”) and its directly and indirectly owned subsidiaries as a combined entity, except where otherwise stated or where it is clear that the terms mean only SiriusPoint exclusive of its subsidiaries. The statements in this discussion regarding business outlook, our expectations regarding our future performance, liquidity and capital resources and other non-historical statements in this discussion are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described in “Risk Factors” of our 2025 Form 10-K and in “Cautionary Note Regarding Forward-Looking Statements” below. Our actual results may differ materially from those contained in or implied by any forward-looking statements. ### Cautionary Note Regarding Forward-Looking Statements Certain statements contained or incorporated in this Form 10-Q may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, without limitation, statements regarding prospects for our industry, our business strategy, plans, goals, and expectations concerning our market position, international expansion, investment portfolio expectations, future operations, margins, profitability, efficiencies, capital expenditures, liquidity and capital resources and other non-historical financial and operating information. When used in this discussion, the words “believes,” “intends,” “seeks,” “anticipates,” “aims,” “plans,” “targets,” “estimates,” “expects,” “assumes,” “continues,” “should,” “could,” “will,” “may” and the negative of these or similar terms and phrases are intended to identify forward-looking statements. Forward-looking statements reflect our current expectations regarding future events, results, or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results, and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties, and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the following: - the frequency, severity, and development of insured losses, including natural catastrophes, extreme weather events, epidemics, pandemics, man-made events, and other large loss occurrences across many classes of insurance business, along with the amount of insurance losses that may ultimately be ceded to the reinsurance market, supply chain issues, labor shortages and related increased costs; - the adequacy, accuracy and development of pricing or loss and loss adjustment expense reserves, the lack of available capital, and periods characterized by excess underwriting capacity and unfavorable premium rates; - our ability to maintain or improve underwriting discipline, risk selection, and portfolio diversification across lines and geographies; - the cyclicality of the insurance and reinsurance markets, including changes in pricing, terms, conditions, and capacity; - risks relating to our use of reinsurance, retrocessions, alternative capital and third party capital arrangements, including the availability and cost of such protections and the creditworthiness of counterparties; - our ability to compete successfully in the insurance and reinsurance market and the effect of consolidation in the insurance and reinsurance industry; - operational, cybersecurity, and technology-related risks, including system failures, data breaches, ransomware attacks, supply chain compromises of third party service providers, or other business interruption events, including those resulting from a malicious cyber-attack on us or our business partners or service providers; - the effects of global climate change, including increased severity and frequency of weather-related natural disasters and catastrophes, including wildfires, heat waves, and increased coastal flooding in many geographic areas; - geopolitical uncertainty, including the ongoing conflicts in Europe, South America, and the Middle East; - risks related to inflation, social information, and shifts in judicial, legislative, or regulatory environments; 34 - our ability to attract, develop, and retain key personnel, distribution partners, and underwriting talent; - a downgrade or withdrawal of our financial ratings; - fluctuations in our results of operations; - the performance of strategic partnerships, joint ventures, delegated underwriting authorities, and other third party relationships, including risks associated with delegating authority to third party managing general agents (“MGAs”); - legal restrictions on certain of SiriusPoint’s insurance and reinsurance subsidiaries’ ability to pay dividends and other distributions to SiriusPoint; - the outcome of legal and regulatory proceedings; - regulatory, legal, and compliance developments affecting our insurance, reinsurance, MGAs, Lloyd’s or international operations, including capital, solvency, reporting, conduct risk, and data protection requirements; - reduced returns or losses in SiriusPoint’s investment portfolio, including the impact of market volatility, credit events, interest rate movements, inflation, foreign exchange fluctuations, and changes in asset valuations; - our exposure or potential exposure to corporate income tax in Bermuda and the EU, U.S. federal income and withholding taxes and our significant deferred tax assets, which could become devalued if we do not generate future taxable income or applicable corporate tax rates are reduced; - future strategic transactions such as acquisitions, dispositions, investments, mergers, or joint ventures; - SiriusPoint’s response to any acquisition proposal that may be received from any party, including any actions that may be considered by the Company’s Board of Directors or any committee thereof; and - other risks and factors listed under “Risk Factors” in our 2025 Form 10-K and other subsequent periodic reports filed with the Securities and Exchange Commission. Any one of these factors or a combination of these factors could materially affect our financial condition or future results of operations and could influence whether any forward-looking statements contained in this report ultimately prove to be accurate. Our forward-looking statements are not guarantees of future performance, and you should not place undue reliance on them. All forward-looking statements speak only as of the date made and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. ### Overview We are a global underwriter of insurance and reinsurance, domiciled in Bermuda. We have licenses to write property, casualty and accident & health insurance and reinsurance globally, including admitted & non-admitted licensed companies in the United States, a Bermuda Class 4 company, a Lloyd’s of London (“Lloyd’s”) syndicate and managing agency, and an internationally licensed company domiciled in Sweden. Our operating companies have a financial strength rating of A (Positive) from AM Best, Fitch Ratings (“Fitch”), and Standard & Poor's (“S&P”) and A3 (Stable) from Moody’s Ratings (“Moody’s”). We aim to drive excellence as a best-in-class underwriter, with a diverse and low-volatility portfolio of specialty lines. We seek to apply our underwriting talent, capabilities, and management expertise to underwrite a profitable book of business and identify new opportunities to create value. Our approach is to be nimble and attuned to market opportunities within our segments of Insurance & Services and Reinsurance, allocating capital where we see profitable opportunity, while remaining disciplined and focused on our specified risk tolerances and areas of expertise. Distribution relationships are particularly important to us. A majority of our premium is produced via MGAs, including both our consolidated MGAs and non-consolidated MGAs. We seek to create capacity partnerships with MGAs that have high integrity and transparent leaders, and teams with deep underwriting expertise and track records of success, and no longer take capital positions in those business partners. Our partnerships are focused on underwriting in concentrated, niche businesses that often offer new exposure to our portfolio, while we provide guidance and oversight. As of June 30, 2026, we had equity stakes in 16 entities (MGAs, Insurtech and Other) which underwrite or distribute a wide range of lines of business, including general liability, professional liability, directors & officers, credit and bond, cyber, commercial automobile, workers’ compensation, accident & health, and other specialty insurance classes. 35 ### Products & Services Insurance & Services Segment In our Insurance & Services segment, we predominantly provide insurance coverage in addition to receiving fees for services provided within Insurance & Services and to third parties. Insurance & Services revenue allows us to diversify our traditional reinsurance portfolio and generally has lower capital requirements. In addition, service fees from MGAs and their insurance provided are generally not as prone to the volatile underwriting cycle that is common in reinsurance marketplace. The Insurance & Services segment provides coverage in Accident & Health (“A&H”), Property & Casualty, and Other Specialties. Reinsurance Segment In our Reinsurance segment, we provide reinsurance products to insurance and reinsurance companies, government entities, and other risk bearing vehicles. We participate in the reinsurance market with a global focus through the broker market distribution channel. We primarily write treaty reinsurance, on both a proportional and excess of loss basis, and provide facultative reinsurance in some of our business lines. In the United States and Bermuda, our core focus is on distribution, risk and clients located in North America while our international operation is focused primarily on distribution, risks and clients located in Europe. The Reinsurance segment predominantly underwrites Casualty, Property and Other Specialties lines of business. ### Investment Management We manage our investment portfolio to balance quality, liquidity, and diversification with asset/liability matching and investment return. Our investment objective is to optimize risk-adjusted net investment income after tax while (1) maintaining a high quality, diversified investment portfolio, (2) maintaining adequate liquidity, and (3) complying with the regulatory, rating agency, and internal risk and capital management requirements, all in support of the company goal of meeting policyholder obligations. ### Recent Developments ### Acquisition of Assist America On December 31, 2025, we, through our wholly owned subsidiaries, entered into an agreement to acquire Assist America Inc. and its affiliates (“Assist America”) for $44.0 million in cash and other contingent considerations. Pursuant to the agreement, we consolidated Assist America as of January 1, 2026 and recognized goodwill of $18.6 million in our Insurance & Services segment. Assist America provides reliable global emergency assistance to over 40 million members across Asia, the Middle East, and North America. The acquisition bolsters our third-party medical and travel assistance revenue, increases our scale in the U.S., and expands our coverage to Asia and the Middle East. ### Acquisition of World Nomads On February 12, 2026, we, through our subsidiary, Sirius International UK Holdings II Ltd (“SIUK II”), entered into a purchase agreement with nib Travel Pty Ltd., an Australian proprietary limited company (“nib”), in which SIUK II or its subsidiaries will purchase equity interests and assets comprising the World Nomads travel insurance business currently operated by nib (collectively, “World Nomads”). An initial closing on the majority of the World Nomads business is expected to occur in the second half of 2026, and a final closing is expected to occur in the second half of 2027, subject to the satisfaction of other customary closing conditions. ### Ratings On February 25, 2026, Fitch upgraded the financial strength rating of our operating subsidiaries to ‘A’ (Strong) from ‘A-’, followed by AM Best’s upgrade to ‘A’ (Excellent) from ‘A-’ on April 16, 2026 and S&P’s upgrade to ‘A’ (Strong) from ‘A-’ on April 21, 2026. ### Redemption of Series B Preference Shares On February 26, 2026, we redeemed all 8,000,000 of our issued and outstanding 8.0% Series B preference shares for a redemption price of $25.00 per share, plus $0.49, which reflects unpaid, accrued cumulative dividends, to, but excluding, 36 February 26, 2026, for an aggregate redemption price of $203.9 million. We delisted the Series B preference shares from the New York Stock Exchange and deregistered the Series B preference shares under the Securities Exchange Act of 1934. The redemption helps simplify and optimize our capital structure and financial leverage, while also eliminating the cost of capital and related cash servicing associated with the Series B preference shares. ### Key Performance Indicators We believe that the following key financial indicators are the most important in evaluating our performance for the three and six months ended June 30, 2026 and 2025, and as of June 30, 2026 and December 31, 2025: _($ in millions, except for ratios)_ | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Combined ratio | 88.5% | 86.1% | 88.2% | 88.8% | | Core combined ratio ⁽¹⁾ | 91.4% | 89.5% | 90.1% | 92.4% | | Core underwriting income ⁽¹⁾ | $55.0 | $67.6 | $125.9 | $96.1 | | Core net services income ⁽¹⁾ | $9.9 | $8.7 | $18.3 | $27.6 | | Annualized return on average common shareholders’ equity attributable to SiriusPoint common shareholders | 12.0% | 12.7% | 14.8% | 12.8% | | Line item | June 30,2026 | December 31,2025 | | --- | --- | --- | | Book value per common share | $19.61 | $19.40 | | Book value per diluted common share | $19.30 | $18.61 | | Tangible book value per diluted common share ⁽¹⁾ | $17.98 | $17.62 | (1) Core underwriting income, Core net services income, Core income, and Core combined ratio are non-GAAP financial measures. See definitions in “Non-GAAP Financial Measures” and reconciliations in “Segment Results” below and Note 4 “Segment reporting” in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. Tangible book value per diluted common share is a non-GAAP financial measure. See definition and reconciliation in “Non-GAAP Financial Measures.” ### Core Results See “Segment Results” below for additional information. ### Annualized Return on Average Common Shareholders’ Equity Attributable to SiriusPoint Common Shareholders Annualized return on average common shareholders’ equity attributable to SiriusPoint common shareholders is calculated by dividing annualized net income available to SiriusPoint common shareholders for the period by the average common shareholders’ equity determined using the common shareholders’ equity balances at the beginning and end of the period. Annualized return on average common shareholders’ equity attributable to SiriusPoint common shareholders for the three and six months ended June 30, 2026 and 2025 was calculated as follows: _($ in millions)_ | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Net income available to SiriusPoint common shareholders | $68.6 | $59.2 | $168.2 | $116.8 | | Common shareholders’ equity attributable to SiriusPoint common shareholders - beginning of period | 2,302.4 | 1,825.2 | 2,269.8 | 1,737.4 | | Common shareholders’ equity attributable to SiriusPoint common shareholders - end of period | 2,275.9 | 1,905.7 | 2,275.9 | 1,905.7 | | Average common shareholders’ equity attributable to SiriusPoint common shareholders | $2,289.2 | $1,865.5 | $2,272.9 | $1,821.6 | | Annualized return on average common shareholders’ equity attributable to SiriusPoint common shareholders | 12.0% | 12.7% | 14.8% | 12.8% | The decrease in annualized return on average common shareholders’ equity attributable to SiriusPoint common shareholders for the three months ended June 30, 2026 was primarily driven by increased common shareholders’ equity compared to the prior period reflecting continuous positive underwriting and investment results. 37 The increase in annualized return on average common shareholders’ equity attributable to SiriusPoint common shareholders for the six months ended June 30, 2026 was driven by higher net income, primarily resulting from the gain on the sale of Arcadian Risk Capital Ltd. (“Arcadian”) in the first quarter of 2026, as well as a reduced impact from foreign exchange compared to the prior period, partially offset by increased common shareholders’ equity compared to the prior period, reflecting continuous positive underwriting and investment results. ### Book Value Per Share Book value per common share is calculated by dividing common shareholders’ equity attributable to SiriusPoint common shareholders by the number of common shares outstanding. Book value per diluted common share is calculated by dividing common shareholders’ equity attributable to SiriusPoint common shareholders by the number of diluted common shares outstanding, calculated similar to the treasury stock method. Tangible book value per diluted common share is a non-GAAP financial measure and the most comparable U.S. GAAP measure is book value per common share. See “Non-GAAP Financial Measures” for an explanation and reconciliation. As of June 30, 2026, book value per common share was $19.61, representing a decrease of $0.25 per share, or 1.3%, from $19.86 per share as of March 31, 2026. As of June 30, 2026, book value per diluted common share was $19.30, representing an increase of $0.27 per share, or 1.4%, from $19.03 per share as of March 31, 2026. As of June 30, 2026, tangible book value per diluted common share was $17.98, representing an increase of $0.26 per share, or 1.5%, from $17.72 per share as of March 31, 2026. As of June 30, 2026, book value per common share was $19.61, representing an increase of $0.21 per share, or 1.1%, from $19.40 per share as of December 31, 2025. As of June 30, 2026, book value per diluted common share was $19.30, representing an increase of $0.69 per share, or 3.7%, from $18.61 per share as of December 31, 2025. As of June 30, 2026, tangible book value per diluted common share was $17.98, representing an increase of $0.36 per share, or 2.0%, from $17.62 per share as of December 31, 2025. The increases reflect the continued positive underwriting and investment results during the three and six months ended June 30, 2026. ### Consolidated Results of Operations—Three and six months ended June 30, 2026 and 2025 The following table sets forth the key items discussed in the consolidated results of operations section, and the period over period change, for the three and six months ended June 30, 2026 and 2025: _($ in millions)_ | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Three months ended / Change | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | Six months ended / Change | | --- | --- | --- | --- | --- | --- | --- | | Total underwriting income | $73.5 | $90.2 | $(16.7) | $151.2 | $144.3 | $6.9 | | Net investment income | 65.5 | 68.2 | (2.7) | 131.9 | 139.4 | (7.5) | | Net investment gains (losses) | 7.9 | 0.7 | 7.2 | 19.3 | 0.4 | 18.9 | | Other revenues | 30.4 | 27.3 | 3.1 | 88.3 | 57.0 | 31.3 | | Net corporate and other expenses | (73.7) | (70.9) | (2.8) | (144.9) | (131.5) | (13.4) | | Intangible asset amortization | (2.4) | (2.8) | 0.4 | (5.0) | (5.7) | 0.7 | | Interest expense | (18.7) | (21.1) | 2.4 | (35.5) | (39.2) | 3.7 | | Foreign exchange gains (losses) | 1.8 | (16.7) | 18.5 | 0.5 | (14.5) | 15.0 | | Income tax expense | (15.8) | (11.6) | (4.2) | (35.0) | (24.9) | (10.1) | | Net income | $68.5 | $63.3 | $5.2 | $170.8 | $125.3 | $45.5 | The key changes in our consolidated results for the three and six months ended June 30, 2026 compared to the prior year periods are discussed below. ### Underwriting results The decrease in net underwriting results for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 was primarily a result of earned premium growing at a slower pace than written due to a shift in our business mix, 38 and higher acquisition costs, partially offset by a lower attritional loss ratio and increased favorable prior year loss reserve development. The improvement in net underwriting results for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 was primarily driven by a decrease in catastrophe losses as the prior period included losses from the California wildfires, partially offset by higher expenses. Increased acquisition costs primarily resulted from profit commission accruals related to favorable loss experience and increased other underwriting expense is largely driven by expenses related to incentive compensation award outperformance. ### Investments Investment Portfolio The following table presents the carrying value of our total investments, cash and cash equivalents and restricted cash and cash equivalents as of June 30, 2026 and December 31, 2025: _($ in millions)_ | Line item | June 30,2026 | December 31, 2025 | | --- | --- | --- | | Debt securities, available for sale | $5,156.9 | $5,168.6 | | Debt securities, trading | 64.8 | 90.3 | | Total debt securities (1) | 5,221.7 | 5,258.9 | | Short-term investments | 7.5 | 28.3 | | Other long-term investments (2) | 285.8 | 315.1 | | Total investments | 5,515.0 | 5,602.3 | | Cash and cash equivalents | 614.8 | 731.2 | | Restricted cash and cash equivalents (3) | 131.1 | 171.2 | | Total invested assets and cash | $6,260.9 | $6,504.7 | (1) Includes $193.4 million of investments in the Third Point Optimized Credit portfolio (“TPOC Portfolio”) as of June 30, 2026 (December 31, 2025 - $652.8 million). (2) Includes $62.5 million of strategic investments as of June 30, 2026 (December 31, 2025 - $102.2 million). (3) Primarily consists of cash and fixed income securities such as U.S. Treasuries, money markets funds, and sovereign debt, securing our contractual obligations under certain (re)insurance contracts that we will not be released from until the underlying risks have expired or have been settled. The decrease in total invested assets and cash was primarily driven by the use of cash and investments to fund the redemption of the Series B preference shares of $203.9 million and the common share repurchases of $73.3 million. The duration of our fixed income portfolio, excluding cash and cash equivalents, is 3.1 years (December 31, 2025 - 3.2 years). The duration remained consistent from the comparative period due to our efforts to match our asset duration with economic liabilities in the current interest rate environment. The average credit rating of our investment portfolio is “AA-” as of June 30, 2026 (December 31, 2025 - “AA-”) with no defaults in the investment portfolio. The following table provides a breakdown of structured products between investment and non-investment grade securities as of June 30, 2026 and December 31, 2025. These are fixed income investments which are included in debt securities in the 39 table above. Refer to Note 7 “Investments” to our unaudited consolidated financial statements included elsewhere in this Form 10-Q for further discussion of these securities. _($ in millions)_ | Line item | June 30, 2026 / Investment Grade (1) | June 30, 2026 / Non-investment Grade (2) | December 31, 2025 / Investment Grade (1) | December 31, 2025 / Non-investment Grade (2) | | --- | --- | --- | --- | --- | | Asset-backed securities | $469.1 | $34.9 | $583.5 | $18.9 | | Collateralized loan obligations | 344.0 | — | 324.6 | — | | Total asset-backed securities | 813.1 | 34.9 | 908.1 | 18.9 | | Agency residential mortgage-backed securities | 759.1 | — | 799.2 | — | | Non-agency residential mortgage-backed securities | 208.9 | 19.0 | 186.7 | 22.2 | | Total residential mortgage-backed securities | 968.0 | 19.0 | 985.9 | 22.2 | | Agency commercial mortgage-backed securities | 47.1 | — | 48.1 | — | | Non-agency commercial mortgage-backed securities | 235.3 | 0.1 | 215.2 | 0.5 | | Total commercial mortgage-backed securities | 282.4 | 0.1 | 263.3 | 0.5 | | Total mortgage-backed securities | 1,250.4 | 19.1 | 1,249.2 | 22.7 | | Total asset and mortgage-backed securities | $2,063.5 | $54.0 | $2,157.3 | $41.6 | (1) Investment grade securities are considered rated BBB or higher. (2) Non-investment grade securities are considered rated below BBB. Investment Results Net investment income for the three and six months ended June 30, 2026 and 2025 consisted of the following: | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | | ($ in millions) | | | | | Debt securities, available for sale | $60.2 | $61.6 | $124.9 | $122.9 | | Debt securities, trading | 0.4 | 1.2 | 2.2 | 4.3 | | Short-term investments | 0.2 | (0.2) | 0.5 | 1.0 | | Other long-term investments | 3.5 | 2.8 | 3.8 | 4.4 | | Cash, cash equivalents and other | 6.0 | 6.5 | 11.3 | 15.8 | | Gross investment income | 70.3 | 71.9 | 142.7 | 148.4 | | Investment expenses | (4.8) | (3.7) | (10.8) | (9.0) | | Net investment income | $65.5 | $68.2 | $131.9 | $139.4 | The decrease in net investment income for the three and six months ended June 30, 2026 compared to the three and six months ended June 30, 2025 is primarily driven by sales of investments in the TPOC Portfolio as compared to the prior period, combined with higher expenses related to incentive compensation award outperformance. 40 Net investment gains (losses) for the three and six months ended June 30, 2026 and 2025 consisted of the following: _($ in millions)_ | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | | --- | --- | --- | --- | --- | | Debt securities, available for sale | | | | | | Gross realized gains | $5.2 | $3.0 | $15.2 | $10.1 | | Gross realized losses | (3.4) | (5.4) | (6.4) | (14.5) | | Net realized gains (losses) on Debt securities, available for sale | 1.8 | (2.4) | 8.8 | (4.4) | | Debt securities, trading | | | | | | Net realized gains (losses) | (1.3) | (0.3) | (1.3) | (1.8) | | Net unrealized gains (losses) | 1.4 | 2.0 | (0.2) | 3.8 | | Other long-term investments | | | | | | Net realized gains (losses) | 44.5 | (0.2) | 58.9 | (2.3) | | Net unrealized gains (losses) | (39.4) | 1.1 | (47.8) | 3.7 | | Other (1) | 0.9 | 0.5 | 0.9 | 1.4 | | Net investment gains (losses) | $7.9 | $0.7 | $19.3 | $0.4 | (1) Includes short-term investments, cash and cash equivalents, and derivatives. The increase in net investment gains (losses) for the three and six months ended June 30, 2026 compared to the three and six months ended June 30, 2025 was primarily due to gains from fair value changes in the Company's investments managed by related parties, which are included in Other long-term investments. The six months ended June 30, 2026 also includes gains on private equity funds, also classified in Other long-term investments, when compared to the six months ended June 30, 2025. Refer to Part I, Item 3. “Quantitative and Qualitative Disclosures about Market Risks” of this Form 10-Q for a discussion of certain risks and factors that could adversely impact our investments results. ### Other Revenues For the three months ended June 30, 2026, other revenues primarily consisted of $29.6 million of service fee revenue from MGAs, compared to $26.4 million of service fee revenue from MGAs for the three months ended June 30, 2025. The increase in service fee revenue is primarily driven by increases in International Medical Group, Inc. (“IMG”) from continued growth of its travel business and the acquisition of Assist America, partially offset by the deconsolidation of ArmadaCorp Capital, LLC (“Armada”). For the six months ended June 30, 2026, other revenues primarily consisted of $25.2 million from the gain on the sale of Arcadian and $60.5 million of service fee revenue from MGAs, compared to $58.3 million of service fee revenue from MGAs for the six months ended June 30, 2025. The increase in service fee revenue is primarily driven by increases in IMG from continued growth of its travel business and the acquisition of Assist America, partially offset by the deconsolidation of Armada. ### Net Corporate and Other Expenses Net corporate and other expenses include costs associated with operating as a publicly-traded company and non-underwriting activities, including services expenses from our MGA subsidiaries, and current expected credit losses from our insurance and reinsurance balances receivable and loss and loss adjustment expenses recoverable. The increase in net corporate and other expenses for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 was primarily driven by increases in expenses related to incentive compensation award outperformance attributable to the recent gains on sales of Armada and Arcadian and expenses associated with non-recurring projects. For the three months ended June 30, 2026 compared to the three months ended June 30, 2025, services expenses remained stable at $49.6 million. The increase in net corporate and other expenses for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 was primarily driven by increases in expenses related to incentive compensation award outperformance attributable to the recent gains on sales of Armada and Arcadian and expenses associated with non-recurring projects, as well 41 as increases in services expenses. For the six months ended June 30, 2026, services expenses increased to $95.7 million compared to $92.7 million for the six months ended June 30, 2025, primarily driven by increases in expenses from IMG from continued growth of its travel business and the acquisition of Assist America, partially offset by the deconsolidation of Armada. ### Amortization of Intangible Assets Amortization of intangible assets for the three and six months ended June 30, 2026 was $2.4 million and $5.0 million (2025 - $2.8 million and $5.7 million, respectively). The changes in amortization are due to the use of amortization patterns which are based on the period over which they are expected to generate future net cash inflows from the use of the underlying intangible assets. ### Interest Expense Interest expense and finance costs are related to interest due on our senior and subordinated notes, as well as interest associated with certain reinsurance contracts. Interest expense for the three and six months ended June 30, 2026 was $18.7 million and $35.5 million, respectively, compared to $21.1 million and $39.2 million for the three and six months ended June 30, 2025. The decrease was primarily driven by decreases in funds withheld interest on loss portfolio transfers. ### Foreign Currency Translation Except for the Canadian reinsurance operations of SiriusPoint America and certain subsidiaries of IMG, the U.S. dollar is the functional currency for our business. Assets and liabilities are remeasured into the functional currency using current exchange rates; revenues and expenses are remeasured into the functional currency using the average exchange rate for the period. The remeasurement process results in foreign exchange (gains) losses in the consolidated results of operations. Foreign exchange (gains) losses exclude investment generated net realized and unrealized investment gains as addressed in Investment Results above. Foreign exchange (gains) losses were $(1.8) million and $(0.5) million for the three months and six months ended June 30, 2026, respectively, compared to $16.7 million and $14.5 million for the three months and six months ended June 30, 2025, respectively. The foreign exchange losses in prior year were primarily driven by the impact of certain foreign exchange exposures related to underwriting activities from our international operations, partially offset by the impact of our currency hedges. On an aggregate basis, the effects of foreign exchange resulted in benefits (charges) to net income of $1.1 million and $(1.2) million, as well as benefits (charges) to comprehensive income of $1.1 million and $(5.3) million for the three and six months ended June 30, 2026, respectively. The effects of foreign exchange are consistent with the recent market fluctuations in rates and our economic currency hedging strategy. ### Income Tax Expense The increases in income tax expense for the three and six months ended June 30, 2026 compared to the three and six months ended June 30, 2025 were consistent with the increases in pre-tax income. ### Segment Results — Three and six months ended June 30, 2026 and 2025 The determination of our reportable segments is based on the manner in which management monitors the performance of our operations. We classify our business into two reportable segments - Insurance & Services and Reinsurance. Collectively, the sum of these two segments constitute “Core” results. Core underwriting income, Core net services income, Core income, and Core combined ratio are non-GAAP financial measures. We believe it is useful to review Core results as it better reflects how management views the business and reflects our decision to exit the run off business. The sum of Core results and Corporate results are equal to the consolidated results of operations. Corporate results include all run off business, which represents certain classes of business that we ceased underwriting as part of fundamental changes to our business strategy, including the effect of the restructuring of the underwriting platform announced in 2022 and certain reinsurance contracts that have interest crediting features. Corporate results also include asbestos and environmental and other latent liability exposures on a gross basis, which have mostly been ceded, as well as specific workers’ compensation and cyber programs which we no longer write. 42 The following tables set forth the operating segment results and ratios for the three months ended June 30, 2026 and 2025: _Three months ended June 30, 2026_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $644.6 | $336.9 | $981.5 | — | $(3.3) | — | $978.2 | | Net written premium | 422.4 | 287.1 | 709.5 | — | 0.8 | — | 710.3 | | Net earned premium | 381.7 | 257.1 | 638.8 | — | 1.5 | — | 640.3 | | Loss and loss adjustment expenses incurred, net | 216.5 | 140.1 | 356.6 | (1.8) | 3.4 | — | 358.2 | | Acquisition costs, net | 104.2 | 75.7 | 179.9 | (20.7) | (2.4) | — | 156.8 | | Other underwriting expenses | 25.6 | 21.7 | 47.3 | — | 4.5 | — | 51.8 | | Underwriting income (loss) | 35.4 | 19.6 | 55.0 | 22.5 | (4.0) | — | 73.5 | | Services revenues | 59.4 | — | 59.4 | (29.8) | — | (29.6) | — | | Services expenses | 49.6 | — | 49.6 | — | — | (49.6) | — | | Net services fee income | 9.8 | — | 9.8 | (29.8) | — | 20.0 | — | | Services noncontrolling loss | 0.1 | — | 0.1 | — | — | (0.1) | — | | Net services income | 9.9 | — | 9.9 | (29.8) | — | 19.9 | — | | Segment income (loss) | $45.3 | $19.6 | $64.9 | $(7.3) | $(4.0) | $19.9 | $73.5 | | Attritional losses | $231.3 | $140.7 | $372.0 | $(1.8) | $1.7 | — | $371.9 | | Catastrophe losses | 1.3 | — | 1.3 | — | — | — | 1.3 | | Prior year loss reserve development | (16.1) | (0.6) | (16.7) | — | 1.7 | — | (15.0) | | Loss and loss adjustment expenses incurred, net | $216.5 | $140.1 | $356.6 | $(1.8) | $3.4 | — | $358.2 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 60.6% | 54.7% | 58.2% | | | | 58.0% | | Catastrophe loss ratio | 0.3% | — | 0.2% | | | | 0.2% | | Prior year loss development ratio | (4.2)% | (0.2)% | (2.6)% | | | | (2.3)% | | Loss ratio | 56.7% | 54.5% | 55.8% | | | | 55.9% | | Acquisition cost ratio | 27.3% | 29.4% | 28.2% | | | | 24.5% | | Other underwriting expenses ratio | 6.7% | 8.4% | 7.4% | | | | 8.1% | | Combined ratio | 90.7% | 92.3% | 91.4% | | | | 88.5% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. 43 _Three months ended June 30, 2025_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $560.4 | $369.7 | $930.1 | — | $18.1 | — | $948.2 | | Net written premium | 392.8 | 307.0 | 699.8 | — | 4.6 | — | 704.4 | | Net earned premium | 369.2 | 276.4 | 645.6 | — | 6.4 | — | 652.0 | | Loss and loss adjustment expenses incurred, net | 209.2 | 156.4 | 365.6 | (1.5) | 8.5 | — | 372.6 | | Acquisition costs, net | 97.9 | 70.5 | 168.4 | (28.2) | 0.7 | — | 140.9 | | Other underwriting expenses | 22.6 | 21.4 | 44.0 | — | 4.3 | — | 48.3 | | Underwriting income (loss) | 39.5 | 28.1 | 67.6 | 29.7 | (7.1) | — | 90.2 | | Services revenues | 58.1 | — | 58.1 | (31.7) | — | (26.4) | — | | Services expenses | 49.6 | — | 49.6 | — | — | (49.6) | — | | Net services fee income | 8.5 | — | 8.5 | (31.7) | — | 23.2 | — | | Services noncontrolling loss | 0.2 | — | 0.2 | — | — | (0.2) | — | | Net services income | 8.7 | — | 8.7 | (31.7) | — | 23.0 | — | | Segment income (loss) | $48.2 | $28.1 | $76.3 | $(2.0) | $(7.1) | $23.0 | $90.2 | | Attritional losses | $218.9 | $161.0 | $379.9 | $(1.5) | $3.4 | — | $381.8 | | Catastrophe losses | — | (0.5) | (0.5) | — | — | — | (0.5) | | Prior year loss reserve development | (9.7) | (4.1) | (13.8) | — | 5.1 | — | (8.7) | | Loss and loss adjustment expenses incurred, net | $209.2 | $156.4 | $365.6 | $(1.5) | $8.5 | — | $372.6 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 59.3% | 58.3% | 58.8% | | | | 58.5% | | Catastrophe loss ratio | — | (0.2)% | (0.1)% | | | | (0.1)% | | Prior year loss development ratio | (2.6)% | (1.5)% | (2.1)% | | | | (1.3)% | | Loss ratio | 56.7% | 56.6% | 56.6% | | | | 57.1% | | Acquisition cost ratio | 26.5% | 25.5% | 26.1% | | | | 21.6% | | Other underwriting expenses ratio | 6.1% | 7.7% | 6.8% | | | | 7.4% | | Combined ratio | 89.3% | 89.8% | 89.5% | | | | 86.1% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. ### Core Premium Volume Gross written premium increased by $51.4 million, or 5.5%, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. Net written premium increased by $9.7 million, or 1.4%, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. Net earned premium decreased by $6.8 million, or 1.1%, for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increases in written premium were driven by our Insurance & Services segment, including new program growth, mainly in General Liability, as well as continued growth in London MGAs, partially offset by decreases in our Reinsurance segment, primarily in Casualty and Property Catastrophe. The decrease in net earned premium was primarily a result of earned premium growing at a slower pace than written due to a shift in our business mix, as well as a reduction in net earned premium related to the inception of an aggregate reinsurance program in 2026. 44 ### Core Underwriting Results The decrease in underwriting income of $12.6 million was primarily driven by decreased earned premiums and higher acquisition costs, partially offset by increased favorable prior year loss reserve development. For the three months ended June 30, 2026, favorable prior year loss reserve development was $16.7 million compared to $13.8 million for the three months ended June 30, 2025, primarily driven by favorable development in A&H and Property. ### Core Services Results Services revenues increased to $59.4 million for the three months ended June 30, 2026 compared to $58.1 million for the three months ended June 30, 2025 primarily driven by growth in the IMG travel business and the acquisition of Assist America, partially offset by the deconsolidation of Armada in the fourth quarter of 2025. Net services income increased to $9.9 million for the three months ended June 30, 2026 compared to $8.7 million during the three months ended June 30, 2025, also driven by growth in IMG and the acquisition of Assist America, partially offset by the deconsolidation of Armada. Service margin, which is calculated as Net service fee income as a percentage of services revenues, increased to 16.5% for the three months ended June 30, 2026 from 13.5% for the three months ended June 30, 2025, when adjusted to exclude Armada, driven by the acquisition of Assist America. _Six months ended June 30, 2026_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $1,329.2 | $656.1 | $1,985.3 | — | $(4.2) | — | $1,981.1 | | Net written premium | 883.5 | 522.8 | 1,406.3 | — | (0.8) | — | 1,405.5 | | Net earned premium | 761.8 | 515.3 | 1,277.1 | — | 2.1 | — | 1,279.2 | | Loss and loss adjustment expenses incurred, net | 432.2 | 274.1 | 706.3 | (3.6) | 18.4 | — | 721.1 | | Acquisition costs, net | 212.2 | 139.5 | 351.7 | (44.5) | (2.6) | — | 304.6 | | Other underwriting expenses | 51.9 | 41.3 | 93.2 | — | 9.1 | — | 102.3 | | Underwriting income (loss) | 65.5 | 60.4 | 125.9 | 48.1 | (22.8) | — | 151.2 | | Services revenues | 113.4 | — | 113.4 | (52.9) | — | (60.5) | — | | Services expenses | 95.7 | — | 95.7 | — | — | (95.7) | — | | Net services fee income | 17.7 | — | 17.7 | (52.9) | — | 35.2 | — | | Services noncontrolling loss | 0.6 | — | 0.6 | — | — | (0.6) | — | | Net services income | 18.3 | — | 18.3 | (52.9) | — | 34.6 | — | | Segment income (loss) | $83.8 | $60.4 | $144.2 | $(4.8) | $(22.8) | $34.6 | $151.2 | | Attritional losses | $462.1 | $286.4 | $748.5 | $(3.6) | $2.4 | — | $747.3 | | Catastrophe losses | 1.3 | 5.4 | 6.7 | — | — | — | 6.7 | | Prior year loss reserve development | (31.2) | (17.7) | (48.9) | — | 16.0 | — | (32.9) | | Loss and loss adjustment expenses incurred, net | $432.2 | $274.1 | $706.3 | $(3.6) | $18.4 | — | $721.1 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 60.6% | 55.6% | 58.6% | | | | 58.5% | | Catastrophe loss ratio | 0.2% | 1.0% | 0.5% | | | | 0.5% | | Prior year loss development ratio | (4.1)% | (3.4)% | (3.8)% | | | | (2.6)% | | Loss ratio | 56.7% | 53.2% | 55.3% | | | | 56.4% | | Acquisition cost ratio | 27.9% | 27.1% | 27.5% | | | | 23.8% | | Other underwriting expenses ratio | 6.8% | 8.0% | 7.3% | | | | 8.0% | | Combined ratio | 91.4% | 88.3% | 90.1% | | | | 88.2% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. 45 _Six months ended June 30, 2025_ | Line item | Insurance & Services | Reinsurance | Core | Eliminations (2) | Corporate | Segment Measure Reclass | Total | | --- | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $1,195.5 | $724.5 | $1,920.0 | — | $12.9 | — | $1,932.9 | | Net written premium | 876.3 | 575.5 | 1,451.8 | — | (4.4) | — | 1,447.4 | | Net earned premium | 705.4 | 566.0 | 1,271.4 | — | 7.3 | — | 1,278.7 | | Loss and loss adjustment expenses incurred, net | 419.1 | 351.7 | 770.8 | (3.5) | 7.1 | — | 774.4 | | Acquisition costs, net | 185.2 | 137.6 | 322.8 | (56.2) | 4.0 | — | 270.6 | | Other underwriting expenses | 41.5 | 40.2 | 81.7 | — | 7.7 | — | 89.4 | | Underwriting income (loss) | 59.6 | 36.5 | 96.1 | 59.7 | (11.5) | — | 144.3 | | Services revenues | 120.2 | — | 120.2 | (61.9) | — | (58.3) | — | | Services expenses | 92.7 | — | 92.7 | — | — | (92.7) | — | | Net services fee income | 27.5 | — | 27.5 | (61.9) | — | 34.4 | — | | Services noncontrolling loss | 0.1 | — | 0.1 | — | — | (0.1) | — | | Net services income | 27.6 | — | 27.6 | (61.9) | — | 34.3 | — | | Segment income (loss) | $87.2 | $36.5 | $123.7 | $(2.2) | $(11.5) | $34.3 | $144.3 | | Attritional losses | $426.5 | $325.0 | $751.5 | $(3.5) | $1.9 | — | $749.9 | | Catastrophe losses | 4.8 | 62.6 | 67.4 | — | — | — | 67.4 | | Prior year loss reserve development | (12.2) | (35.9) | (48.1) | — | 5.2 | — | (42.9) | | Loss and loss adjustment expenses incurred, net | $419.1 | $351.7 | $770.8 | $(3.5) | $7.1 | — | $774.4 | | Underwriting Ratios: (1) | | | | | | | | | Attritional loss ratio | 60.4% | 57.3% | 59.1% | | | | 58.7% | | Catastrophe loss ratio | 0.7% | 11.1% | 5.3% | | | | 5.3% | | Prior year loss development ratio | (1.7)% | (6.3)% | (3.8)% | | | | (3.4)% | | Loss ratio | 59.4% | 62.1% | 60.6% | | | | 60.6% | | Acquisition cost ratio | 26.3% | 24.3% | 25.4% | | | | 21.2% | | Other underwriting expenses ratio | 5.9% | 7.1% | 6.4% | | | | 7.0% | | Combined ratio | 91.6% | 93.5% | 92.4% | | | | 88.8% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. (2) Insurance & Services MGAs recognize fees for service using revenue from contracts with customers accounting standards, whereas insurance companies recognize acquisition expenses using insurance contract accounting standards. While ultimate revenues and expenses recognized will match, there will be recognition timing differences based on the different accounting standards. ### Core Premium Volume Gross written premium increased by $65.3 million, or 3.4%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025. Net written premium decreased by $45.5 million, or 3.1%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025. Net earned premium increased by $5.7 million, or 0.4%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025. The increases in gross written premium and net earned premium were driven by our Insurance & Services segment, primarily driven by new program growth, mainly in General Liability, as well as continued organic growth in existing programs and growth in A&H, partially offset by decreases in our Reinsurance segment, mainly in Casualty, Property Catastrophe, and Other Specialties. The decrease in net written premium was primarily driven by the decreases in our Reinsurance segment and the ceded premium related to the inception of an aggregate reinsurance program in 2026. ### Core Underwriting Results The improvement in underwriting income of $29.8 million for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 was primarily driven by decreased catastrophe losses, partially offset by higher acquisition costs and other underwriting expense. Catastrophe losses were $6.7 million, or 0.5 percentage points on the combined ratio, for the six months ended June 30, 2026 compared to $67.4 million, or 5.3 percentage points on the combined ratio, for the six 46 months ended June 30, 2025, primarily driven by the California wildfires in the prior period. Increased acquisition costs primarily resulted from profit commission accruals related to favorable loss experience and increased other underwriting expense is largely driven by expenses related to incentive compensation award outperformance. ### Core Services Results Services revenues decreased to $113.4 million for the six months ended June 30, 2026 compared to $120.2 million for the six months ended June 30, 2025 primarily due to the deconsolidation of Armada in the fourth quarter of 2025, partially offset by growth in the IMG travel business and the acquisition of Assist America. Net services income decreased to $18.3 million for the six months ended June 30, 2026 from $27.6 million for the six months ended June 30, 2025 also driven by the deconsolidation of Armada, partially offset by growth in IMG and the acquisition of Assist America. Service margin, which is calculated as Net service fee income as a percentage of services revenues, increased to 15.6% for the six months ended June 30, 2026 compared to 13.6% for the six months ended June 30, 2025, when adjusted to exclude Armada, driven by the acquisition of Assist America. ### Insurance & Services Segment In our Insurance & Services segment, we underwrite primary insurance in several sectors globally. We offer innovative insurance solutions to meet the changing risk circumstances of our clients. The Insurance & Services segment includes A&H, Property & Casualty, and Other Specialties. As of June 30, 2026, we have equity stakes in 16 entities (MGAs, Insurtech and Other), which underwrite or distribute a wide range of lines of business, including general liability, professional liability, directors & officers, credit and bond, cyber, commercial automobile, workers’ compensation, accident & health, and other specialty insurance classes. As of June 30, 2026, we consolidated two MGAs in our financial statements: Alta Signa Holdings (“Alta Signa”) and IMG. Effective November 1, 2025, we deconsolidated Armada upon the sale to Ambac Financial Group Inc. We will continue our underwriting capacity partnership with Armada until the end of 2030. We provide underwriting capacity in the form of insurance or reinsurance to 8 non-consolidated entities in addition to the two consolidated MGAs. We also have investment stakes in 6 other entities where we have no underwriting relationships. The investment interests in the non-consolidated entities are included in strategic investments within Other long-term investments on the consolidated balance sheet. 47 The following table sets forth underwriting results, net MGA results, and ratios for the segment results, and the period over period changes, for the three and six months ended June 30, 2026 and 2025: _($ in millions)_ | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Three months ended / Change | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | Six months ended / Change | | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $644.6 | $560.4 | $84.2 | $1,329.2 | $1,195.5 | $133.7 | | Net written premium | 422.4 | 392.8 | 29.6 | 883.5 | 876.3 | 7.2 | | Net earned premium | 381.7 | 369.2 | 12.5 | 761.8 | 705.4 | 56.4 | | Loss and loss adjustment expenses incurred, net | 216.5 | 209.2 | 7.3 | 432.2 | 419.1 | 13.1 | | Acquisition costs, net | 104.2 | 97.9 | 6.3 | 212.2 | 185.2 | 27.0 | | Other underwriting expenses | 25.6 | 22.6 | 3.0 | 51.9 | 41.5 | 10.4 | | Underwriting income | 35.4 | 39.5 | (4.1) | 65.5 | 59.6 | 5.9 | | Services revenues | 59.4 | 58.1 | 1.3 | 113.4 | 120.2 | (6.8) | | Services expenses | 49.6 | 49.6 | — | 95.7 | 92.7 | 3.0 | | Net services fee income | 9.8 | 8.5 | 1.3 | 17.7 | 27.5 | (9.8) | | Services noncontrolling loss | 0.1 | 0.2 | (0.1) | 0.6 | 0.1 | 0.5 | | Net services income | 9.9 | 8.7 | 1.2 | 18.3 | 27.6 | (9.3) | | Segment income | $45.3 | $48.2 | $(2.9) | $83.8 | $87.2 | $(3.4) | | Underwriting ratios: (1) | | | | | | | | Loss ratio | 56.7% | 56.7% | — | 56.7% | 59.4% | (2.7)% | | Acquisition cost ratio | 27.3% | 26.5% | 0.8% | 27.9% | 26.3% | 1.6% | | Other underwriting expense ratio | 6.7% | 6.1% | 0.6% | 6.8% | 5.9% | 0.9% | | Combined ratio | 90.7% | 89.3% | 1.4% | 91.4% | 91.6% | (0.2)% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. ### Premium Volume Gross written premium increased by $84.2 million, or 15.0%, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025, primarily driven by new program growth, mainly in General Liability, as well as continued growth in London MGAs. Gross written premium increased by $133.7 million, or 11.2%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025, primarily driven by new program growth, mainly in General Liability, as well as continued organic growth in existing programs and growth in North America A&H. Consolidated MGAs Gross written premium generated by the consolidated MGAs in the aggregate decreased by $10.7 million, or 15.0%, to $60.8 million for the three months ended June 30, 2026 compared to $71.5 million for the three months ended June 30, 2025. 48 Gross written premium generated by the consolidated MGAs in the aggregate decreased by $47.7 million, or 28.3%, to $120.3 million for the six months ended June 30, 2026 compared to $168.0 million for the six months ended June 30, 2025. The decreases for the three and six months ended June 30, 2026 primarily resulted from the deconsolidation of Armada in the fourth quarter of 2025. Book value for the consolidated MGAs was $110.7 million as of June 30, 2026, compared to $80.3 million as of December 31, 2025. The increase in book value from December 31, 2025 was a result of the acquisition of Assist America, which was effective as of January 1, 2026. ### Underwriting Results The decrease in underwriting income of $4.1 million for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 was primarily a result of earned premium growing at a slower pace than written due to a shift in our business mix, as well as expenses related to incentive compensation award outperformance. The improvement in underwriting income of $5.9 million for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 was primarily driven by increased favorable prior year loss reserve development, partially offset by increased expenses. For the six months ended June 30, 2026, favorable prior year loss reserve development was $31.2 million compared to $12.2 million for the six months ended June 30, 2025, primarily driven by favorable development in A&H. Increased acquisition costs primarily resulted from profit commission accruals related to favorable loss experience and increased other underwriting expense is largely driven by expenses related to incentive compensation award outperformance. ### Services Results The increase in services revenues of $1.3 million and net services income of $1.2 million for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 were primarily driven by growth in the IMG travel business and the acquisition of Assist America, partially offset by the deconsolidation of Armada in the fourth quarter of 2025. The decrease in services revenues of $6.8 million and net services income of $9.3 million for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 were primarily due to the deconsolidation of Armada in the fourth quarter of 2025, partially offset by growth in the IMG travel business and the acquisition of Assist America. ### Reinsurance Segment The Reinsurance segment predominantly underwrites Casualty, Property and Other Specialties lines of business on a worldwide basis. The following table sets forth underwriting results and ratios and the period over period changes for the Reinsurance segment for the three and six months ended June 30, 2026 and 2025: _($ in millions)_ | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Three months ended / Change | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | Six months ended / Change | | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $336.9 | $369.7 | $(32.8) | $656.1 | $724.5 | $(68.4) | | Net written premium | 287.1 | 307.0 | (19.9) | 522.8 | 575.5 | (52.7) | | Net earned premium | 257.1 | 276.4 | (19.3) | 515.3 | 566.0 | (50.7) | | Loss and loss adjustment expenses incurred, net | 140.1 | 156.4 | (16.3) | 274.1 | 351.7 | (77.6) | | Acquisition costs, net | 75.7 | 70.5 | 5.2 | 139.5 | 137.6 | 1.9 | | Other underwriting expenses | 21.7 | 21.4 | 0.3 | 41.3 | 40.2 | 1.1 | | Underwriting income | $19.6 | $28.1 | $(8.5) | $60.4 | $36.5 | $23.9 | | Underwriting ratios: (1) | | | | | | | | Loss ratio | 54.5% | 56.6% | (2.1)% | 53.2% | 62.1% | (8.9)% | | Acquisition cost ratio | 29.4% | 25.5% | 3.9% | 27.1% | 24.3% | 2.8% | | Other underwriting expense ratio | 8.4% | 7.7% | 0.7% | 8.0% | 7.1% | 0.9% | | Combined ratio | 92.3% | 89.8% | 2.5% | 88.3% | 93.5% | (5.2)% | (1) Underwriting ratios are calculated by dividing the related expense by net earned premium. 49 ### Premium Volume Gross written premium in the Reinsurance segment decreased by $32.8 million, or 8.9%, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025, primarily driven by deliberate reductions in Casualty and rate and exposure reductions in Property Catastrophe. Gross written premium in the Reinsurance segment decreased by $68.4 million, or 9.4%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025, primarily driven by deliberate reductions in Casualty, rate and exposure reductions in Property Catastrophe, and reductions in Other Specialties. ### Underwriting Results The decrease in net underwriting income for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 was primarily driven by decreased net earned premiums in Casualty and Property Catastrophe and higher acquisition costs in Property and Other Specialties, partially offset by a lower attritional loss ratio. The increase in net underwriting results for the six months ended June 30, 2026 compared to the six months ended June 30, 2025, was primarily driven by decreased catastrophe losses, as the six months ended June 30, 2025 included losses of $62.6 million, or 11.1 percentage points on the combined ratio, primarily from the California wildfires. This was partially offset by lower favorable prior year loss reserve development of $17.7 million for the six months ended June 30, 2026, compared to $35.9 million for the six months ended June 30, 2025, mainly from reserve releases in Property relating to prior year’s catastrophe events. ### Corporate Corporate results include all run off business, which represents certain classes of business that we ceased underwriting as part of fundamental changes to our business strategy, including the effect of the restructuring of the underwriting platform announced in 2022 and certain reinsurance contracts that have interest crediting features. Corporate results also include asbestos and environmental and other latent liability exposures on a gross basis, which have mostly been ceded, as well as specific workers’ compensation and cyber programs which we no longer write. The following table sets forth underwriting results and the period over period changes for the three and six months ended June 30, 2026 and 2025: _($ in millions)_ | Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Three months ended / Change | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 | Six months ended / Change | | --- | --- | --- | --- | --- | --- | --- | | Gross written premium | $(3.3) | $18.1 | $(21.4) | $(4.2) | $12.9 | $(17.1) | | Net written premium | 0.8 | 4.6 | (3.8) | (0.8) | (4.4) | 3.6 | | Net earned premium | 1.5 | 6.4 | (4.9) | 2.1 | 7.3 | (5.2) | | Loss and loss adjustment expenses incurred, net | 3.4 | 8.5 | (5.1) | 18.4 | 7.1 | 11.3 | | Acquisition costs, net | (2.4) | 0.7 | (3.1) | (2.6) | 4.0 | (6.6) | | Other underwriting expenses | 4.5 | 4.3 | 0.2 | 9.1 | 7.7 | 1.4 | | Underwriting loss | $(4.0) | $(7.1) | $3.1 | $(22.8) | $(11.5) | $(11.3) | Minimal premium volume for the three and six months ended June 30, 2026 reflect the expiration and non-renewal of the classes of business that we no longer actively underwrite. The increase in the underwriting loss for the six months ended June 30, 2026 compared the six months ended June 30, 2025 was primarily driven by adverse prior year loss reserve development of $16.0 million, mainly from one large claim settlement. ### Non-GAAP Financial Measures We have included certain financial measures that are not calculated under standards or rules that comprise U.S. GAAP. Such measures, including Core underwriting income, Core net services income, Core income, Core combined ratio, accident year loss ratio, accident year combined ratio, attritional loss ratio and tangible book value per diluted common share, are referred to as non-GAAP financial measures. These non-GAAP financial measures may be defined or calculated differently by other companies. We believe these measures allow for a more complete understanding of our underlying business. These measures are used by management to monitor our results and should not be viewed as a substitute for those determined in accordance with U.S. GAAP. Reconciliations of non-GAAP measures to the most comparable U.S. GAAP measures are included below. 50 ### Core Results Collectively, the sum of the Company's two segments, Insurance & Services and Reinsurance, constitute "Core" results. Core underwriting income, Core net services income, Core income and Core combined ratio are non-GAAP financial measures. We believe it is useful to review Core results as it better reflects how management views the business and reflects our decision to exit the run off business. The sum of Core results and Corporate results are equal to the consolidated results of operations. Core underwriting income - calculated by subtracting loss and loss adjustment expenses incurred, net, acquisition costs, net, and other underwriting expenses from net premiums earned. Core net services income - consists of services revenues which include commissions, brokerage and fee income related to consolidated MGAs, and other revenues, as well as services expenses which include direct expenses related to consolidated MGAs and services noncontrolling income which represent minority ownership interests in consolidated MGAs. Net services income is a key indicator of the profitability of the Company's services provided. Core income - consists of two components, core underwriting income and core net services income. Core income is a key measure of our segment performance. Core combined ratio - calculated by dividing the sum of Core loss and loss adjustment expenses incurred, net, acquisition costs, net and other underwriting expenses by Core net premiums earned. Accident year loss ratio and accident year combined ratio are calculated by excluding prior year loss reserve development to present the impact of current accident year net loss and loss adjustment expenses on the Core loss ratio and Core combined ratio, respectively. Attritional loss ratio excludes catastrophe losses from the accident year loss ratio as they are not predictable as to timing and amount. These ratios are useful indicators of our underwriting profitability. See Note 4 “Segment reporting” to our unaudited consolidated financial statements included elsewhere in this Form 10-Q for additional information and a calculation of Core results. ### Tangible Book Value Per Diluted Common Share Tangible book value per diluted common share, as presented, is a non-GAAP financial measure and the most directly comparable U.S. GAAP measure is book value per common share. Tangible book value per diluted common share excludes goodwill and intangible assets. Management believes that effects of goodwill and intangible assets make book value comparisons to less acquisitive peer companies less meaningful. The following table sets forth the computation of book value per common share, book value per diluted common share and tangible book value per diluted common share as of June 30, 2026 and December 31, 2025: _($ in millions, except share and per share amounts)_ | Line item | June 30,2026 | December 31,2025 | | --- | --- | --- | | Common shareholders’ equity attributable to SiriusPoint common shareholders | $2,275.9 | $2,269.8 | | Intangible assets | 137.4 | 121.2 | | Goodwill | 18.6 | — | | Tangible common shareholders' equity attributable to SiriusPoint common shareholders | $2,119.9 | $2,148.6 | | Common shares outstanding | 116,065,965 | 116,989,799 | | Effect of dilutive stock options and restricted share units | 1,848,708 | 4,983,345 | | Book value per diluted common share denominator | 117,914,673 | 121,973,144 | | Book value per common share | $19.61 | $19.40 | | Book value per diluted common share | $19.30 | $18.61 | | Tangible book value per diluted common share | $17.98 | $17.62 | 51 ### Liquidity and Capital Resources ### Liquidity Requirements Liquidity is a measure of a company’s ability to generate cash flows sufficient to meet short-term and long-term cash requirements of its business operations. SiriusPoint’s insurance and reinsurance operations are subject to regulation and supervision in each of the jurisdictions where they are domiciled and licensed to conduct business. Generally, regulatory authorities have broad supervisory and administrative powers over such matters as licenses, standards of solvency, premium rates, policy forms, investments, security deposits, methods of accounting, form and content of financial statements, reserves for unpaid loss and loss adjustment expenses, reinsurance, minimum capital and surplus requirements, dividends and other distributions to shareholders, periodic examinations, and annual and other report filings. In general, such regulation is for the protection of policyholders rather than shareholders. SiriusPoint manages its liquidity needs primarily through the maintenance of a short duration and high quality fixed income portfolio. SiriusPoint is a holding company and has no substantial operations of its own and its assets consist primarily of its investments in subsidiaries. Its cash needs primarily consist of the payment of corporate expenses, interest and principal payments on debt obligations and investment opportunities. SiriusPoint may also require cash to repurchase shares of our common stock pursuant to the share repurchase program or redeem other securities issued by us. For further details, see Note 14 “Shareholders' equity” in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. Cash at the subsidiaries is used primarily to pay loss and loss adjustment expenses, reinsurance premiums, acquisition costs, interest expense, taxes, general and administrative expenses and to purchase investments. The insurance and reinsurance business of our operating subsidiaries inherently provide liquidity, as premiums are received in advance of the time losses are paid. However, the amount of cash required to fund loss payments can fluctuate significantly from period to period, due to the low frequency/high severity nature of certain types of business we write. For additional commitments and contingencies that may affect our liquidity requirements see Note 17 “Commitments and contingencies” in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. ### Dividend Capacity and Capital We are subject to regulations and other constraints that affect our ability to pay dividends. During both the three and six months ended June 30, 2026, SiriusPoint paid dividends of $2.6 million to the Series B preference shareholders as the Series B preference shares were fully redeemed on February 26, 2026 (2025 - $4.0 million and $8.0 million, respectively). See Note 14 “Shareholders' equity” in our unaudited consolidated financial statements included elsewhere in this Form 10-Q for further discussion on the redemption. During the three and six months ended June 30, 2026, SiriusPoint did not pay any dividends to its common shareholders. For the three and six months ended June 30, 2026, SiriusPoint received distributions of $45.0 million from SiriusPoint Bermuda Insurance Company Ltd. (“SiriusPoint Bermuda”), its immediate wholly-owned subsidiary (2025 - $10.0 million and $435.0 million, respectively). We believe the dividend/distribution capacity of SiriusPoint’s subsidiaries, which was approximately $694.7 million as of December 31, 2025, provides SiriusPoint with sufficient liquidity for the foreseeable future. For a further discussion of the various restrictions on SiriusPoint Bermuda’s ability to pay dividends, see Part I, Item 1 “Business - Regulation” in our 2025 Form 10-K. In addition to the regulatory and other contractual constraints to paying dividends, we manage the capital of the group and each of our operating subsidiaries to support our current ratings from AM Best, Fitch, S&P and Moody’s. This could further reduce the ability and amount of dividends that could be paid from subsidiaries to SiriusPoint. In addition, the Company annually files the prescribed form of capital and solvency return, which comprises the insurer’s Bermuda Solvency Capital Requirement (“BSCR”) model. The BSCR model is a risk-based capital model which provides a method for determining a Class 3A and Class 4 insurer’s capital requirements (statutory economic capital and surplus) by taking into account the risk characteristics of different aspects of the Class 3A and Class 4 insurer’s business. Our filed 2025 BSCR ratio is 256%. The Company is also currently completing its second quarter 2026 Bermuda Quarterly Financial Return, with an estimated ratio of 239%. ### Sources of Liquidity Our operating subsidiaries sources of liquidity have primarily consisted of net written premium, reinsurance recoveries, investment income and proceeds from sales of or dividends or distributions attributable to investments. Other potential sources of liquidity include borrowings under our credit facilities, the Federal Home Loan Bank of New York (“FHLBNY”) advance program and issuances of securities. Effective December 19, 2024, we entered into a four-year, $400.0 million senior unsecured revolving credit facility (the “Facility”) with JPMorgan Chase Bank, N.A. as administrative agent. The Facility includes an option for the Company to request a 12-month extension, subject to satisfaction of certain conditions including, but not limited to, the consent of lenders representing a majority-in-interest of commitments, of the Facility maturity date. Subject to customary conditions precedent upon any borrowing request, the Facility provides access to loans for working capital and general corporate purposes, as well as letters of credit to support obligations under insurance and reinsurance agreements, retrocessional agreements and for general corporate purposes. As of June 30, 2026, the Company was in compliance with all of the covenants under the Facility and there were no outstanding borrowings under the Facility. Effective September 2025, we became a member of the FHLBNY. As a member, we may borrow through the advance program of the FHLBNY. The FHLBNY advance program provides short- and long-term, fully collateralized loans, called advances, to their members. We have the ability to obtain this funding based on a percentage of the value of our admitted assets in the State of New York, subject to availability of eligible collateral. As of June 30, 2026, there were no outstanding FHLBNY borrowings. ### Financing We expect that our cash and cash equivalents on the balance sheet and cash flow from operations will provide us with the financial flexibility to execute our strategic objectives. Our ability to generate cash, however, is subject to our performance, general economic conditions, industry trends, and other factors. To the extent cash and cash equivalents on the balance sheet, investment returns and cash flow from operations are insufficient to fund our future activities and requirements, we may need to raise additional funds through public or private equity or debt financing. If we issue equity securities in order to raise additional funds, substantial dilution to existing shareholders may occur. If we raise cash through the issuance of additional indebtedness, we may be subject to additional contractual restrictions on our business. There is no assurance that we would be able to raise the additional funds on favorable terms or at all. The following table represents a summary of our debt obligations as of June 30, 2026 and December 31, 2025: | Line item | June 30, 2026 / Amount | June 30, 2026 / Effective rate (1) | December 31, 2025 / Amount | December 31, 2025 / Effective rate (1) | | --- | --- | --- | --- | --- | | 2024 Senior Notes, at face value | $400.0 | 7.4% | $400.0 | 7.4% | | Unamortized discount and issuance costs | (3.4) | | (4.0) | | | 2024 Senior Notes, carrying value | 396.6 | | 396.0 | | | 2017 SEK Subordinated Notes, at face value | 284.1 | 6.2% | 298.2 | 7.1% | | Unamortized discount | (5.2) | | (5.6) | | | 2017 SEK Subordinated Notes, carrying value | 278.9 | | 292.6 | | | Total debt | $675.5 | | $688.6 | | (1) Effective rate considers the effect of the debt issuance costs, discount, and premium. For further details and discussion with respect to the 2024 Senior Notes and 2017 SEK Subordinated Notes, please refer to Note 14 “Debt and letter of credit facilities” of Part II, Item 8. “Financial Statements and Supplementary Data” included in our 2025 Form 10-K. Debt Covenants As of June 30, 2026, we were in compliance with all of the covenants under the 2024 Senior Notes and the 2017 SEK Subordinated Notes. ### Letter of Credit Facilities As of June 30, 2026, letters of credit in the amount of $810.0 million had been issued by the Company to various insurance and reinsurance counterparties. Each of the facilities contain customary events of default and restrictive covenants, including but not limited to, limitations on liens on collateral, transactions with affiliates, mergers, and sales of assets, as well as solvency and maintenance of certain minimum pledged equity requirements and a minimum rating from rating agencies. Each restricts issuance of any debt without the consent of the letter of credit provider. Additionally, if an event of default exists under any of the letter of credit facilities, our subsidiaries could be prohibited from paying dividends. We were in compliance with all of the covenants under the aforementioned letter of credit facilities as of June 30, 2026. For further details and discussion with respect to letter of credit facilities, see Note 12 “Debt and letter of credit facilities” in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. ### Cash Secured Letter of Credit Agreements Under the cash secured letter of credit facilities, we provide collateral that consists of cash and cash equivalents and debt securities. As of June 30, 2026, total cash and cash equivalents and debt securities with a fair value of $879.4 million were pledged as collateral against the letters of credit issued. We believe that we have adequate capacity between our existing cash secured letter of credit agreements as well as available investments to post in reinsurance trusts to meet our collateral obligations under our existing and future reinsurance business. For further details and discussion with respect to cash secured letter of credit agreements, see Note 12 “Debt and letter of credit facilities” in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. ### Cash, Restricted Cash and Cash Equivalents and Restricted Investments Cash and cash equivalents consist of cash held in banks and other short-term, highly liquid investments with original maturity dates of 90 days or less. We invest a portion of the collateral securing certain reinsurance contracts in U.S. treasury securities and sovereign debt. This portion of the collateral is included in debt securities in the consolidated balance sheets and is disclosed as part of restricted investments. In addition, restricted investments also pertain to limited partnership interests in Third Point funds securing the Company’s contractual obligations under certain reinsurance contracts that the Company will not be released from until the underlying risks have expired or have been settled. Restricted cash and cash equivalents and restricted investments decreased to $1.9 billion as of June 30, 2026 from $2.2 billion as of December 31, 2025. The decrease was primarily due to the release of collateral pledged against prior underwriting years’ contracts. For additional information on restricted cash, cash equivalents and investments, see Note 5 “Cash, cash equivalents, restricted cash and restricted investments” in our unaudited consolidated financial statements included elsewhere in this Form 10-Q. ### Cash Flows Our cash flows from operations generally represent the difference between: (1) premiums collected and investment income and (2) loss and loss expenses paid, reinsurance purchased, underwriting and other expenses paid. Cash flows from operations may differ substantially from net income and may be volatile from period to period depending on the underwriting opportunities available to us and other factors. Due to the nature of our underwriting portfolio, claim payments can be unpredictable and may need to be made within relatively short periods of time. Claim payments can also be required several months or years after premiums are collected. In addition, as discussed above, SiriusPoint has access to the $400.0 million Facility that provides access to loans for working capital and general corporate purposes, and letters of credit to support obligations under insurance and reinsurance agreements and retrocessional agreements. Operating, investing, and financing cash flows for the six months ended June 30, 2026 and 2025 were as follows: _($ in millions)_ | Line item | 2026 | 2025 | | --- | --- | --- | | Net cash provided by (used in) operating activities | $136.7 | $(26.8) | | Net cash provided by (used in) investing activities | (2.4) | 565.8 | | Net cash used in financing activities | (290.8) | (510.4) | | Net increase (decrease) in cash, cash equivalents and restricted cash | (156.5) | 28.6 | | Cash, cash equivalents and restricted cash at beginning of period | 902.4 | 894.6 | | Cash, cash equivalents and restricted cash at end of period | $745.9 | $923.2 | Operating Activities Cash flows provided by operating activities can fluctuate due to timing differences between the collection of premiums and reinsurance recoverable, the payment of losses and loss expenses, and the payment of premiums to reinsurers. The increase in cash flows provided by operating activities for the six months ended June 30, 2026 was primarily driven by an increase in the collection of premiums consistent with the underlying growth of the business, compared to cash flows used in operating activities for the six months ended June 30, 2025 primarily relating to payments for California wildfire claims. Investing Activities Cash flows used in investing activities for the six months ended June 30, 2026 were driven by lower proceeds from sales and maturities of debt securities compared to purchases during the period and cash used to complete the acquisition of Assist America. The decrease in cash flows provided by investing activities for the six months ended June 30, 2026 compared to the six months ended June 30, 2025 was driven by changes in our investment portfolio, primarily purchases and sales of fixed income and short-term investments. Financing Activities Cash flows used in financing activities for the six months ended June 30, 2026 primarily consisted of a $203.9 million payment for the redemption of the Series B Preference share and $73.3 million in payments for share repurchases. Cash flows used in financing activities for the six months ended June 30, 2025 primarily consisted of $490.8 million in payments for share repurchases. ### Financial Condition As of June 30, 2026, total shareholders’ equity was $2,276.7 million, compared to $2,470.9 million as of December 31, 2025. The decrease was primarily driven by the redemption of the Series B preference shares of $203.9 million, common share repurchases of $73.3 million and the accumulated other comprehensive loss from unrealized losses from AFS debt securities of $85.1 million, partially offset by net income of $168.2 million for the six months ended June 30, 2026. ### Contractual Obligations There have been no material changes to our contractual obligations from our 2025 Form 10-K. ### Critical Accounting Policies and Estimates For a summary of our significant accounting and reporting policies, please refer to Note 2 “Significant accounting policies” of Part II, Item 8. “Financial Statements and Supplementary Data” included in our 2025 Form 10-K. Our consolidated financial statements are prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported and disclosed amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and such differences could be material to the financial statements. As of December 31, 2025, the accounting policies that required the most significant judgments and estimations by management include, but are not limited to: (1) premium revenue recognition, (2) loss and loss adjustment expense reserves, (3) fair value measurements related to our investments and (4) income taxes. If actual events differ significantly from the underlying judgments or estimates used by management in the application of these accounting policies, there could be a material adverse effect on our results of operations and financial condition. Refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our 2025 Form 10-K. ## ITEM 3. Quantitative and Qualitative Disclosures About Market Risk Our consolidated balance sheets include a substantial amount of assets and liabilities whose fair values are subject to market risk. The term market risk refers to the risk of loss arising from adverse changes in interest rates, credit spreads, equity markets prices, and other relevant market rates and prices. Due to our sizable investment portfolio, market risk can have a significant effect on our consolidated financial position. We believe we are principally exposed to the following types of market risk: - interest rate risk; and - foreign currency exchange risk. ### Interest Rate Risk Interest rate risk is the price sensitivity of a security to changes in interest rates. Our investment portfolio includes fixed income investments, whose fair values will fluctuate with changes in interest rates. Increases and decreases in prevailing interest rates generally translate into decreases and increases in fair values of fixed income investments, respectively. Additionally, fair values of interest rate sensitive instruments may be affected by the creditworthiness of the issuer, prepayment options, relative values of alternative investments, the liquidity of the instrument, and other market factors. We manage the interest rate risk associated with our portfolio of fixed income investments by matching assets backing reserves with that of our economic liabilities, in addition to monitoring the average yield of investment-grade corporate securities; U.S. government and agency securities; foreign government, agency and provincial obligations; preferred stocks; asset-backed and mortgage-backed securities; and municipal obligations. The following table summarizes the estimated effects of hypothetical increases and decreases in market interest rates on our debt securities as of June 30, 2026: _($ in millions)_ | Line item | Fair value | Assumed change in interest rate | Estimated fair value after change in interest rate | Pre-tax increase (decrease) in carrying value | | --- | --- | --- | --- | --- | | Debt securities | $5,221.7 | 300 bp decrease | $5,672.2 | $450.5 | | | | 200 bp decrease | 5,519.1 | 297.4 | | | | 100 bp decrease | 5,366.0 | 144.3 | | | | 50 bp decrease | 5,289.4 | 67.7 | | | | 50 bp increase | 5,132.4 | (89.3) | | | | 100 bp increase | 5,051.7 | (170.0) | | | | 200 bp increase | 4,889.2 | (332.5) | | | | 300 bp increase | $4,725.4 | $(496.3) | The magnitude of the fair value decrease in rising rates scenarios may be more significant than the fair value increase in comparable falling rates scenarios. This can occur because (i) the analysis floors interest rates at a de minimis level in falling rate scenarios, muting price increases, (ii) portions of the fixed income investment portfolio may be callable, muting price increases in falling interest rate scenarios and/or (iii) portions of the fixed income investment portfolio may experience cash flow extension in higher interest rate environments, which generally results in lower fixed income asset prices. Interest payments on our 2017 SEK Subordinated Notes are required to be serviced in Swedish kronor by reference to Stockholm Interbank Offered Rate, a floating interest rate benchmark. This benchmark rate has increased year to date and it is possible that it will continue to do so, which could result in increasing our interest expense in U.S. dollars. ### Foreign Currency Exchange Risk In the ordinary course of business, we hold non-U.S. dollar denominated assets and liabilities, which are valued using period-end exchange rates. Non-U.S. dollar denominated foreign revenues and expenses are valued using average exchange rates over the period. Foreign currency exchange-rate risk is the risk that we will incur losses on a U.S. dollar basis due to adverse changes in foreign currency exchange rates. We aim to mitigate foreign currency exchange risk through the use of foreign currency forwards. Refer to Note 8 “Derivatives” to our unaudited consolidated financial statements included elsewhere in this Form 10-Q for additional information on foreign currency hedging. The following table, presented net of currency hedges, summarizes the estimated effects of a hypothetical 10% increase and decrease in the value of the U.S. dollar against select foreign currencies would have had on the carrying value of our net assets as of June 30, 2026: | | | | | | | --- | --- | --- | --- | --- | | | 10% increase | | 10% decrease | | | | ($ in millions) | | | | | Swedish Krona to U.S. Dollar | $ | $(2.7) | $ | $2.7 | | British Pound to U.S. Dollar | (0.4) | | 0.4 | | | Swiss Franc to U.S. dollar | (0.1) | | 0.1 | | | Euro to U.S. Dollar | (2.2) | | 2.2 | | | Canadian Dollar to U.S. Dollar | $ | $1.0 | $ | $(1.0) | ## ITEM 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of June 30, 2026. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2026. ### Changes in Internal Control Over Financial Reporting There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) that occurred during the three months ended June 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. PART II - Other Information ## Item 1. Item ### ITEM 1. Legal Proceedings The Company and its subsidiaries are subject to lawsuits and regulatory actions in the normal course of business that do not arise from or directly relate to claims on reinsurance treaties or contracts or direct surplus lines insurance policies. In the Company’s industry, business litigation may involve allegations of underwriting or claims-handling errors or misconduct, disputes relating to the scope of, or compliance with, the terms of delegated underwriting agreements, employment claims, regulatory actions, or disputes arising from the Company’s business ventures. The Company’s operating subsidiaries are subject to claims litigation involving, among other things, disputed interpretations of policy coverages. Generally, the Company’s direct insurance operations are subject to greater frequency and diversity of claims and claims-related litigation than its reinsurance operations and, in some jurisdictions, may be subject to direct actions by allegedly injured persons or entities seeking damages from policyholders. These lawsuits, which involve or arise out of claims on policies issued by the Company’s subsidiaries, are typical to the insurance industry in general and in the normal course of our business. These claims are considered in the Company’s loss and loss expense reserves. In addition, the Company may from time to time engage in litigation or arbitration related to its claims for payment in respect of ceded reinsurance, including disputes that challenge the Company’s ability to enforce its underwriting intent. Such matters could result, directly or indirectly, in providers of protection not meeting their obligations to the Company or not doing so on a timely basis. The Company may also be subject to other disputes from time to time relating to operational or other matters distinct from insurance or reinsurance claims. Any litigation or arbitration, or regulatory process, contains an element of uncertainty, and the value of an exposure or a gain contingency related to a dispute is difficult to estimate. The Company believes that no individual litigation or arbitration to which it is presently a party is likely to have a material adverse effect on its results of operations, financial condition, business, or operations. ## Item 1A. Item ### ITEM 1A. Risk Factors Our business is subject to a number of risks, including those described in the Company’s risk factors disclosed in Part I, Item 1A of our 2025 Form 10-K, that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, cash flows and results of operations. There have been no material changes to the risk factors disclosed in our 2025 Form 10-K. ## Item 2. Item ### ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities Under the share repurchase program, the Company may repurchase its common stock from time to time, in amounts, at prices and at times the Company deems appropriate in its sole discretion, subject to market conditions and a variety of factors, including legal requirements, price and economic conditions. Shares of common stock may be repurchased in open market purchases, privately negotiated transactions or otherwise. The Company expects that the program will be in effect until the maximum approved dollar amount has been used. The program does not require the Company to repurchase any specific number of shares of common stock, and the program may be suspended, modified or discontinued at any time. The following table summarizes our repurchase of common shares during the three months ended June 30, 2026: | Line item | (b) Average price paid per share (1) | (d) Maximum $ value of shares that may yet be purchased under the plans or programs (2) | | --- | --- | --- | | April 1, 2026 - April 30, 2026 | $23.09 | $135,315,648 | | May 1, 2026 - May 31, 2026 | 23.16 | 119,470,948 | | June 1, 2026 - June 30, 2026 | 22.79 | 101,065,457 | | Total | $23.00 | $101,065,457 | (1) Including commissions. (2) Maximum value of common shares that may yet be purchased under the share repurchase programs previously authorized on May 4, 2016, February 28, 2018, and July 31, 2024. ## Item 3. Item ### ITEM 3. Defaults Upon Senior Securities None. ## Item 4. Item ### ITEM 4. Mine Safety Disclosures Not applicable. ## Item 5. Item ### ITEM 5. Other Information During the three months ended June 30, 2026, none of the Company’s directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended). ## Item 6. Item ITEM 6. Exhibits | | | | --- | --- | | 31.1 | Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | 31.2 | Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | | 32.1** | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | 32.2** | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | | 10.1* | Employment Letter, dated June 18, 2026, with Scott Egan | | 10.2* | Employment Letter, dated July 21, 2026, with David Govrin | | 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | | 101.SCH | Inline XBRL Taxonomy Extension Schema Document | | 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | | 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | | 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | | 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL with applicable taxonomy extension information contained in Exhibits 101) | * Management contracts or compensatory plans or arrangements. ** This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SiriusPoint Ltd. Date: July 29, 2026 /s/ Scott Egan Scott Egan Chief Executive Officer (Principal Executive Officer) /s/ Jim McKinney Jim McKinney Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) --- ## EX-10.1 EMPLOYMENT LETTER SEC source: [a101employmentletterdatedj.htm](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/a101employmentletterdatedj.htm) SiriusPoint International Insurance Corporation 3rd Floor, 33 Gracechurch Street, London, EC3V 0BT 18 June 2026 Scott Egan Via email to the confidential email address maintained in the Company’s records Dear Scott: We are pleased to offer you employment with SiriusPoint International Insurance Corporation. whose registered office is 3rd Floor, 33 Gracechurch Street, London, EC3V 0BT (the “Company”), subject to and on the terms and conditions outlined in this offer letter including its Exhibits (the “Offer Letter” and the “Employment”). This Offer Letter which supersedes and replaces your offer letter with SiriusPoint Bermuda Insurance Company Ltd May 17, 2023 (the "Bermudian Contract") and all related contractual terms governing your employment with that entity, except for any accrued rights and any provisions expressly preserved by this Offer Letter. The parties agree that the transition to this Offer Letter will not trigger any entitlement arising from a termination, resignation, dismissal, termination without Cause, resignation for Good Reason, including notice pay, payment in lieu of notice, severance, bonus, accelerated vesting or any other termination-related payment or benefit, except as expressly provided in this Offer Letter or the governing equity or incentive terms. - Position and Duties. You will serve as the CEO of SiriusPoint Ltd. (“SiriusPoint”), reporting directly to the Board of Directors from time to time of SiriusPoint (the “Board”, which definition includes any committee of the Board to which powers have been properly delegated or such person or persons designated by the Board from time to time as its representative for the purposes of the Offer Letter). In this role, you shall perform such senior executive duties, services, and responsibilities on behalf of SiriusPoint or any Group Company which are consistent with the CEO position as may be reasonably assigned to you from time to time by the Board. You agree to act subject to and in accordance with the Company's and SiriusPoint Ltd.’s memorandum of association and bye-laws as amended from time to time (the “Articles of Association”). Without prejudice to the generality of the foregoing, you will be bound by the additional duties and obligations, and give the representations and warranties, set out in Exhibit B. - Start Date. Subject to the Contingent Offer section below, your Employment commenced on 18th May 2026 under these terms and conditions. The Employment shall continue until terminated by either party as set out in the Termination of Employment – Notice and Termination of Employment – “Cause” sections below. - Base Salary. You will be paid a base salary at a rate of £1,054,530 per annum less applicable deductions. Your base salary shall accrue day to day and be payable by equal monthly instalments into a bank account you nominate for this purpose. Your base salary will be subject to review on an upwards only basis in connection with regular senior management reviews in the first quarter of each calendar year. Your base salary will next be reviewed in 2027. There is no obligation on the Company to increase your base salary pursuant to any such review or otherwise. There will be no review of the base salary after either party has given notice to terminate the Employment. - Annual Bonus. You will be eligible for an annual bonus equal to, at target levels of performance, 140% of your then-current base salary (the “Target Bonus”), and subject to generally applicable threshold and maximum levels set by the Compensation Committee of the Board as to individual and corporate performance goals. Whether any annual bonus is payable in respect of any year and, if so, how much, will be determined by the Board in its sole discretion, such discretion to be exercised in a bona fide and rational manner. Payment of your annual bonus (if any) for any year will generally 1 occur in the first quarter of the subsequent year at the same time as annual bonuses are paid to other members of the senior management team. You acknowledge that you have no contractual right to receive a bonus (save as set out below) and that receipt of any bonus payment in respect of any financial year or otherwise would not entitle you to any bonus payment in respect of any subsequent periods. The bonus for the 2026 performance year will be calculated and paid based on actual business performance and not at 100% of target level of performance. For 2026 onwards and save as provided for below in respect of a Resignation for Good Reason /Termination not for Cause, you will have no entitlement whatsoever to receive a bonus payment, any outstanding bonus payment, or pro rata entitlement, or to accrue any bonus for the year in which your employment terminates pursuant to any such bonus scheme if, on or prior to the date that the bonus for the relevant bonus period is declared or would otherwise have been paid to you or the bonus would otherwise have accrued, you are: (i) no longer employed by the Company or any Group Company; or (ii) under notice of termination of employment (whether such notice is given by you or the Company), including during any period of Garden Leave; or (iii) suspended pursuant to the terms of the Offer Letter and the Employment is subsequently terminated in connection (whether directly or indirectly) with the circumstances which gave rise to such suspension; or (iv) subject to any disciplinary process and the Employment is subsequently terminated in connection (whether directly or indirectly) with the circumstances which gave rise to such process (whereby entitlement to be considered for a bonus shall be reinstated if no disciplinary sanction is imposed); or (v) no longer in satisfaction of any eligibility criteria set out in the relevant plan rules. - Annual Long-Term Incentive Awards. You will be eligible to participate in SiriusPoint’s long-term incentive (“LTI”) program with other members of senior management of SiriusPoint. Your annual LTI award will have a target grant date value equal to 350% of your then-current base salary (calculated in the same manner as other LTI award recipients), to be provided in the same type of award(s) and ratio as granted to other members of senior management. Your annual LTI award will be granted annually at the same time as awards are granted to other members of senior management (expected to be no later than the second quarter of each calendar year), and will be subject to the terms set forth in the implementing award agreements, of which yours will be no less favorable than the agreements evidencing awards granted to other members of senior management. - Remuneration – general. oThe remuneration and benefits referred to anywhere in the Offer Letter or otherwise provided to you in connection with the Employment shall be subject always to any applicable regulatory requirements and applicable remuneration codes. If any such remuneration or benefits do not comply or cease to comply with any such regulatory requirements or remuneration codes, you acknowledge and agree that such remuneration and benefits may be reduced, amended or withdrawn to the extent necessary to comply with any such requirements or codes. oParticipation and/or continued participation in any bonus scheme (and the payment of any amounts under the bonus scheme) or any share scheme (and the receipt of benefits under any share scheme) shall be conditional upon you agreeing (including entering into such documentation as the Board reasonably requires) to deferral, malus, claw back and forfeiture terms in relation to any benefits received under such schemes as the Board determines are reasonable and appropriate. oAny awards or payments made pursuant to the sections entitled Annual Bonus, Annual Long-Term Incentive Awards and Sign-On and Additional LTI Awards will not form part of the fixed or pensionable salary under the Offer Letter (notwithstanding anything to the contrary contained in the rules of any relevant bonus scheme, share scheme or pension scheme). 2 oYour rights and obligations in connection with the Employment will not be affected by your participation in the LTI or any other long term incentive arrangements or scheme, or any right you may have to participate in the same. In participating in the LTI or any other such arrangements or schemes, you waive all and any rights to compensation or damages in respect of your participation in the LTI or any other long term incentive arrangements or scheme (but not otherwise) in consequence of: (i) the termination of the Employment or your position as CEO and/or giving notice of termination of employment with any Group Company for any reason whatsoever (whether lawful or unlawful); and/or (ii) the lawful exercise or failure to exercise any discretion conferred by the rules of the LTI or any other such arrangements or schemes, insofar as those rights arise or may arise from you losing, or failing to receive, any rights or benefits under the same or from the loss or diminution in value of such rights or benefits as a result of such termination or such lawful exercise or failure to exercise a discretion. oYour base salary is inclusive of any fees to which you may be entitled as a director of SiriusPoint or any Group Company or of any other company or any unincorporated body in which you hold the office as nominee or representative of SiriusPoint. oPayment of your base salary and bonus (if any) and the provision of benefits (if any) to you will be made either by the Company or by a Group Company and, if by more than one company, in such proportions as the Board may from time to time think fit. - Pension. From the commencement of your employment in UK, you will be eligible to be enrolled in the Company's UK pension scheme. The Company currently makes contributions equal to 12% of employees’ base salary and requires 1.5% employee contributions. You will have the option to contribute additional amounts to your pension, subject to the terms and conditions of the plan. - Relocation Benefits. You are entitled to be reimbursed up to £8,000 for other expenses incurred by you in relocating to the United Kingdom, subject to production of receipts or other evidence of payment. To the extent this reimbursement is deemed a taxable benefit, the Company will make you whole so you receive the full amount of the reimbursement net of taxes. - Insurance Benefits. You will be eligible to participate in the Company’s health, life, accidental dismemberment and death, and long-term disability policies, for which the Company currently pays 100% of the cost. The Company will provide you with additional information regarding these plans and additional provisions relating to the same are set out below: oEligibility to join, continued coverage under and benefits under, any insurance scheme are subject to the rules of the scheme and the terms of any applicable insurance policy from time to time in force and are conditional on you (and where relevant your spouse, civil partner or dependent children) complying with and continuing to comply with and satisfying and continuing to satisfy any applicable requirements of the insurer and the Company being able to obtain and maintain cover in respect of you (and where relevant your spouse, civil partner or dependent children) on commercial terms reasonably acceptable to the Company, subject to compliance with English law. Copies of these rules and policies and particulars of the requirements (when notified to the Company) will be provided to you on request. oThe Company reserves the right to amend, alter or replace any such insurance schemes, in which event you will be eligible to participate in the other or additional schemes put in place for you and your family, which will be no less favorable than are put in place for other members of senior management, and subject to compliance with English law. oThe Company will not have any liability to provide or pay any benefit or compensation to you or your spouse, civil partner or dependent children under any insurance scheme unless it receives payment of the benefit from the insurer or to take any legal action to enforce the 3 provision of such benefits in circumstances where the scheme provider refuses for any reason whatsoever to provide any benefits to you (or where applicable your spouse, civil partner or dependent children). The Company will however provide all reasonable assistance in seeking payment of such benefits and compensation short of legal action. In addition, in the event that you (or your family) request that the Company takes any legal action against any scheme provider in relation to the provision of such benefits which it is not otherwise required by law to take and the Company agrees to do so you agree to reimburse the Company for the reasonable costs incurred by it in taking any such action including any legal fees, all such costs to be agreed in advance with you or your family. oNotwithstanding the generality of the foregoing, the Company may withdraw the benefits of and/or terminate your membership of the insurance schemes once you have reached the age of 65 or the State Pensionable Age (as determined in accordance with the rules in paragraph 1 of Schedule 4 of the Pensions Act 1995), if higher. Any entitlement to benefits which have already accrued will be dealt with in accordance with the rules of the scheme for the time being in force - Holiday and other leave. You will be entitled to take thirty (30) days’ paid holiday in each holiday year (plus all public holidays normally observed in England). The Company’s holiday year currently runs from January to December. The times at which you take holiday must be agreed in writing in advance with the Board. You may carry forward up to five days holiday to the next holiday year, in all other circumstances failure to take holiday entitlement in the year in which it accrued will, save as required by law and on termination (in respect of which see Exhibit C), lead to the forfeiture of such accrued but untaken holiday without any right to payment in lieu thereof. Exhibit C contains further provisions relating to holiday and other leave in connection with the Employment. - Sickness absence. Details of the Company’s policy on sickness absence can be found in the Employee Handbook. You shall be entitled to up to 6 months' company sick pay paid at the rate of your then salary in any 12 month period. - Expenses. The Company will reimburse you in respect of all expenses, wholly, exclusively and necessarily incurred by you in the proper performance of the duties hereunder subject to you providing such receipts or other evidence as the Company may reasonably require and subject to the Company’s rules and policies from time to time relating to expenses. - Hours of Work. Your normal working hours shall be from 9.00 a.m. to 6.00 p.m. Monday to Friday, and such additional hours (without further remuneration) as are necessary for the proper performance of the duties hereunder. Notwithstanding the foregoing, you acknowledge that because of the autonomous nature of your role the duration of your working time is not measured or monitored or determined by the Company so that the limit on weekly working time set out in Regulation 4 of the Working Time Regulations 1998 (or such other regulations as may from time to time come into force) does not apply to the Employment. - Work Location; Travel. Unless otherwise mutually agreed with the Company, your principal place of work will be the Company's office in England. The Company may require you to work on a temporary basis at any offices of the Company or any Group Company. In the performance of your duties hereunder, you will be required to travel and undertake your duties both throughout and outside England (including in the United States and Bermuda). In addition, the Company will reimburse you up to £70,000 per year of costs incurred by you in connection with spousal travel (1) with you, or (2) to and from the United Kingdom from any business location to which your spouse has traveled with you (which amounts you acknowledge may result in taxable income to you). - Relocation. Without prejudice to any other provision in the Offer Letter, if in due course you and the Company agree that you will relocate to the United States or elsewhere on a full- or part- time 4 basis you and the Company will act reasonably and co-operate in good faith when seeking to agree the terms and conditions applicable to, and to the Employment following, such relocation, and you will enter into all documentation reasonably required by the Company in connection with the same. - Termination of Employment – on Notice. The Company must provide you with six (6) months’ advance written notice of termination of the Employment for any reason other than “Cause” (as defined herein). You must provide the Company with six (6) months' advance written notice of termination of the Employment for any reason other than “Good Reason” (as defined herein). Termination for “Good Reason” is subject to the process set out in Severance below. - Payment in Lieu of Notice. The Company reserves the right in its absolute discretion to elect to terminate the Employment with immediate effect and to pay in lieu of all or any part of the notice of termination (whether given by the Company or by you) by notifying you that the Company is exercising its rights under this section and that, subject to the remaining terms of this section, paying you within thirty (30) days of the date on which such written notice is given, a payment in lieu of notice of the whole or the remaining (if part of the notice period has already expired) period of notice. A dismissal without notice shall not, of itself, constitute or imply an election under this section either to pay in lieu of notice or by instalment. For this purpose, you agree that: oAny payment pursuant to this section is, if so required by the Company, in its absolute discretion, conditional on you entering into a valid form of settlement agreement in terms which are satisfactory to the Company. oPayment in lieu will consist solely of: - the base salary you would have been paid had you served the relevant notice period, or the remaining part of it, less deductions for income tax, National Insurance contributions and any other deductions required by law, and will exclude any bonus, pension contributions, allowance, benefit, equity award, long-term incentive award or other emolument, except to the extent expressly provided in the Severance section; and - for the avoidance of doubt, if the Company elects to exercise its rights to pay in lieu of notice pursuant to this section, the Sign-On LTI Awards, the Additional RSUs and any other equity grants you have received from the Company will continue to be governed by the controlling award agreement(s) and plan document(s). oFor the avoidance of doubt, if the Company elects to exercise its rights to pay in lieu of notice, pursuant to this “Payment in Lieu of Notice” section, the Sign-On LTI Awards, the Additional RSUs, and any other equity grants you’ve received from the Company, will continue to be governed by the controlling award agreement(s) and plan document(s). - Garden Leave. During any period of notice of termination or part thereof (whether given by you or the Company), or if you seek to resign without giving full notice, the Company shall be: (i) under no obligation to assign or vest any duties to you or to provide any work for you; and/or (ii) entitled to require you to carry out alternative duties commensurate with your seniority and experience; and/or (iii) entitled to require that you only perform such specific duties as are assigned you and as are commensurate with your seniority and experience; and/or (iv) entitled to exclude you from its premises or any Group Company’s premises; and/or (v) entitled to direct that you refrain from contacting or dealing with (or attempting to contact or deal with), save in a purely social capacity or in order to seek new employment, any customers, clients, suppliers, agents, professional advisers, officers or employees of the Company or any Group Company; and/or (vi) entitled to direct that you refrain from accessing the computer or other data or similar system of the Company or any Group Company (whether directly or indirectly); and/or (vii) entitled to remove you from office as a director of the Company and any Group Company and from all or any offices held by you in the Company or any Group Company and to revoke any powers you hold on behalf of the Company or 5 any Group Company; and/or (viii) entitled to require you to take any paid holiday entitlement which is untaken as at the commencement and/or which is likely to accrue during Garden Leave, provided that you shall at all time continue to receive your base salary and other contractual benefits during Garden Leave. For the avoidance of doubt, during such period both you and the Company shall continue to be bound by the same obligations to each other as were owed prior to the commencement of the period including for the avoidance of doubt (in your case) the duty of good faith and fidelity. During any period of Garden Leave, you shall remain contactable on your work mobile telephone number (save for holidays or sick days taken in the normal way). - Severance. In addition, in the event of the termination of the Employment, you shall be entitled to the payments and benefits as set forth below. Notwithstanding any other provision of this Agreement or any policy, plan or arrangement of the Company or any Group Company, in the event of any inconsistency, conflict or ambiguity relating to severance or termination-related benefits, the terms of (i) this Offer Letter and (ii) the Company’s Executive Severance Plan (as in effect from time to time) shall prevail. In the event of any conflict between this Offer Letter and the Executive Severance Plan, the terms of this Offer Letter shall govern to the extent of such conflict, unless expressly stated otherwise herein. oAny Termination: In the event the Employment is terminated for any reason, you shall be entitled to receive (in the case of (i)-(iv) below inclusive) within 30 days of the termination date, or, if later, the due stated payment date therefor: (i) any accrued and unpaid base salary up to the termination date; (ii) all accrued and unpaid benefits and awards under any benefit or equity plans, policies, programs, or arrangements in which you participated or received awards under up to the termination date, subject to and in accordance with the applicable terms and conditions of such plans, policies, programs, or arrangements; (iii) reimbursement of any business expenses incurred by you in connection with the Employment on behalf of the Company on or prior to the termination date and reimbursable under applicable Company policies but not previously reimbursed to you (the “Accrued Compensation”). In addition the equity awards held by you at the termination date shall be treated as set forth in the applicable award documentation. oResignation for Good Reason / Termination of Employment not for Cause: In the event that the Employment is terminated by the Company without “Cause” (excluding your death or permanent disability) or if you resign for “Good Reason”, in addition to the Accrued Compensation, and conditional on you entering into a valid form of settlement agreement within forty-five (45) days following the termination date, you shall be eligible to receive the following severance payments and termination benefits: - an annual bonus for the year of termination based on actual performance for the year in which the termination date occurs (whereby the Company shall disclose relevant details of performance to you to assist in calculation of such bonus), prorated for the period of the Employment during such year, and payable at such time as annual bonuses are paid in the ordinary course to similarly situated senior executives; - a cash severance payment equal to eighteen (18) months of your base salary at the rate in effect on your termination date, payable on the Company’s normal payroll dates and as provided in the next following sentence, with the first such instalment being paid on the first available payroll date following the termination date and including any installments that would have been paid if the release of claims were effective on your termination date. The cash severance pay shall be paid as follows: (x) an amount equal to one year of base salary shall be paid in twelve (12) monthly instalments over the twelve (12) months following the date of termination (and the first of such instalments shall be paid on the first 6 payroll date after the 45th day following the termination date and shall include any installment that would have been paid if the release of claims was effective on the termination date); and (y) an amount equal to the remaining six (6) months of base salary shall be paid in the fiscal year following the fiscal year in which the termination date occurs on dates selected by the Company in its sole discretion but not less frequently than in monthly instalments over the six (6) months following the first anniversary of the termination date. The cash severance payment shall be reduced by an amount equal to any base salary paid by the Company in respect of any worked notice period and/or salary paid in lieu of notice pursuant to the payment in lieu of notice clause) and shall be inclusive of statutory severance payments, if any, due to you in connection with the termination of the Employment; and - subject to plan rules, and the terms applicable to such benefits set out in the Offer Letter, and the scheme providers agreeing to continue to provide coverage (whereby the Company will make all reasonable efforts to obtain such coverage) continued medical and life insurance benefits for eighteen (18) months following your termination date at the same premium rates that active employees pay for such coverage or, if that is not possible due to the rules of the applicable insurance, pay to you the value of the premium cost to the Company for such cover. oFor purposes of this Offer Letter, “Good Reason” means (A) the assignment to you of duties that are significantly different from, or that result in a substantial diminution of, your title, duties, authorities or responsibilities hereunder; (B) mutual agreement that there has been a material erosion in the working relationship between you and the Chairman or the Board that compromises your ability to effectively perform the CEO role; (C) a reduction in your base salary of greater than 10%; (D) a material breach by the Company or any Group Company of this Offer Letter, including its exhibits and attachments, or any other material agreement with the Company or any Group Company; or (E) the termination of your Employment by reason of your death or permanent disability; provided that, if you resign with Good Reason, (1) your notice of resignation must be delivered to the Company within thirty (30) days following the claimed occurrence of Good Reason and must specify in reasonable detail the circumstances claimed to constitute Good Reason, (2) the Company shall have thirty (30) days from receipt of such notice to cure such Good Reason event, (3) failing such cure, the notice of resignation shall be effective as of the final day of the Company’s thirty (30) day cure period and the Employment will terminate with immediate effect without further notice or payment in lieu of notice on that day, and (4) if such Good Reason event is cured, the notice of resignation shall be deemed withdrawn and without effect. - For purposes of this Offer Letter, “Cause” as used herein shall mean: (i) the grossly negligent performance of your duties (other than any such failure due to your physical or mental illness) that has caused a material injury to the Company or any Group Company; (ii) you having engaged in wilful and serious gross misconduct that has caused a material injury to the Company or any Group Company; (iii) a wilful and material violation by you of a Company or Group Company policy that has caused a material injury to the Company or any Group Company; (iv) the wilful and material breach by you of any of your obligations under this Offer Letter, including its exhibits and attachments or any other material agreement to which you and the Company or any Group Company are parties; (v) failure by you to comply with a lawful and reasonable direction or instruction given to you by the Board; or (vi) your conviction of, or entrance into a plea of guilty or no contest to, a crime that constitutes a felony (or comparable crime in any jurisdiction that uses a different nomenclature), whereby road traffic offences that do not result in a term of imprisonment are excluded from this provision ; (vii) fraud, dishonesty or breach of fiduciary duty by you, whether or not relating to the 7 Employment; (viii) you failing or ceasing to hold any regulatory approval or right to work in the United Kingdom required for the proper performance of your duties; or (ix) any serious breach by you of the Company’s anti-corruption and bribery, anti-facilitation of tax evasion or anti-fraud policies. Provided that, if the Company terminates for Cause, (1) its notice of termination must be delivered to you within thirty (30) days following the claimed occurrence of Cause and must specify in reasonable detail the circumstances claimed to constitute Cause, (2) if the Board determines reasonably and in good faith that such circumstances are curable, you shall have thirty (30) days from receipt of such notice to cure such circumstances claimed to constitute Cause, (3) failing such cure, the notice of termination shall be effective as of the final day of your thirty (30) day cure period and the Employment will terminate with immediate effect without further notice or payment in lieu of notice on that day, and (4) if such Cause event is cured to the Company's reasonable satisfaction, the notice of termination shall be deemed withdrawn and without effect. - Termination for Cause. Notwithstanding the other provisions of this Offer Letter, and without prejudice to the Company’s right at common law to terminate the Employment in response to a fundamental breach of contract by you, the Employment shall be subject to termination by the Company by summary notice in writing (notwithstanding that the Company may on a former occasion have waived its rights under this section) if you are in breach of any of the warranties in Exhibit B or if you have committed an act or omission which constitutes “Cause” (as defined herein). - Suspension. If the Company becomes entitled to terminate the Employment for “Cause” or whilst the Company or any external body investigates any disciplinary matter involving you (regardless of whether it is an allegation which would or may entitle the Company to terminate the Employment for “Cause”) or while any disciplinary proceeding or process against you is outstanding or on-going, the Company shall be entitled (but without prejudice to its right subsequently to terminate the Employment on the same or any other ground) to suspend you for a period not to exceed ninety (90) days. During any period of suspension the Company shall have the same rights as during a period of Garden Leave. During any such period of suspension, the Company will continue to pay your base salary and other contractual benefits. If any period of suspension is lifted and no disciplinary sanction is applied to you, then your entitlement to receive any other bonus, share entitlement, allowance or any other remuneration or benefits shall be reinstated. If a disciplinary sanction short of dismissal is applied to you then the Company reserves the right to reduce such other bonus, share entitlement, allowance or any other remuneration or benefits to take reasonable account of the disciplinary sanction. - Actions on termination. On or following the termination of the Employment (howsoever arising) or at any time following either the Company or you having served notice of such termination or the Company exercising its right of suspension or during any period of Garden Leave or long term sickness absence, you will: oAt the request of the Company resign from office as a director of the Company and all offices you held in any Group Company and shall transfer without payment to the Company or as the Company may direct any third party any shares or other securities you held in the Company (or any Group Company) as a nominee or trustee for the Company (or any Group Company) and deliver to the Company the related certificates, provided however that such resignation shall be without prejudice to any claims which you may have against the Company or any Group Company arising out of the termination of the Employment. In the event you unreasonably refuse to sign reasonably appropriate resignation documentation, the Company may sign such resignation documentation on your behalf. oForthwith deliver to the Company all Confidential Information and materials containing the same and all other Company and Group Company property which are in your possession or 8 under your power or control and on the Company's request provide a signed statement that you have fully complied with the obligations hereunder. oCooperate with the Company and any Group Company by providing such assistance as may reasonably be required during normal working hours in connection with any handover arrangements or any claim made by or against the Company or any Group Company. For the avoidance of doubt, such assistance may include, but not be limited to, attending meetings, reviewing documents, giving and signing statements/affidavits and attending hearings and giving evidence. oProvide the Company with all necessary information as may be necessary to allow such person as the Company may determine to access any IT equipment, hard drive, memory stick or other equipment used by you in the course of the Employment whether or not such equipment is owned by the Company or any Group Company. - Directors & Officers Insurance. You will be covered under a directors and officers’ liability insurance maintained by SiriusPoint to the same extent as other directors and officers of SiriusPoint. You will continue to be covered by such insurance for six (6) years following your termination of employment for any reason. - Contingent Offer. This offer of employment is contingent upon: oYour execution of the form of Restrictive Covenant Agreement attached to this offer letter as Exhibit A. oYou being approved by any relevant regulatory authorities to hold any relevant regulated positions in connection with the Employment. This offer will be withdrawn if any of the above conditions are not satisfied and all liabilities of the parties pursuant to or in connection with the Offer Letter shall cease and determine and neither party shall have any claim against the other. For clarity, the termination and severance provisions of the Offer Letter would not apply under these circumstances. - Tax and deductions. The following arrangements apply to the Employment: oSave for sums deducted by the Company pursuant to PAYE, you will be solely responsible for taxes imposed on you by reason of any remuneration and benefits provided to you by the Company, and all such remuneration and benefits (including without limitation your base salary and bonuses (if any)) will be subject to applicable withholding and deductions. For the purposes of the Employment Rights Act 1996, you hereby authorise the Company to deduct from the remuneration and any other payments hereunder and/or in connection with the Employment any sums due from you to the Company and/or any Group Company including, without limitation, any overpayments, loans or advances made to you by the Company and/or any Group Company, repayment of holiday pay taken in excess of accrued entitlement. oIf you incur US income tax liabilities as a direct result of performing duties for the Company in the United States, the Company shall operate a tax-equalisation arrangement. Under this arrangement, the Company shall reimburse you only for the excess (if any) of your total US income tax liability over the amount of UK income tax and National Insurance contributions that would have been payable had your duties been performed exclusively in the United Kingdom. oThis provision shall not apply to any US tax liabilities arising from yourother employment, personal income, investments, or activities unrelated to your duties for the Company. You must promptly provide all information reasonably required to determine the appropriate tax equalisation amount. 9 oYou shall be fully responsible for the payment of all taxes, National Insurance contributions, filings, and any other statutory obligations arising from their participation in any share scheme, equity incentive plan, option plan, or similar arrangement offered by the Company or any Group Company. The Company will not provide tax equalisation, reimbursement, or financial support in respect of such liabilities, and you agree to comply with all personal reporting and payment requirements associated with these arrangements. - Data Protection. oYou hereby acknowledge that: - SiriusPoint and the Company will collect and process information about you, such as your name and contact details, as well as more sensitive information for various purposes in connection with the Employment, including to manage benefits and payments, to manage expenses, to manage recruitment and on-boarding, to manage absences, for security purposes, to handle with claims and disciplinary actions, to monitor performance and use of the IT systems, to conduct certain background checks and to comply with SiriusPoint’s the Company's legal obligations; - SiriusPoint and the Company will collect from you and store personal data about your next of kin, such as their name and contact details, for use in emergency situations, and you have informed such individuals that their details have been provided to SiriusPoint and the Company; - SiriusPoint and the Company may pass your information to third parties such as your previous employers, companies for which you provided services, public authorities, law enforcement agencies, fraud prevention agencies and regulators who use it in connection with the purposes set out above. SiriusPoint or the Company may also pass your information to third party agents who handle it on behalf of SiriusPoint or the Company; and - depending on the circumstances, SiriusPoint’s or the Company’s use of personal data may involve a transfer of data outside of the UK and the European Economic Area. oThe Company’s data privacy notice as amended from time to time (the “Data Privacy Notice”) gives more details of the personal information about you and your next of kin that SiriusPoint or the Company collect and process. You confirm that you will read the notice. The Data Privacy Notice does not form part of the terms and conditions of the Employment, and the Company reserves the right to amend it from time to time and to update the uses of personal data listed above and in the notice. oYou shall comply with the Company’s data protection policy, when in force and as amended from time to time relating to processing of personal data under the Data Protection Legislation (the “Data Protection Policy”) when handling personal data in the course of the Employment including personal data relating to any employee, customer, client, supplier or agent of the Company. You will also comply with the Company’s other policies in force from time regarding IT and communications systems. oFailure to comply with the Data Protection Policy or any of the other policies referred to above may be dealt with under the Company’s disciplinary procedure and, in serious cases, may be treated as gross misconduct leading to summary dismissal. oOn termination of the Employment for whatever reason, the Company will provide full and frank references in accordance with any applicable regulatory requirements to any potential employer. In providing a reference or otherwise complying with any regulatory requirement you agree that SiriusPoint or the Company may provide to a potential 10 employer or to a relevant regulator information or opinions which are personal data (including “special categories” of personal data) within the meaning of data protection legislation. oYou agree that the SiriusPoint, the Company and any Group Company may intercept, process and monitor communications transmitted by or to you via any private telecommunication systems (including e-mail) or services of any Group Company. - Miscellaneous Matters. oDefinitions. Defined terms have the meanings given to them and: - “Group Company” means a company within the Company Group. - “Company Group” means the Company and any holding company or parent undertaking for the time being of the Company or any subsidiary or subsidiary undertaking for the time being of the Company or of any such holding company or parent undertaking (for which purpose the expressions “holding company” and “subsidiary” shall have the meanings ascribed thereto by section 1159 Companies Act 2006 (UK) and the expressions “parent undertaking” and “subsidiary undertaking” shall have the meanings ascribed thereto by section 1162 Companies Act 2006 (UK)). - “Recognised Investment Exchange” means an investment exchange granted recognition under section 285 (1) Financial Services and Markets Act 2000 (UK) including a recognised overseas investment exchange. oNotices. Any notice or other document to be given under this Offer Letter shall be in writing and may be given personally to you or to the Secretary of the Company (as the case may be) or may be sent by first class post or other fast postal service or by facsimile or email transmission to, in the case of the Company, its registered office for the time being and in your case either to your address shown on the face hereof or to your last known place of residence or in the case of email to your work email address and/or the last personal email address the Company holds on record for you. Any such notice shall be deemed served when in the ordinary course of the means of transmission it would first be received by the addressee in normal business hours. oNon Reliance. You acknowledge and agree that, in entering into this Offer Letter, you do not rely on and shall have no remedy in respect of any statement, representation, assurance or warranty (whether made negligently or innocently) other than as expressly set out in this Offer Letter. Nothing in this clause shall operate to limit or exclude liability for fraud or fraudulent misrepresentation. oVariation. No variation or agreed termination of the Offer Letter will be effective unless it is in writing and signed by or on behalf of the parties (or their authorised representatives), save that the Company reserves the right to make reasonable changes to the Offer Letter and you will be notified in writing of any change as soon as possible and in any event within one month of the change. oThird Party Rights. No term of the Offer Letter is enforceable under the Contracts (Rights of Third Parties) Act 1999 by a person who is not a party to the Offer Letter, other than a Group Company. oAssignment. You expressly consent to the Company’s assignment of its rights and obligations under the Offer Letter to any Group Company at any time. oOther Agreements. This Offer Letter (together with the other policies and documents referred to in the Offer Letter) constitute the entire agreement of the parties and shall be in substitution for any previous letters of appointment, agreements or arrangements, whether written, oral or 11 implied relating to your employment by the Company or any Group Company, including (without limitation) the Bermudian Contract and the 2022 UK Contract. Without prejudice to the foregoing, in the event of any conflict between the terms of the Offer Letter and any other document purporting to relate to your employment by the Company or any Group Company, the terms of the Offer Letter prevail. You hereby acknowledge that you have no outstanding claims of any kind against the Company or any Group Company, including (without limitation) in connection with any such previous agreement and/or its termination. Each party acknowledges that in entering into the Offer Letter it has not relied on and shall have no remedy in respect of any undertaking, promise, assurance, statement, representation, warranty or understanding (whether in writing or not) or any person (whether party to the Offer Letter or not) relating to the Employment which is not expressly set out in the Offer Letter or any documents referred to it, including, in particular any offer letter. Each party agrees that its only liability in respect of those representations and warranties that are set out in the Offer Letter (whether made innocently or negligently) shall be for breach of contract. Nothing in the Offer Letter will limit or exclude any liability for fraud. oLaw and jurisdiction. The Offer Letter and any non-contractual obligations connected with it shall be governed by and interpreted in accordance with the laws of England and Wales. You and the Company hereby irrevocably submit to the exclusive jurisdiction of the English courts in respect of the interpretation and enforcement of the provisions of this letter. We believe that the Company presents a tremendous value creation opportunity and we view you as an important part of our future successes. We look forward to working with you. [Signature page follows] 12 THIS DEED has been executed as a deed, and it has been delivered on the date stated at the beginning of this Deed. SIGNED as a DEED by SiriusPoint International Insurance Corporation acting by Jason Robart, as Chair of the Compensation Committee of SiriusPoint Ltd. /s/ Jason Robart________ SIGNED as a DEED by Scott Egan in the presence of a witness /s/ Sarah Smith___________ Witness Witness Name: Sarah Smith Witness Occupation: Interim Chief Human Resource Officer 13 Exhibit A SiriusPoint International Insurance Corporation Executive Restrictive Covenant Agreement This Executive Restrictive Covenant Agreement (the “Agreement”) is entered into by and between SiriusPoint International Insurance Corporation. whose registered office 3rd Floor, 33 Gracechurch Street, London, EC3V 0BT, England (the “Company”), and the undersigned (the “Executive”). In consideration of the Executive’s employment by the Company and compensation and benefits to be provided pursuant to such employment, which the Executive acknowledges to be good and valuable consideration for the Executive’s obligations hereunder, the Company and the Executive hereby agree as follows: 1.Confidentiality. The Executive agrees and understands that in the Executive’s position with the Company, the Executive will be exposed to and will receive information relating to the confidential affairs of the Company Group, including but not limited to, technical information, intellectual property, business and marketing plans, strategies, customer information, other information concerning the products, promotions, development, financing, expansion plans, business policies and practices of the Company Group, and other forms of information considered by the Company Group reasonably and in good faith to be confidential and in the nature of trade secrets (“Confidential Information”). The Executive agrees that during the term of the Executive’s employment and thereafter, the Executive will not, other than on behalf of the Company Group, disclose such Confidential Information, either directly or indirectly, to any third person or entity without the prior written consent of the Company; provided, that disclosure may be made to the extent required by law, regulation, or order of a regulatory body, in each case so long as the Executive gives the Company as much advance notice of the disclosure as possible to enable the Company to seek a protective order, confidential treatment, or other appropriate relief. This confidentiality covenant has no temporal, geographical, or territorial restriction. Upon termination of the Executive’s employment, the Executive will promptly supply to the Company (i) all property of the Company Group and (ii) all notes, memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data, or any other tangible product or document containing Confidential Information produced by, received by, or otherwise submitted to the Executive during or prior to the Executive’s employment. Nothing in this Agreement shall prevent the Executive from: a.making a protected disclosure in accordance with s43A Employment Rights Act 1996 and the Public Interest Disclosure Act 1998; or b.making any disclosures permitted under section 17 of the Victims and Prisoners Act 2024; or c.discussing any of the matters referred to in this clause with any professional advisers, medical professionals or other health care providers who owe you a duty of confidentiality; or making a disclosure to a regulator regarding any misconduct, wrongdoing or serious breach of regulatory requirements, or reporting a criminal offence to any law enforcement agency; or d.cooperating with any law enforcement agency regarding a criminal investigation or prosecution; or e.cooperating with any legal or regulatory process to which the Executive is obliged to provide information or assistance; or 14 f.disclosing information to HMRC for the purposes of establishing and paying (or recouping) tax and national insurance liabilities arising from your employment or its termination; or g.making any other disclosure as required by law. 2.Noncompetition. By and in consideration of the Executive’s employment by the Company and the payments to be made and benefits to be provided by the Company in connection with the Executive’s employment [as referenced above], and further in consideration of the Executive’s exposure to the proprietary information of the Company Group and knowledge of and influence over the Company Group’s customers and workforce, the Executive agrees that the Executive will not, during the Noncompetition Term (as defined below), directly or indirectly, invest in, lend to, own, manage, operate, join, control, be employed by or otherwise provide services to, or participate in the ownership, management, operation or control of, including but not limited to holding any position as a shareholder, director, officer, consultant, independent contractor, employee, partner, or investor in, any Restricted Enterprise (as defined below); provided, that in no event shall ownership as a passive investor only, of not more than 5% of the issued ordinary shares of or any issuer whose securities are listed or traded on any Recognised Investment Exchange, be prohibited by this Section 2. Following termination of the Executive’s employment, upon request of the Company during the Noncompetition Term, the Executive shall notify the Company of the Executive’s then-current employment status. 3.Nonsolicitation of staff. During the Nonsolicitation Term, the Executive shall not directly or indirectly, and shall not directly or indirectly cause any other person to, (i) interfere with or harm, or attempt to interfere with or harm, the relationship of any member of the Company Group with any Restricted Employee (as defined below), or (ii) endeavor to entice any Restricted Employee away from the Company Group. For the avoidance of doubt, it shall not be a breach of this clause for any Restricted Employee to respond to a bona fide advertisement or approach from a recruitment consultant on behalf of a third party employer, provided you are not directly or indirectly involved in such recruitment. 4.Nonsolicitation/Nondealing with Customers. During the Nonsolicitation Term the Executive shall not directly or indirectly, and shall not directly or indirectly cause any other person to (i) interfere with or harm, or attempt to interfere with or harm, the relationship of any member of the Company Group with any Restricted Customer; or (ii) endeavor to entice any Restricted Customer away from the Company Group where such enticement relates to Restricted Goods or Services; or (iii) have any dealings with any Restricted Customer relating to Restricted Goods or Services. 5.Non disparagement. While employed by the Company and thereafter, neither the Company (by formal press release, or by authorized statement of any of the members of its board of directors or executive officers made in circumstances reasonably expected to become publicly known) nor the Executive shall make or publish any disparaging statements (whether written or oral) regarding each other (or in the Executive's case) any of the Company’s affiliates, directors, officers, or employees. 6.Proprietary Rights. If at any time in the course of the employment, the Executive makes or discovers or participates in the making or discovery of any Intellectual Property relating to or capable of being used in the business of the Company or any member of the Company Group the Executive shall immediately disclose full details of such Intellectual Property to the Company and, at the request and expense of the Company, shall do all things which may be necessary or desirable for obtaining appropriate forms of protection for the Intellectual Property and for 15 vesting all rights in the same in the Company or relevant member of the Company Group or their nominees. The Executive irrevocably appoints any director of the Company to be his attorney in his name and on his behalf to sign, execute or do any instrument or thing and generally to use his name for the purpose of giving to the Company or any member of the Company Group or their nominees the full benefit of the provisions of this section and in favour of any third party a certificate in writing signed by any director or the secretary of the Company that any instrument or act falls within the authority conferred by this section shall be conclusive evidence that such is the case. The Executive acknowledges and agrees that he will not (whether during or after the employment) apply or join in applying for any patent, registered design, trade mark or other intellectual property protection in respect of any Intellectual Property without the prior written approval of the Company. The Executive waives all his rights (as defined in the Copyright Designs and Patents Act 1988) in respect of any acts of the Company or any acts of third parties done with the Company’s authority in relation to any Intellectual Property which is the property of the Company by virtue of this section. All rights and obligations under this section in respect of Intellectual Property made or discovered by the Executive during the employment shall continue in full force and effect after the termination of the employment and shall be binding upon your personal representatives. “Intellectual Property” for the purposes of this section shall mean: (a)discovery, patents, trademarks, service marks, registered designs, applications for any of those rights, trade and business names (including internet domain names and e-mail address names), unregistered trademarks and service marks, copyrights, improvements in procedure, formulae, design rights, moral rights, rights in performances, database rights, rights in know-how and designs and inventions; (b)rights of the equivalent or similar effect or nature to those in paragraph (a); and (c)rights under licences, consent orders, statutes or otherwise in relation to a right in paragraphs (a) or (b), (d)in each case in any jurisdiction where any of the above may exist. 7.Remedies. The Executive agrees that any material breach of the terms of this Agreement might result in irreparable injury and damage to the Company Group for which the Company may have no adequate remedy at law; the Executive therefore also agrees that in the event of such breach or any threat of breach, the Company may be entitled to an immediate injunction and restraining order to prevent such breach, threatened breach, or continued breach by the Executive and any and all persons or entities acting for or with the Executive, without having to prove damages, in addition to any other remedies to which the Company or the Company Group may be entitled at law or in equity. The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including but not limited to, the recovery of damages from the Executive. The Executive and the Company further agree that the provisions of the covenants contained in this Agreement are reasonable and necessary to protect the business of the Company Group because of the Executive’s access to Confidential Information and his material participation in the operation of such business. While the restrictions in this Agreement (on which the Executive has had the opportunity to take independent advice, as the Executive hereby 16 acknowledges) are considered by the parties to be reasonable in all the circumstances, it is agreed that if any such restrictions, by themselves, or taken together, shall be adjudged to go beyond what is reasonable in all the circumstances for the protection of the legitimate interests of the Company or member of the Company Group but would be adjudged reasonable if part or parts of the wording thereof were deleted, the relevant restriction or restrictions shall apply with such deletion(s) as may be necessary to make it or them valid and effective. 8.The benefit of this Agreement shall be held on trust by the Company for each member of the Company Group and the Company reserves the right to assign the benefit of such provisions to any Group Company. Each of the obligations undertaken by the Executive pursuant to this Agreement shall, with respect to each such member of the Company Group, constitute a separate and distinct covenant and the invalidity or unenforceability of any such covenant shall not affect the validity or enforceability of the other such covenants in favour of any other member of the Company Group or the Company. The Executive agrees that each of the restrictions set out in this Agreement constitutes entirely separate, severable and independent restrictions on him and the sections and sub-sections of this Agreement shall operate independently of each other and shall not affect the interpretation of any other section or sub-section. 9.Certain Definitions. For purposes of this Agreement: a.The “Noncompetition Term” shall mean the period beginning on the start date of the Executive’s employment and ending six (6) months following the Executive’s termination of employment. b.The “Nonsolicitation Term” shall mean the period beginning on the start date of the Executive’s employment and ending twelve (12) months following the Executive’s termination of employment. The periods for which the restrictions in Sections 2, 3 and 4 apply following termination of the Executive’s employment shall be reduced by any period of Garden Leave occurring during any period of notice to terminate the Employment given by either party. c.“Recognised Investment Exchange” means an investment exchange granted recognition under section 285(1) Financial Services and Markets Act 2000 (UK), including a recognised overseas investment exchange. d.“Relevant Period” means the period of 12 months ending on the Executive’s termination of employment or, in the event that no duties were assigned to the Executive for any part of the duration of the notice period, the 12 months immediately preceding the last day on which the Executive carried out any duties for the Company or any member of the Company Group. e.“Restricted Enterprise” shall mean (x) on any date during the Executive’s employment, any person, corporation, partnership, or other entity that competes, directly or indirectly, in the Territory with any material business activity engaged in by any member of the Company Group on such date and (y) on and after the date of the Executive’s termination, any person, corporation, partnership or other entity that otherwise competes, directly or indirectly, in the Territory with any material business activity engaged in by any member of the Company Group and with which the Executive was involved to a material extent at any time during the Relevant Period. f.“Restricted Customer” shall mean (x) on any date during the Executive’s employment with the Company any person, corporation, partnership or other entity which was a customer or intermediary (including, without limitation, any broker or other insurance 17 intermediary) of any member of the Company Group, or otherwise had a material relationship with any member of the Company Group and (y) on and after the date of the Executive’s termination any person corporation, partnership or other entity which was a customer or intermediary (including, without limitation, any broker or other insurance intermediary) of any member of the Company Group, or otherwise had a material business relationship with any member of the Company Group, and in each case with whom the Executive had material dealings in the course of his employment at any time during the Relevant Period. g.“Restricted Employee” shall mean (x) on any date during the Executive’s employment with the Company any person who is employed or engaged by any member of the Company Group and (y) on and after the date of the Executive’s termination any person who was employed or engaged by any member of the Company Group and serves on the Executive Leadership Team or Senior Leadership Team and with whom the Executive had material dealings in the course of his employment at any time during the Relevant Period. h.“Restricted Goods or Services” shall mean (x) on any date during the Executive’s employment with the Company any goods or services which are the same as or similar to goods or services supplied by any member of the Company Group and (y) on and after the date of the Executive’s termination any goods or services which are the same as or similar to the goods or service supplied by any member of the Company Group to the extent that the Executive’s duties were materially involved with such goods or services or which he was responsible for at any time during the Relevant Period. i.The “Territory” shall mean (i) on any date during the Executive’s employment: (x) the geographic markets in which the business of the Company Group is then being conducted by the Company Group and (y) any other geographic market as to which the Company Group has, during the twelve (12) months preceding such date, devoted more than de minimis resources as a prospective geographic market for the business of the Company Group; and (ii) on and after the date of the Executive’s termination: (x) the geographic markets in which the business of the Company Group or any of its members (with which the Executive was involved to a material extent at any time during the Relevant Period) was being conducted during the Relevant Period and (y) any other geographic market as to which the Company Group has, or any of its members have, during the twelve (12) months preceding the date of the Executive’s termination devoted more than de minimis resources as a prospective geographic market for the business of the Company Group (with which the Executive was involved to a material extent at any time during the Relevant Period). j.“Company Group” means the Company and any holding company or parent undertaking for the time being of the Company or any subsidiary or subsidiary undertaking for the time being of the Company or of any such holding company or parent undertaking (for which purpose the expressions “holding company” and “subsidiary” shall have the meanings ascribed thereto by section 1159 Companies Act 2006 (UK) and the expressions “parent undertaking” and “subsidiary undertaking” shall have the meanings ascribed thereto by section 1162 Companies Act 2006 (UK)). 10.No Waiver of Rights. The failure to enforce at any time the provisions of this Agreement or to require at any time performance by any other party of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this 18 Agreement or any part hereof, or the right of any party to enforce each and every provision in accordance with its terms. 5.Binding Effect/Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto, and the Company Group, and each of their respective heirs, executors, personal representatives, estates and successors (including, without limitation, by way of merger), and assigns. Notwithstanding the provisions of the immediately preceding sentence, the Executive shall not assign all or any portion of this Agreement without the prior written consent of the Company. 6.Entire Agreement. This Agreement sets forth the entire understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, written or oral, between them as to such subject matter. 7.Severability. If any provision of this Agreement, or any application thereof to any circumstances, is invalid, in whole or in part, such provision or application shall to that extent be severable and shall not affect other provisions or applications of this Agreement. 8.Governing Law; Consent to Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of England and Wales, without reference to the principles of conflict of laws. Each party hereby irrevocably submits to the exclusive jurisdiction of the English courts. 9.Modifications and Waivers. No provision of this Agreement may be modified, altered, or amended except by an instrument in writing executed by the parties hereto. No waiver by any party hereto of any breach by any other party hereto of any provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions at the time or at any prior or subsequent time. 10.Headings. The headings contained herein are solely for the purposes of reference, are not part of this Agreement, and shall not in any way affect the meaning or interpretation of this Agreement. 11.Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. [signature page follows] 19 THIS DEED has been executed as a deed and it has been delivered on the date stated at the beginning of this deed. Signed as a deed by SiriusPoint International Insurance Corporation. Signed as a deed by SiriusPoint International Insurance Corporation. Jason Robart, as Chair of the Compensation Committee of SiriusPoint Ltd. /s/ Jason Robart________ SIGNED as a DEED by Scott Egan in the presence of a witness: /s/ Sarah Smith___________ Witness Witness Name: Sarah Smith Witness Occupation: Interim Chief Human Resource Officer 20 Exhibit B Duties, obligations and Warranties Duties and obligations - In connection with the Employment you will: 1.during normal business hours (excluding holiday and sickness absence) devote the whole of your time, attention and skill to your duties; 2.at all times and in all respects and in willing cooperation with others, faithfully and diligently perform such duties and exercise such powers consistent with your position as may from time to time be reasonably assigned to or vested in you by the Board; 3.obey the reasonable and lawful directions of the Board; 4.comply with duties for directors set out in applicable legislation; 5.comply with the Articles of Association and comply with all the Company's and relevant Group Companies’ codes, rules, regulations, policies and procedures and any such code, practice, rules or regulations of any association or professional body to which the Company and/or any Group Company and/or you belong from time to time including without limitation any regulatory authorities relevant to you, the Company or any Group Company including without limitation the SEC and the Financial Conduct Authority;(g) neither commit or attempt to commit the criminal offence of insider dealing nor contravene Articles 14, 15 or 19 of the Market Abuse Regulation (Regulation 596/2014/EU) or any applicable laws having the same or similar effect in any other jurisdiction; 6.keep the Board and, if applicable, any other Group Board at all times promptly and reasonably informed (in writing if so requested) of your conduct and activities in relation to the business of the Company and any Group Company for which you are required to perform duties and provide such explanations in connection therewith as the Board may reasonably require from time to time including for the avoidance of doubt, any activity (actual or threatened) which might affect the material interests of the Company or any Group Company; any actual potential or maturing business opportunity potentially applicable to the Company or any Group Company; any offer of engagement or approach made by a competing business to any employee, worker or officer of the Company or any Group Company of which you are aware; the intention of any employee, worker or officer of the Company or any Group Company who reports directly or indirectly to you to resign from your employment or engagement with the Company or any Group Company and of which you are aware; 7.report to the Board your own wrongdoing and any wrongdoing or proposed or suspected wrongdoing of any agent, employee, worker or director of the Company or any Group Company of which you are aware, including any circumstances that could lead and/or have led to an offence constituting a fraud offence or an economic offence under the Economic and Corporate Transparency Act 2023 or a tax evasion offence under the Criminal Finances Act 2017; 8.comply with the Company’s anti-corruption and bribery policy, anti-facilitation of tax evasion policy, anti-fraud policy and related procedures in place from time to time and the Bribery Act 2010, the Criminal Finances Act 2017 and any applicable laws having the same or similar effect in any other jurisdiction; 9.comply with every regulation of the Company for the time being in force in relation to dealings in shares or other securities of the Company or any Group Company insofar as they may affect you, the Company, any Group Company or its or their directors, officers or employees; and 21 10.use all reasonable endeavours to develop the business of the Company and the Company Group and build and form client relationships on behalf of the Company and the Company Group. - The Company reserves the right to: (i) request that you with immediate effect to carry out the duties of another position of equivalent status either in addition to or instead of your duties as CEO; and (ii) by agreement with you appoint any other person or persons to act jointly with you or in your place (if you are not performing the duties under the Offer Letter on a full time basis, are absent on sick leave, suspended, on family related leave or placed on garden leave or otherwise) in any position to which you may be assigned from time to time. - You will, if and so long as the Company requires and without any further remuneration therefore (except as otherwise agreed), carry out duties commensurate with your seniority and experience on behalf of any Group Company and/or act as a director or officer of any Group Company. At any time at the request of the Company, you must resign from office as a director or officer of any Group Company. You must not resign from such positions except at the request or direction of the Company, or in circumstances where you reasonably believe that you are no longer able to carry out your duties. - The Company takes a zero tolerance approach to tax evasion. You must not engage in any form of facilitating tax evasion, whether under UK law or under the law of any foreign country. You must report any request or demand from a third party to facilitate the evasion of tax or any concerns that such a request or demand may have been made immediately to the Board. You must comply at all times with the Company’s anti facilitation of tax evasion policy or anti-corruption and bribery policy and any relevant policy of any relevant Group Company as such may be amended from time to time. Failure to do so will be treated as a disciplinary matter and may result in immediate termination. - You will provide a copy of Exhibit A to any person, firm, company or other entity making an offer of employment, appointment as a director or officer, agency, consultancy, partnership or joint venture to you during the Employment or thereafter whilst any restrictions in Exhibit A remain in force immediately upon receiving any such offer. - You will enter into any documentation required by the Company in connection with you holding any position(s) or discharging any duties in connection with the Employment for which approval is required from, or which is or are otherwise subject to regulatory oversight by, any regulator relevant to the Company or any relevant Group Company. - Other than in the proper and normal course of your duties, you will not at any time during the Employment, without the prior written consent of the Board, have any direct or indirect interest as agent, beneficiary, consultant, director, employee, partner, proprietor, shareholder or otherwise in any trade, business, profession or occupation or the setting up of the same other than the business of the Company or any Group Company. Warranties You represent and warrant to the Company that to the best of your knowledge: - You are not bound by or subject to any court order, agreement, covenant, arrangement, regulatory code or undertaking or has any other interest or obligation which in any way restricts or prohibits you from entering into this Offer Letter or from performing the duties hereunder and you undertake to indemnify and hold harmless the Company against all claims, costs, damages and expenses which the Company incurs in connection with any claim in relation to any such court order, covenant, arrangement, regulatory code or undertaking or any other interest or obligation by which you are or were so bound or subject. 22 - You are not subject to any restrictions which prevent you from holding office as a director of the Company or any Group Company. - You have disclosed or will disclose to the Company on a continuing basis all information which is necessary to ensure that the Company or any relevant Group Company can fully comply with its notification regulations in connection with the Employment arising from or in connection with any rules applicable to the listing of shares of the Company or any Group Company on any Recognised Investment Exchange or in respect of any other regulatory obligations. - You are qualified to perform the position to which you are appointed. - All of the information provided to the Company, and any third party acting on behalf of the Company is complete, true and up to date and you have not deliberately omitted any information relevant to the Employment. 23 Exhibit C Further Section 6 particulars - Continuity of employment. Your period of continuous employment with the Company shall be deemed to have commenced on September 21, 2022. - Probationary period. The Employment is not subject to a probationary period. - Holiday. If the Employment starts or finishes part way through the holiday year, your holiday entitlement during that year shall be calculated on a pro rata basis. You will be deemed to have taken the statutory basic annual leave entitlement first then any additional contractual leave entitlement. In the respective holiday years in which the Employment commences or terminates, your holiday entitlement will accrue on a pro rata basis for each complete month of service during the relevant holiday year. Notwithstanding the foregoing, on the termination of the Employment, no payment in lieu will be made in respect of any public or bank holidays. During any period of notice or Garden Leave, the Company may require you to take any holiday entitlement accrued but untaken in the holiday year in which the Employment terminates or may make a payment in lieu of the same. If, on the termination of the Employment, you have taken more than your accrued holiday entitlement, you will repay the excess to the Company from any sums due to you and, for the purposes of the Employment Act 1996, you hereby authorise the Company to make such deduction. The calculation of any entitlement to accrued and untaken holiday or deductions where you have, on termination, taken more than your accrued holiday entitlement shall be based on 1/260th of your then base salary for each untaken or excess day of the entitlement for the holiday year in which termination takes place. - Other leave. You may be eligible to take the following types of paid leave, subject to any statutory eligibility requirements or conditions and the Company's rules applicable to each type of leave in force from time to time: (i) statutory paternity leave; (ii) adoption leave; (iii) shared parental leave; (iv) parental leave; and (v) bereavement leave. Further details of such leave and, where applicable, pay during such leave are available from the Employee Handbook. The Company may replace, amend or withdraw the Company's policy on any of the above types of leave at any time. - Grievance procedures. If you wish to obtain redress of any grievance relating to the Employment or are dissatisfied with any reprimand, suspension or other disciplinary step taken by the Company, you may apply in writing to the Chairperson of the Board, setting out the nature and details of any such grievance or dissatisfaction. If you are not satisfied with the decision of the Chairperson, you may within seven days of the decision appeal in writing to a non-executive director of SiriusPoint nominated by the Board. - Disciplinary. The disciplinary rules applicable to you are set out in the Employee Handbook. The disciplinary procedure is not contractually binding on the Company and the Company may in its absolute discretion and for any reason decide not to follow the disciplinary procedure. - Bullying and Harassment. The Company has a policy statement on bullying and sexual harassment which is contained in the Employee Handbook. - Dress Code: The Company's dress code is contained in the Employee Handbook. - Collective Agreements. There are no collective agreements that affect the terms and conditions of the Employment. 24 --- ## EX-10.2 EMPLOYMENT LETTER SEC source: [a102employmentletterdatedj.htm](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/a102employmentletterdatedj.htm) PRIVATE AND CONFIDENTIAL David Govrin 21 July 2026 Dear David, I am writing on behalf of SiriusPoint America Insurance Company (the “Company”) to set out the arrangements we've agreed to support your temporary assignment to additional duties in the UK, focused on supporting the growth of the London Specialty Market. The purpose of this letter is to record the practical arrangements that will apply during your assignment. It is not intended to replace your existing employment agreement with the Company dated 31 October 2022 (the “Employment Agreement”) and those terms will continue to apply, save where expressly amended by this letter. Purpose of the assignment The purpose of the assignment is to enable you to support the continued growth and development of SiriusPoint’s London Specialty Market business. The assignment is expected to commence on 1 August 2026 and is currently anticipated to continue until on or around 31 July 2027, subject to business requirements and review. The dates and duration of the assignment are indicative only and may be varied by the Company to meet business, immigration or regulatory requirements. Employment status Throughout the assignment you will remain employed by the Company under the Employment Agreement, which will continue to apply except as specifically set out in this letter. Nothing in this letter is intended to create a separate employment relationship between you and any UK SiriusPoint entity. Except as expressly set out in this letter, nothing in this letter changes your reporting lines, your status as an executive officer, or your duties or position within the SiriusPoint group. Your compensation and benefits arrangements will continue in accordance with the Employment Agreement and your existing arrangements unless otherwise agreed separately in writing. Duties and responsibilities During the assignment you will continue in your existing employment with the Company and will spend the majority of your time in the US fulfilling your current duties in your existing role as President & CEO of Global Reinsurance. However, you will also perform certain services from SiriusPoint International Insurance Corporation (publ) UK Branch in order to undertake such additional responsibilities as may reasonably be required in connection with the growth and development of SiriusPoint's London Specialty Market operations. Regulatory responsibilities Subject to obtaining all necessary approvals, SiriusPoint intends to nominate you to perform a Senior Management Function role for SiriusPoint International Managing Agency (SIMA). Any such appointment is subject to all applicable regulatory approvals and may be withdrawn, modified or delayed by the Company or the relevant regulators, and the assignment does not guarantee that any such appointment will be made or maintained. UK immigration support The Company will arrange and fund the immigration sponsorship process required to facilitate your assignment to the UK, including obtaining and maintaining an appropriate sponsor licence (if required), issuing a Certificate of Sponsorship and meeting the associated application costs for your work visa. This arrangement is conditional on you obtaining and maintaining the necessary UK immigration permission. You will need to keep the Company updated on anything that affects your right to work throughout the period of the assignment. You agree to provide all information and documentation reasonably requested by the Company in connection with immigration applications and related compliance obligations. Accommodation For the duration of your assignment, the Company will make available accommodation in London through a company-leased apartment. The apartment may be shared with, or made available to, other SiriusPoint executives from time to time and therefore should not be regarded as accommodation provided exclusively for your use. The Company may change, relocate or withdraw the accommodation arrangements from time to time based on business needs and availability. Tax support The Company will provide tax equalisation in respect of qualifying days spent working in London in relation to base salary, short-term incentive arrangements and long-term incentive arrangements. The anticipated arrangement is that your time in London will generally not exceed one week per calendar month. Should you wish, or be required, to exceed this level of presence in London, prior approval should be obtained from the Company due to the potential additional business cost and proxy disclosure implications. In the absence of such approval, the Company reserves the right not to provide tax equalisation in respect of the additional period, and you will become personally liable for the resulting tax delta. The Company will provide reasonable tax support for your personal tax filings in the UK and US for as long as this is required because of the time you spend fulfilling the duties of your assignment in London. Tax equalisation and related tax support will be administered in accordance with the Company’s applicable tax equalisation policies and procedures, as amended from time to time. You agree to cooperate with the tax advisers engaged by the Company and to provide the information reasonably required to administer these arrangements. End of assignment The Company may also amend, suspend or bring the assignment to an end at any time in its discretion, subject to applicable law and regulatory requirements, in which case you will continue in your employment with the Company under the Employment Agreement. Continuing obligations and data privacy Your existing obligations to the Company, including any confidentiality, restrictive covenant, code of conduct and securities compliance obligations under the Employment Agreement or applicable policies, will continue to apply during the assignment. You acknowledge that your personal data may be processed and transferred internationally by the Company and its advisers as necessary to administer the assignment, including for immigration, tax, payroll and regulatory purposes. If you're happy with these arrangements, please sign and date below and return a copy to me for our records. Yours sincerely, _/s/ Sarah Smith_________________ Sarah Smith Interim Chief Human Resource Officer I confirm my agreement to the above arrangements: Signed: _/s/ David Govrin____________ David Govrin Date: __July 29, 2026________________ --- ## EX-31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER SEC source: [exhibit31163026.htm](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit31163026.htm) Exhibit 31.1 SiriusPoint Ltd. CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) OF THE EXCHANGE ACT, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Scott Egan, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of SiriusPoint Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: July 29, 2026 /s/ Scott Egan Scott Egan Chief Executive Officer (Principal Executive Officer) --- ## EX-31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER SEC source: [exhibit31263026.htm](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit31263026.htm) Exhibit 31.2 SiriusPoint Ltd. CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) OF THE EXCHANGE ACT, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jim McKinney, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of SiriusPoint Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: July 29, 2026 /s/ Jim McKinney Jim McKinney Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) --- ## EX-32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER SEC source: [exhibit32163026.htm](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit32163026.htm) Exhibit 32.1 SiriusPoint Ltd. CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Scott Egan, Chief Executive Officer of SiriusPoint Ltd. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) the Quarterly Report on Form 10-Q of the Company for the fiscal period ended June 30, 2026 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: July 29, 2026 /s/ Scott Egan Scott Egan Chief Executive Officer (Principal Executive Officer) --- ## EX-32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER SEC source: [exhibit32263026.htm](https://www.sec.gov/Archives/edgar/data/1576018/000157601826000085/exhibit32263026.htm) Exhibit 32.2 SiriusPoint Ltd. CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Jim McKinney, Chief Financial Officer of SiriusPoint Ltd. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) the Quarterly Report on Form 10-Q of the Company for the fiscal period ended June 30, 2026 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: July 29, 2026 /s/ Jim McKinney Jim McKinney Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)